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Abstract 
GLUT1-mediated, facilitated sugar transport is proposed to be an example of transport by a 
carrier that alternately presents exofacial (e2) and endofacial (e1) substrate binding sites, 
commonly referred to as the alternating access carrier model. This hypothesis is incompatible 
with observations of co-existent exo- and endofacial ligand binding sites, transport allostery, and 
e1 ligand (e.g. cytochalasin B) induced GLUT1 sugar occlusion. The fixed-site carrier model 
proposes co-existent, interacting e2 and e1 ligand binding sites but involves sugar translocation 
by geminate exchange through internal cavities. Demonstrations of membrane-resident dimeric 
and tetrameric GLUT1 and of e2, e1 and occluded GLUT conformations in GLUT crystals of 
monodisperse, detergent-solubilized proteins suggest a third model. Here, GLUT1 is an 
alternating access carrier but the transporter complex is a dimer of GLUT1 dimers, in which 
subunit interactions produce two e2 and two e1 conformers at any instant. The crystallographic 
structures in different conformations can be utilized to further understand the transport cycle, 
ligand binding behavior and complex kinetics observed in GLUT1. Specifically, the GLUT1 
crystal structure and homology models based upon related major facilitator superfamily proteins 
were used in this study, to understand inhibitor binding, ligand binding induced GLUT1 
transport allostery and the existence of helix packing/oligomerization motifs and glycine induced 
flexibility. These studies suggest that GLUT1 functions as an oligomeric allosteric carrier where 
cis-allostery is an intramolecular behavior and trans-allostery is an intermolecular behavior. 
Additionally, mutations of a dynamic glycine affect the turnover of the transporter while 
mutations to helix packing motifs affect affinity. 
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CHAPTER 1: 
Introduction: 
Glucose Transport Protein Literature Review 
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Why Study Carrier Mediated Transport? 
 Homeostasis is the process through which the internal environment of cells is maintained at 
a steady-state, wherein flux and consumption are balanced. In order to maintain this balance, 
cells rely upon integral membrane proteins (IMP) to catalyze the transport of molecules across 
the cell membrane. Investigating the relationships between IMP structure, ligand binding and 
transport mechanism is necessary if our goal is to understand a vast number of biological 
processes including metabolism, cell signaling, and cellular/organismal homeostasis. The 
importance of understanding the relationships between IMPs and cellular and organismal 
homeostasis is also of fundamental interest to the pharmaceutical industry as more than 50% of 
drug targets fall within this class of proteins (1). This thesis will focus on the human erythrocyte 
facilitative glucose transporter (GLUT1), a member of the major facilitator superfamily (MFS), 
and an IMP which plays a central role in cellular and organismal homeostasis and is implicated 
in both cancer and metabolic diseases.  
The Plasma Membrane 
 Both prokaryotic and eukaryotic cells are surrounded by a plasma membrane that seals the 
cell from its external environment and maintains the internal volume and composition of the cell. 
The membrane is composed of amphipathic lipids, specifically: phospholipids, sterols and 
glycolipids. Phospholipids, the most abundant lipid in membranes, combine a hydrophilic 
phosphate head group with a hydrophobic tail of uncharged, non-polar long chain fatty acids. 
The fatty acid chains self-associate to form a hydrophobic bilayer while the hydrophilic head 
groups interact with both the interstitium and the cytoplasm. The continuous envelope of lipid 
bilayer is interspersed with glycolipids and sterols. Glycolipids, a lipid moiety modified with a 
sugar, primarily serve as recognition sites for cell-cell interaction. Sterols, a subgroup of steroids, 
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the most well-known of which is cholesterol are necessary to maintain the plasticity of the 
membrane (2).  
Transport across Cell Membranes 
 Molecules can cross the cell membrane in several ways. Non-Stokesian diffusion is one 
such process whereby molecules must first partition into the bilayer, diffuse across the bilayer 
then partition out at the opposite, trans-side of the membrane (3). Partitioning into and out of the 
bilayer is governed by the membrane solubility of the molecular diffusant - hydrophobic 
molecules are characterized by lower standard chemical potentials in hydrophobic solvents and 
thus accumulate more readily in the bilayer. Diffusion across the bilayer is governed by 
molecular diffusant size. The bilayer core behaves as a polymer and thus the rate of diffusion is 
governed by the probability of a diffusant encountering a void volume of sufficient size to permit 
diffusant entry (3). The average volume of void spaces in the human erythrocyte bilayer is a 
mere 8.4 cm3/mol - the size of a methylene group and smaller than the van der Waal’s volume of 
water [3]. These principles explain why transbilayer molecular diffusion of only the smallest and 
most hydrophobic of biological substrates (e.g. O2, CO2) is sufficient to explain physiological 
rates of transport. For most other molecules (sugars, amino acids, nucleosides, ions) transbilayer 
diffusion is too slow and nonspecific to be compatible with cellular function [3]. These 
molecules use IMPs to cross the membrane in a process referred to as protein-mediated 
transport.  
 IMPs catalyze two types of membrane transport. Passive transport (sometimes referred to 
as facilitated diffusion) results in the transmembrane movement of molecules down an 
electrochemical gradient. Active transport results in the net transport of molecules against an 
electrochemical gradient and requires an energy input to catalyze the movement of a solute 
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against its electrochemical gradient [3]. This is accomplished in nature in two ways: 1) by 
coupling uphill transport to an exergonic process such as ATP hydrolysis (primary active 
transport) or 2) by coupling uphill transport to the transport of a second molecule down a 
favorable electrochemical gradient (a process known as secondary active transport) [3]. Within 
these general classifications of passive and active transport mechanisms, there exists three 
different operational transport modes: 1) uniport, where the transport of a molecule does not 
require the transport of a counter species in the opposite direction; 2) symport, where multiple 
different molecules are transported across the membrane in the same direction, and 3) antiport, 
where two or more different molecules are transported across the membrane in opposite 
directions [3]. 
Membrane Proteins 
 The plasma membrane comprises a lipid bilayer with associated peripheral and integral 
membrane proteins. Peripheral membrane proteins non-covalently attach to the cell membrane, 
primarily at the cytoplasmic surface (4). Integral membrane proteins may be subdivided into 
three types: monotopic IMPs, bitopic IMPs and transmembrane proteins (5). Monotopic IMPs 
are permanently attached to one side of the plasma membrane and penetrate the bilayer without 
crossing it. Bitopic or single-pass IMPs cross the membrane only once and have N- and C-
termini on opposite sides of the membrane. Transmembrane or multi-pass IMPs cross the 
membrane multiple times and can have N- and C-termini at the same or opposite sides of the 
membrane. Coupled together the plasma membrane and associated proteins function to limit and 
regulate the passage of molecules and information into and out of the cell. 
 Three types of membrane transport proteins mediate transport: pores, channels and carriers. 
(Figure 1.1) These proteins differ in their transport mechanism, permeation pathway and form of 
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solute movement. While all three protein types mediate facilitated diffusion, only carriers can 
mediate active transport [3]. Pore proteins stabilize an opening in the membrane, presenting 
simultaneous access at both sides of the plasma membrane to molecules compatible with the size 
and charge constraints of the membrane pore [3]. Similarly, channel proteins transport ions 
across the cell membrane by stabilizing an opening in the cell membrane. However, in the case 
of channel proteins, access to both sides of the membrane is temporary and conditional. Channels 
exist in either an open or closed state triggered by a small conformational change. Open channels 
are much like pores in that they are open to both sides of the membrane simultaneously allowing 
a continuous flow of solutes without interruption. A selectivity filter controls what class and type 
of ions can pass through the open-channel pore. Sodium, potassium, calcium, and chloride are 
common ions that enter and exit the cell through channels. Unlike pores and channels, carriers 
are thought not to present simultaneous access to both the intra- and extracellular environments. 
Carrier proteins instead undergo a series of conformational changes to facilitate translocation of 
substrate. Both the rate of the conformational change and stoichiometry of binding combine to 
limit the number of molecules transported per event.  
 6 
 
Figure 1.1: Diffusion across a membrane bilayer. A lipid bilayer is shown (pink) providing 
a barrier between extracellular (above) and intracellular space (below). The yellow circles 
represent the substrate and are at a higher concentration outside the cell. Passive diffusion 
processes, simple of facilitated diffusion (pores, channels, carriers), don’t require an energy 
input and mediate transport from high to low concentrations. Active transport, mediated by 
carriers requires an energy input to transport the ligand against the concentration gradient.   
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The Major Facilitator Superfamily 
 Carrier proteins can be further sub-categorized as subclasses or superfamilies of proteins 
based upon function and structure. GLUT1 is a member of the major facilitator superfamily 
(MFS) (6). These proteins are ubiquitously expressed across all three domains of organisms: 
Archaea, Bacteria, and Eukaryota. They catalyze both passive or secondary active transport of a 
variety of molecules including simple sugars, complex oligosaccharides, drugs, amino acids, ions 
and other molecules utilizing uniport, antiport and symport mechanisms (7). They share a 
common fold, with the majority containing 12 membrane spanning α-helices and cytoplasmic N- 
and C-termini. The proteins average a length of 400-600 amino acids and comprise two six helix 
halves connected by a large intracellular loop between transmembrane domains 6 and 7 (8,9).  
Glucose Homeostasis 
 Glucose occupies a central role in mammalian energy metabolism serving as a preferred 
metabolite in the brain and exercising skeletal muscle. Mammals maintain blood glucose within 
narrow limits (4-12 mM) despite continuously variable carbohydrate ingestion and elimination 
(10). Fifty to seventy-five percent of total glucose metabolism is used to fuel brain metabolism 
(11). 
Why Study Glucose Transport?  
 Glucose through its role as a substrate for ATP synthesis is a critical energy source for life 
on Earth. The human brain consumes approximately 50-75% of the glucose supply in the human 
body while comprising ~2% of total body mass [11]. In addition, glucose serves as an important 
precursor for biomolecule synthesis and plays a significant role in cell signaling. Through 
different mechanisms, glucose can regulate gene transcription, enzyme activity, hormone 
secretion and the activity of glucoregulatory neurons (12). The cellular uptake of glucose 
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precedes any events involving metabolism and signaling and is controlled by the level of glucose 
transporter expression at the cell surface. Three families of transporters have been identified for 
glucose transport: the sodium driven glucose transporter (SGLT), the SWEET transporters 
(SLC50), and the facilitative glucose transporters (GLUT) (13).  
The Glucose Transporter Family 
 The GLUT family of passive sugar transporters maintains glucose hemostasis throughout 
all cell types but in a tissue specific manner (12,14). The GLUT transporter family comprises 14 
members that can be grouped into 3 different classes based upon sequence similarity: class I: 
GLUT1-4 and GLUT14 a gene duplication of GLUT3, class II: GLUT5, 7, 9, and 11 and class 
III: GLUT6, 8, 10, 12, and 13, (GLUT13 is the proton driven myoinositol transporter HMIT) 
(Table 1) (12,14). Each class is characterized by variable substrate specificities including several 
aldoses, myo-inositol, urate, glucosamine, and ascorbate (12,14). The entire family has a 
sequence identity ranging from 28 to 65% and shares specific sugar transporter sugar motifs 
(12,14). All GLUTs have the canonical MFS transporter fold and a single N-linked glycosylation 
site. Class III can be differentiated from class I and II by the position of the glycosylation site 
which is found in exofacial loop 1 in class I and II GLUTs and in exofacial loop 5 in class III 
GLUTs (15).  
 GLUT1 is expressed in almost all human cell types but is most highly concentrated in 
erythrocytes and at the blood brain barrier (16). GLUT1 was one of the first membrane 
transporters to be identified, purified, and cloned (17-19). GLUT2 has a low apparent affinity for 
glucose, can also transport galactose, mannose and fructose with low affinity but transports 
glucosamine with high affinity (20,21). GLUT2 is the major glucose transporter of hepatocytes, 
and is expressed in intestinal absorptive cells, kidney cells, and some neurons and astrocytes (22-
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24). Although GLUT2 is highly expressed in rodent pancreatic α- and β- cells, GLUT1 is the 
major transporter expressed in human pancreatic α- and β- cells (22,25). GLUT3 displays higher 
apparent affinity and high maximum turnover number for glucose than the other class I proteins, 
and its principal physiological substrate is D-glucose (26). GLUT3 is the primary mediator of 
glucose uptake in neurons (27). GLUT4 is expressed most prominently in adipocytes, skeletal 
muscle and cardiomyocytes, residing primarily in intracellular membrane compartments (28). 
GLUT4 is the insulin-responsive glucose transporter. Defects in insulin-mediated GLUT4 
translocation to the plasma membrane coupled with a defect in insulin secretion from pancreatic 
beta cells and insulin resistance in the liver results in type 2 diabetes (29). GLUT5 was the first 
of the class II GLUTs identified and it has a high specificity for fructose but does not transport 
glucose or galactose (30-32). The small intestine regulates dietary fructose absorption where 
GLUT5 mediates fructose transport across the apical membrane (33). It is present in low levels 
in kidney, brain, fat, testes, and muscle (33). GLUT9 has two forms GLUT9a and GLUT9b with 
different cytoplasmic tails. Both forms are expressed in the liver and kidney while GLUT9a is 
also expressed in the intestine, leukocytes and chondrocytes (34). GLUT9 is a urate transporter 
and transport is not competitively inhibited by glucose or fructose (35). GLUT9-mediated urate 
transport is inhibited by phloretin but not by cytochalasin B (CB) (36). GLUT8 is only expressed 
in an intracellular compartment (37). GLUT8 mutations resulting in its cell surface expression 
suggest that GLUT8 has a high affinity for glucose, while also showing affinity for fructose and 
galactose and inhibition by CB (37). GLUT8 is expressed at high levels in the testis and at lower 
levels in the cerebellum, adrenal gland, liver, spleen, brown adipose tissue, and lung (38).  
 GLUT13 or HMIT is a H+/myo-inositol co-transporter (39). While transport by HMIT is 
inhibited by phloretin, phlorizin, and CB, HMIT does not transport glucose [39]. It is expressed 
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most highly in the brain but also in brown adipose tissue and in the kidney [39]. GLUTs 6, 7, 10, 
11, 12, and 14 were identified through the sequencing of the human genome. While each is 
capable of transporting hexoses when expressed in Xenopus oocytes the primary physiological 
substrates for most of these proteins have not been identified definitively (40). 
GLUTs and Disease 
 Due to the ubiquitous expression of GLUTs and their role in maintaining glucose 
homeostasis, disruption to both the regulation of GLUT localization/expression and mutations in 
GLUT transporter gene sequences can have effects on both sugar metabolism and the physiology 
of organ systems where the GLUTs are expressed.  
 While mutations in glucose transporter genes are rare, they can result in severe diseases 
that render sugar consumption impossible. For example, mutations in both GLUT1, resulting in 
GLUT1 deficiency syndrome, and GLUT2, resulting in Fanconi-Bickel syndrome, eliminate the 
ability to ingest sugar without deleterious effects. The first case of GLUT1 deficiency syndrome 
(G1DS) was found to have a null allele producing hemizygosity and haploinsufficiency of the 
GLUT1 gene (41). As of 2012, there were approximately 200 known cases of G1DS resulting 
from different mutations to the GLUT1 gene (42). These mutations give rise to a wide array of 
phenotypes, but they are generally characterized by a low cerebral glucose supply, due to the role 
GLUT1 plays in transporting glucose across the blood brain barrier (43). Lifelong adherence to a 
ketogenic diet can mitigate some of these symptoms if the disease is detected early enough. 
Fanconi-Bickel syndrome is an autosomal recessive disorder where patients can suffer from 
hepatomegaly, nephropathy, fasting hypoglycemia, sugar intolerance, and growth retardation 
(44). For some of the identified mutations, GLUT2 function is abolished and these patients do 
not tolerate simple sugars in their diets (45). 
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 In addition to diseases directly arising from mutations of GLUTs, glucose transporters and 
their trafficking also play a significant role in metabolic disorders. For example, in type II 
diabetes, glucose uptake into muscle and fat is impaired due to insulin resistance (46). The 
transport of glucose into muscle and fat tissue is the rate-limiting step for glucose metabolism in 
these tissues and is mediated by GLUT4 (47). In response to impaired insulin secretion GLUT4 
trafficking to the cell-surface is downgraded, disrupting GLUT4 mediated entry of glucose into 
fat and muscle cells (48,49). An understanding of how GLUT4 is trafficked and transports sugar 
is central to our ability to treat type II diabetes and remains under active investigation. 
 Cancer cells depend on glucose metabolism for energy production and the synthesis of 
biomass to sustain proliferation. The “Warburg effect” refers to human and animal tumor cells 
preference for conversion of glucose to lactate in the presence of oxygen for energy production 
(50). Studies have demonstrated elevated expression of glucose transporters in most cancers and 
some cancers show abnormal transporter expression patterns compared to healthy tissues 
(12,15,51). In particular, high expression of GLUT1 has been documented in a wide range of 
cancer types including lung, brain, breast, bladder, cervical, colorectal, esophageal, 
hepatocelluar, head and neck, gastric, ovarian, renal cell, pancreatic, thyroid, penile, and uterine 
cancers (51). GLUTs pose an interesting avenue both as biomarkers and drug targets for cancer 
therapeutics.  
GLUT1 as an Ideal Model System 
 Studying glucose transport is complicated for a number of reasons. Most tissues express 
multiple GLUTs and the profile of cellular glucose transporter expressions alters upon cell 
isolation and culture. Furthermore, cell culture conditions can promote hypoxia-induced gene 
expression, the up regulation of glycolysis and changes in the level of cell-surface GLUT 
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expression. In addition to phenotypic changes, cell culture can result in a heterogeneous 
population of cell sizes with an attendant range of surface area:volume ratios that make accurate 
transport determinations difficult to achieve.  
 On the other hand, the human red blood cell (RBC) provides an ideal model system for 
studying glucose flux. GLUT1 comprises 10-20% of RBC integral membrane proteins and 
mediates >99% of glucose transport across the plasma membrane (52). RBCs are relatively 
uniform in size and shape, are easily isolated form whole blood and, because rates of glucose 
transport are some 500-fold greater than rates of glucose metabolism, human RBCs are not 
subject to isolation-promoted phenotypic changes in metabolism (53,54). Importantly, an 
established purification protocol was developed by two groups that produces a significant 
amount of pure functional GLUT1 reconstituted in native erythrocyte lipids at greater than 90% 
purity (17,18). The availability of human erythrocytes, coupled with their uniformity in both size 
and surface area and a robust purification protocol have resulted in more than 70 years of 
sophisticated kinetic and biophysical analyses of GLUT1. However, analysis of the role of 
primary structure of GLUT1 requires alternative cell systems as mutagenesis of GLUT1 and its 
expression in red cells is not practical.  
GLUT1 Localization and Function 
 GLUT1 is expressed most highly in erythrocytes, cardiac muscle cells, smooth muscle, 
astrocytes and in the blood brain barrier (BBB) endothelial cells (55). Human red blood cells 
contain 250,000-500,000 copies of GLUT1, where it catalyzes glucose and galactose transport 
(56-58). Due to its presence in the BBB, GLUT1 plays a fundamental role in delivering glucose 
to the central nervous system (59,60). Approximately 20-40% of total cellular GLUT1 is 
expressed at the cell surface of cardiomyocytes, BBB endothelial cells, adipocytes and astrocytes 
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(61-64). Intracellular GLUT1 is located within the endoplasmic reticulum, the Golgi, and 
endosomes, where endosomal GLUT1 cycles between the plasma membrane and endosomal 
compartments in cardiomyocytes in an AMP kinase and phosphatidylinositol 3-kinase dependent 
manner (61).  
 Glucose uptake is rate-limiting for metabolism in cells where glucose transport capacity is 
low relative to the rate of sugar metabolism. These cells typically respond acutely to metabolic 
stress with accelerated net sugar uptake and increased glucose metabolism (64-66). In 
cardiomyocytes, smooth muscle, and astrocytes glucose transport is rate limiting and transport 
regulation is integral for maintaining metabolic homeostasis. In erythrocytes and endothelial 
cells, however, glucose is transported some 50-500 times more rapidly than it is metabolized 
(53,67). Yet, RBCs respond to ATP depletion with 4- to 10-fold increased glucose uptake, and 
endothelial cells respond to acute hypoglycemia with 4- to 10-fold increased glucose uptake and 
respond to chronic hypoglycemia with increased GLUT1 expression (16,68-71). These 
observations have resulted in the rejection of earlier lore that glucose transport is only regulated 
in cells where transport is rate-limiting for cellular glucose metabolism (72). Rather, glucose 
transport appears to be regulated both in cells where transport is rate-limiting for cellular glucose 
metabolism and in cells which serve to deliver glucose to other tissues where glucose is a 
primary metabolic fuel (55,73). 
GLUT1 Substrate Specificity 
 GLUT1 transports both D-glucose and D-galactose, but it has a 10-fold higher affinity for 
D-glucose (74). Competitive inhibition studies suggest that the hydroxyl groups at C1 and C6 of 
D-glucose are solvent exposed at the sugar uptake site in the exofacial (e2) conformation while 
the hydroxyl at C1 is solvent exposed in the e1 conformation at the sugar exit site (74,75). 
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Hydrogen bonding is suggested at the hydroxyl groups at C1, C3, and possibly C4 at the uptake 
site while the hydroxyl group at C6 is involved in hydrogen bonding at the e1 site (74,75). 
Additionally, both transport and crystallization studies of GLUT1 demonstrate that there is no 
difference in the binding and transport behavior by GLUT1 towards α- and β-D-glucose 
suggesting that the position of the C1 hydroxyl is unimportant for hydrogen bond formation 
(76,77). 
GLUT1 Ligand Binding 
 GLUT1 ligand binding studies allow for the direct quantitation of the number of ligand-
binding sites per transporter and allow for analysis of possible drug targets for GLUT1. 
Determination of the sidedness of ligand binding to GLUT1 can be accomplished using two 
approaches: direct measurements of ligand binding to GLUT1 to examine the effects of exo- and 
endofacial substrates on ligand binding or by examining the effects of inhibitors on glucose 
transport. GLUT1 interacts with and is regulated and/or inhibited by several different molecules. 
Disaccharides such as maltose and oligosaccharides, such as maltotriose are inhibitors of GLUT1 
mediated sugar transport (78). As the size of the oligosaccharide increases the strength of 
inhibition decreases (78). The exofacial site of GLUT1 can also interact with and become 
inhibited by a diverse array of molecules including: phloretin, ethylidene glucose, green tea 
catechins, and flavonoids (79-82). Similarly, the endofacial site of GLUT1 interacts with and is 
inhibited by cytochalasin B, forskolin, and methylxanthines including caffeine (83-85). In 
addition, the transporter interacts with and is allosterically inhibited by ATP (86,87).  
 Building upon earlier kinetic and transport studies of NaKATPase that recognized that the 
enzyme isomerized between at least two states - e1 and e2- and that these states presented ligand 
binding cavity at endofacial and exofacial surfaces of the membrane respectively, the sugar 
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transport community has termed the endofacial and exofacial conformations of the glucose 
transporter e1 and e2 conformations respectively (88-90).  
 Early purifications of red blood cell GLUT1 demonstrated that cytochalasin B and 
exofacial inhibitor binding to GLUT1 are mutually exclusive (91-93). However, later studies 
using purified GLUT1, red cell membranes, and intact red cells showed interacting, negatively 
cooperative, e2 (exofacial) and e1 (endofacial) ligand binding sites (79,83,94). For example, 
phloretin, an e2 ligand, exerts a strongly negatively cooperative effect on CB binding to the 
endofacial site (79). At low concentrations, maltose and ethylidene glucose enhance CB binding 
to GLUT1, but at higher concentrations these ligands have a negative cooperative effect, 
suggesting that the e2 and e1 sites are not mutually exclusive (79,80). Additional studies of CB 
binding to purified GLUT1 showed a stoichiometry of 1 molecule of CB per 2 molecules of 
GLUT1. Treatment of the purified transporter with reductant changed the binding stoichiometry 
to 1 molecule of CB to 1 molecule GLUT1 (17,95,96).  
GLUT1 Kinetics 
 Due to the absence of a 3-dimensional structure, GLUT1 behavior and transport models 
have been developed using kinetic measurements. Several common experimental methods were 
developed to analyze the transport behavior of GLUT1, and obtain the VMAX  and KM for both 
sugar exit and entry under different conditions (89,97,98). Three main types of experiments have 
been developed: zero-trans (ZT), equilibrium exchange (EE) and infinite-cis (IC). ZT 
experiments measure unidirectional transport of sugar over a wide range of concentrations of 
sugar from one side (cis) of the cell to the other (trans) where no sugar is initially present. ZT 
experiments can be used to determine kinetic parameters for both sugar uptake and efflux. In EE 
experiments the total concentration of sugar is varied but is the same on both sides of the 
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membrane (i.e. the system is at equilibrium), and the unidirectional transport of radio-tracer 
sugar is measured. IC experiments begin with saturating concentrations of sugar on one side and 
vary the concentration of sugar on the other side of the membrane. IC experiments then measure 
either the rate of net or unidirectional transport from the saturating sugar concentration to the 
opposite side. Infinite cis-exit, for example, measures that concentration of sugar which half-
maximally inhibits saturated net exit.  
GLUT1 Steady-State Kinetics 
 In order to study steady-state kinetics (the concentration dependence) of sugar transport, 
the concentrations of GLUT1 sugar intermediates involved in transport must be unchanged 
during the transport assay. In practice, this means that transport measurements must be made at 
very early time points where the amount of sugar in the cell increases or decreases linearly with 
time. This requires either making measurements in <1s at 37 °C, lowering the temperature to 4 
°C, or using sugar analogs that are transported at slower rates. Despite these challenges, GLUT1 
is the most extensively characterized of the GLUTs due to the experimental advantages posed by 
the human erythrocyte (99). Transport measurements of metabolizable sugars are simplified in 
red cells due to their slower metabolic processes compared to conventional cells (100). However, 
GLUT1 mediated transport has also been characterized in a variety of systems including 
Xenopus oocytes, mammalian cell lines, and yeast (101-105).  
 Studying glucose transport necessitates the use of radiolabeled glucose analogs as tracers 
for sugar movements and the use of specific inhibitors to arrest transport. In order to more 
effectively measure transport rates, glucose analogs are used that are not metabolically 
processed. Two such analogs are 2-deoxy-D-glucose (2DG) and 3-O-methyl-D-glucose (3MG) 
(106). 2DG is used to simplify undirectional sugar uptake measurements as it is phosphorylated 
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by hexokinase to form 2-deoxy-D-glucose-6-phosphate, which is not a substrate for further 
metabolism and is trapped inside the cell (107). 3MG is not metabolized and can be used to 
measure transport into or out of the cell (108). 
Transport Kinetic Asymmetry  
 GLUT1 is an asymmetric transporter (109). This means that VMAX and KM for sugar exit 
into sugar sugar-free medium (ZT exit) are not identical to VMAX and KM for entry into sugar-free 
cells (ZT entry). This behavior does not violate the passive nature of transport because under 
equilibrium exchange conditions (where intracellular [sugar] = extracellular [sugar]), uptake 
must equal efflux and, at sub saturation [sugar],  
uptake = efflux = k[sugar] where k = VMAX / KM. 
Thus, the only requirement of an asymetric, passive transporter is that: VMAX / KM for exit = VMAX 
/ KM for entry. At low temperatures GLUT1 sugar transport in human red cells is increasingly 
asymmetric. At 4 °C VMAX and KM for exit are 10X greater than the equivalent parameters for 
entry (109). In red cell ghosts asymmetry is greatly diminished, due to the loss of allosteric 
regulation by cytoplasmic ATP (86,87,110). Simulations of sugar transport demonstrate that 
asymmetric red cell glucose transport allows cells to equilibrate much more rapidly with 
extracellular sugar, such that glucose-depleted red cells emerging from glucose-consuming 
organs such as the brain or placenta are more readily refilled upon reentering glucose-rich 
circulation (87,111).  
Accelerated Exchange 
 Accelerated exchange transport describes the stimulatory effect that the presence of sugar 
at the trans side of the membrane exerts on the rate of unidirectional sugar flux from the cis to 
the trans side. In red cells preloaded with sugar, unidirectional sugar uptake is accelerated several 
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fold when compared with unloaded cells, similarly unidirectional sugar exit is accelerated by 
extracellular sugar (112). In EE accelerated exchange experiments, intracellular [sugar] = 
extracellular [sugar], and unidirectional sugar uptake/exit is measured using tracer sugars, while 
in infinite trans experiments the concentration of sugar at the trans side is saturating and the 
concentration of sugar at the cis side is varied. Unidirectional radio tracer sugar flux is then 
measured in the direction cis to trans. At 4 °C, VMAX and KM for EE are 50-fold greater than for 
ZT sugar uptake and 5- to 10-fold greater than for ZT sugar exit (113). As temperature increases, 
the difference between exchange and net transport parameters decreases (109). The availability 
of cytoplasmic ATP exaggerates accelerated exchange in red blood cells by suppressing the 
maximum rate of ZT sugar uptake and by decreasing KM for EE (114). Unlike GLUT1, GLUT4 
does not demonstrate trans-acceleration (115). Substitution of GLUT4 transmembrane (TM) 
domain 6 into GLUT1 eliminates trans-acceleration in GLUT1 while substitution of GLUT1 
TM6 into GLUT4 enables GLUT4 to catalyze trans-acceleration. This demonstrates the GLUT1 
TM6 is necessary and sufficient for trans-acceleration, possibly by slowing transport associated 
conformational changes in the absence of intracellular sugar (116).  
Transient Kinetics 
 Transient kinetic studies allow for monitoring of the transition of one conformational state 
of GLUT1 to another. Transient kinetic studies of purified reduced GLUT1 by intrinsic 
tryptophan fluorescence demonstrated that exofacial ligands can trap GLUT1 in one 
conformational state that subsequently relaxes to a second state upon dilution of exofacial ligand 
(117). Studies with non-reduced purified GLUT1 demonstrate that micromolar levels of 
exofacial ligand promote one conformational state whereas higher micromolar levels promote a 
second inhibited state (118). Rapid quench transport measurements in red cells show transient 
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acceleration of glucose uptake after dilution of extracellular maltose. Quench-flow analysis of 
sugar uptake by red cells demonstrates three observable, sequential phases of sugar uptake: the 
first, a rapid but quantitatively small phase describing sugar association with GLUT1 (1 mol 
sugar: 1 mol GLUT1), the second, fast phase, shows sugar import into cytosol and accounts for 
2/3 sugar uptake by red cells and the third slowest phase shows a slowing of transport as 
endofacial sugar binding sites become saturated (119). This same study also demonstrated the 
ability of GLUT1 to occlude or “trap” a sugar molecule within a central cavity when 
conformational changes are “stopped” by CB or phloretin (119).  
GLUT1 Cooperativity 
 Sugar and ligand binding to the transporter have been demonstrated to exert a cooperative 
effect on binding of a second ligand or on sugar transport. Both cis- and trans-cooperative effects 
are seen. Specifically, trans-cooperative effects are seen on both entry and exit of unidirectional 
sugar flux. The experimentally determined KM for infinite trans glucose or 3MG exit from RBCs 
is consistently 5- to 10-fold lower than predicted by standard transport models based on 
measurements from ZT and EE sugar transport experiments, suggesting that saturation of the 
external sugar binding site increases the affinity of the internal sugar binding site(s) for sugar 
(114,120-123). A second trans effect has been demonstrated by the e1 inhibitors CB and 
forskolin. At low concentrations, both ligands increase sugar uptake compared to unliganded 
GLUT1 while inhibiting transport as the concentration is raised (80). Similarly, exofacial 
maltose or maltotriose stimulate sugar uptake at low concentrations before inhibiting uptake as 
the concentration is raised, thus unidirectional sugar uptake is stimulated by the presence of both 
extra- and intracellular inhibitors at low concentrations (78). Additionally, ligand binding also 
demonstrates both cis- and trans-cooperativity. Phloretin has a strong negatively cooperative 
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effect on CB binding (79). Similarly, maltose and ethylidene glucose have a negatively 
cooperative effect on CB binding at high concentrations but a positively cooperative effect at low 
concentrations of maltose and ethylidene glucose (79,80). Similarly, at the endofacial site, 
derivatives of the e1 ligand forskolin have different effects on CB binding. While forskolin is a 
direct inhibitor of CB binding to GLUT1, derivatives of forskolin can have a stimulatory effect 
(7DeA-FSK) and a stimulatory followed by inhibition effect (1DeO-FSK) (84).  
Kinetic and Ligand Binding Derived GLUT1 Transport Models. 
 In absence of a 3D crystal structure, the majority of transport models for GLUT1 were 
developed using kinetic and ligand binding experiments. The two most widely described models 
to explain carrier-mediated transport are the alternating conformer or simple carrier model and 
the fixed-site carrier model.  
 The first proposed model was the mobile carrier hypothesis, where a glucose specific 
molecule bound glucose on one side of the membrane, moved across the membrane and 
deposited the translocated glucose molecule inside the cell (124). While this model was 
physically improbable, it led to the development of the alternating access carrier model (Figure 
1.2). The alternating access carrier model proposes that the transporter alternately presents sugar 
import (e2) and sugar export sites (e1). Sugar binding to the e2 site catalyzes a conformational 
change that results in the sugar molecules translocation across the membrane and released from 
the e1 site. Multiple rounds of transport are processed either by reconversion of e1 to e2 
conformation or substrate binding and translocation. However, the GLUT1 monomer presents 
only one site, e1 or e2 at any one time (125). Further kinetic analysis suggested an intermediate 
occluded state (119). Thus, the transporter when in an e2 conformation binds sugar, and then 
undergoes a conformational change through an occluded state to the e1 state where the sugar is 
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Figure 1.2: The alternating access carrier model. GLUT1 presents either an e2 outward 
facing site or e1 inward facing site. Glucose molecules represented by yellow circles are 
transported by binding at the e2 site, inducing a conformational change through an occluded 
state to the e1 state where the sugar is released. Transport inhibitors maltose (e2, orange) and 
cytochalasin B (e1 green) bind to the transporter and lock it in e2 or e1 conformations, 
respectively.  
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inside the cell. In order to continue translocating sugar into the cell the transporter must relax 
from e1 to the occluded state and then to the e2 state where it binds sugar again to repeat the 
cycle. However, the simple carrier is not compatible with all experimental observed transport 
and ligand binding studies, specifically the demonstrated ability of the transporter to interact with 
multiple substrates simultaneously.  
 Alternatively, the fixed-site carrier model predicts that ligands or sugars can bind at both 
the e1 and e2 sites simultaneously (Figure 1.3) (125,126). This model proposes a higher-affinity 
exofacial binding site and a lower-affinity endofacial binding site, allowing for the greater VMAX 
and KM observed for sugar exit than entry under saturating extracellular sugar concentrations. 
This model allows sugar or inhibitors to interact with the transporter at both sides of the 
membrane at the same time. During transport, bound sugars are released into a central cavity 
whence they exchange with e1 and e2 binding. The sugars then dissociate from the carrier to be 
released at the opposite side of the membrane.  
 23 
 
Figure 1.3: The fixed-site carrier model. In the fixed site carrier model sugar (yellow circles) 
can bind at either the e2 or e1 site simultaneously. Transport is accomplished through a central 
cavity with room for two glucose molecules to pass each other.  
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 The fixed-site carrier explains how the VMAX for exchange can be equal for two substrates 
with dissimilar translocation rates. Additionally, it is compatible with the multiphase nature of 
transport, specifically the rapid, fast and slow phases of glucose transport, potentially describing 
binding at e2, translocation and rebinding at e1, and the slow release of the substrate into the 
cytosolic domain of the transporter. 
 However, neither the simple nor fixed site carrier models can explain the low intracellular 
KM observed in infinite-cis entry or infinite-trans exit experiments. In addition, the fixed site 
carrier model fails to explain allosteric phenomena such as the cooperative binding of 
modulators or inhibitors like ATP, CB, and maltose.  
GLUT1 Structure Function Relationship 
 GLUT1 is a 492 amino acid protein with the canonical MFS protein fold containing 12 
membrane spanning alpha-helices, N- and C-termini in the cytoplasm, an N-linked-glycosylation 
site at asparagine 45 and a large intracellular loop connecting transmembrane domains 6 and 7. 
(Figure 1.4) Due to the difficulty of membrane protein crystallography, early studies focused on 
hydropathy analysis, scanning glycosylation mutagenesis, mass spectrometry of GLUT1 
proteolytic cleavage sites, circular dichroism, fourier transform infrared spectroscopy, and 
analysis of the crystal structures of other MFS transporters combined with homology modeling 
techniques (127-130). Together, these analyses suggested that there are 12 hydrophobic TMs, 
with 8 TMs being highly amphipathic forming a water filled channel for sugar translocation (75). 
TMs 1 and 8 are poised at the limits of membrane solubility, such that TM1 is released by 
trypsin digestion of GLUT1 and TM8 is released by addition of endofacial ligand to trypsinized 
GLUT1 (128).  
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Figure 1.4: GLUT1 primary amino acid sequence and membrane topology from 4PYP 
crystal structure. Transmembrane domains are color-coded based upon their role in the 
transporter. TMs 1, 4, 7, and 10 are colored purple and with TMs 2, 5, 8, and 11, colored blue, 
form the aqueous pore. TMs 3, 6, 9, and 12 act as scaffold domains outside the transport pore. 
The N-linked Glycosylation site at N45 is represented as is the large intracellular loop 
connecting TMs 6 and 7 and containing three short helical regions. 
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MFS Structure 
 Membrane protein crystallography has been much more technically challenging than that 
of soluble proteins. Only 1.7% of over 130,000 structural coordinates deposited in the Protein 
Data Bank (PDB) represents membrane proteins. Of these only 707 out of 2250 are from unique 
proteins. The first MFS transporters crystalized were the lactose/H+ symporter LacY in both e1 
open and e2 partially occluded conformations and the glycerol-3-phosphate/Pi antiporter GlpT in 
an e1 open conformation (8,9). In total, 20 different MFS proteins have been crystalized in 
different liganded states and conformations including: e1 open, e1 partially occluded, e2 open, 
and e2 partially occluded.  
Sugar Transport Protein Structure 
 Sugar transport proteins from both bacteria and human have been crystalized. The 
xylose/H+ symporter, XylE from Escherichia coli was crystallized in e2 occluded, e1 occluded, 
and e1 open conformations with multiple different ligands (6,131). It shares 25% sequence 
homology and 58% sequence similarity with GLUT1. The fucose/H+ symporter (FucP) from E. 
coli was crystalized in an e2 open conformation (132). From, Bos taurus and Rattus norvegicus, 
GLUT5, a fructose uniporter and member of the GLUT family, was crystalized in both an inward 
open and outward open conformation (133). From Homo sapiens GLUT3, a glucose uniporter 
was crystalized in both e2 open and e2 occluded conformations (134). Finally, GLUT1 was 
crystalized in an e1 open conformation with both β-NG, a glycodetergent and CB (4PYP, 5EQI) 
(77,135). All of these structures contained the canonical MFS fold with 12 TM alpha helices, N- 
and C- termini in the cytoplasm, and a large semi-structured loop between TMs 6 and 7. 
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GLUT1 Structure 
 The first crystal structure of GLUT1 was obtained in 2014 in an inward-open conformation 
at 3.15 Å resolution. (Figure 1.5) This was aided by the elimination of the N45 glycosylation, a 
point mutation at E329Q which was predicted to lock the transporter in an inward open 
conformation, by crystallization at 4 °C to restrain conformational changes, and using the 
detergent nonyl-β-D-glucopyranoside (β-NG) to further stabilize the inward open conformation 
(77). The structures with inhibitors were described in 2016 with inhibitors occupying the central 
cavity replacing the β-NG (135). Structures of GLUT1, GLUT3, GLUT5 and the related sugar 
binding MFS proteins all support the alternating access simple carrier model although alternative 
interpretations of the crystal structure are available (136). 
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Figure 1.5: Crystal structure of GLUT1. A. The crystal structure of GLUT1 in an e1 open 
conformation, pdb code 4PYP. Scaffold helices (3, 6, 9, 12) are colored green. Aqueous pore 
helices are colored pink (1, 4, 7, 10) and blue (2, 5, 8, 11). B. GLUT1 inward open 
conformation viewed from the cytoplasm. Helices are labeled H1 – H12. 
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Oligomeric Structure 
 The crystal structure of GLUT1 represents the monomeric form of GLUT1 suggesting that 
the catalytic unit of the transporter is a monomer. Freeze-fracture electron microscopy and 
hydrodynamic size analysis of detergent-solubilized GLUT1 suggest that purified, non-reduced 
GLUT1 is a tetramer and reduced GLUT1 is a dimer (95,102,122,137). Chemical cross linking 
and Bioluminescent Forster Resonance Energy Transfer (BRET) support this conclusion 
(102,138). Additionally, purified GLUT1 binds 0.5 mol CB per mol GLUT1 while reduced 
purified GLUT1 binds 1 mol CB per mol GLUT1, suggesting that reduced dimeric GLUT1 is an 
unlinked dimeric protein comprising one catalytic site per monomer (17,95,96). While GLUT1 
forms homo-oligomers, the available evidence suggests that it does not form hetero-oligomers 
with GLUT3 (139). Chimeric proteins of GLUT1 and GLUT3 were used to probe the regions 
necessary for homo-oligomerization. Substitution of GLUT1 TM9 into GLUT3 led to 
tetramerization of GLUT3 while substitution of GLUT3 TM9 into GLUT1 converted GLUT1 
into a dimer. However, GLUT1(GLUT3 TM9) was still able to catalyze cis-allosteric behavior with 
maltose stimulation of sugar uptake(140).  
GLUT1 Tetramerization Model 
 Neither the simple carrier nor the fixed-site carrier can fully explain all of the kinetic and 
ligand binding behavior observed in GLUT1. To address the allosteric, and cooperative 
behaviors, CB binding stoichiometry, and oligomerization, a hybrid model of simple and fixed 
site carriers has been proposed. In this model, each individual monomer of GLUT1 functions as 
a simple carrier. The carrier subunits are functionally coupled in an obligate anti-parallel fashion 
where each tetramer is made up of a dimer of dimers (Figure 1.6) (141). Each subunit would 
only present a single substrate binding site either e2 or e1. Ligand induced conformational 
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changes would necessitate an equal and opposite conformational change from its functionally 
linked subunit. Sugar would be transported in both directions or unidirectional uptake would 
proceed with two subunit undergoing the conformational change in the absence of sugar.  
 
 
Figure 1.6: GLUT1 tetramer transport model. The GLUT1 tetramer is shown as a dimer of 
4 alternating access carriers. The two upper molecules are shown as a cross-section and the 
two lower molecules are shown from inside the cell. In the absence of inhibitor, glucose (red) 
binds at the high affinity binding site inducing a slow conformational change where it is 
released inside the cell. All four subunits undergo the conformational change. In the presence 
of low concentrations of inhibitor (blue) glucose binds with increased affinity and 
translocation is faster than in the absence of inhibitor. The inhibitor locks two subunits in their 
original orientation.  
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Overall Conclusions and Research Purpose 
  Understanding the relationship between GLUT1 structure and function is critical to 
reconciling kinetic, biochemical and structural information. While the available structural 
information would confirm the simple-carrier model, we know that the simple carrier model does 
not allow for simultaneous ligand binding at opposite sides of the membrane. It is therefore 
necessary to understand the shortcomings in both the biochemical and structural analysis. 
Utilizing the available crystal structures of GLUT1 and other MFS transporters, it is possible to 
more closely examine potential substrate binding sites and transporter transitions.  
 This work attempts to use structural information to understand several interesting 
phenomena observed in GLUT1. Specifically, we utilized molecular docking to search for 
residues that interact with glucose and other ligands in the transport cycle. While molecular 
docking can suggest important residues for hydrogen bonding and steric interference it is 
necessary to validate this through biochemical testing. To this end, we disrupted the potential 
hydrogen bonding residue Q282 observed to form hydrogen bonds with glucose in all four 
conformations of GLUT1. Not only did this mutation decrease glucose transport, it also 
eliminated cis-allostery observed by maltose stimulation of 2DG uptake. However, this mutation 
did not eliminate trans-allostery.  
 In addition to studying ligand binding through structural analysis, the transitions between 
exo- and endofacial conformations of the GLUT1 structure were also examined. Studies in other 
membrane proteins have suggested an important role for the amino acid glycine in both 
stabilizing alpha-helices in the form of GXXXG motifs and in acting as gating hinges. This work 
examines disruptions to GXXXG motifs, dynamic alpha-helix resident glycines and glycines that 
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are conserved throughout the GLUT family through the ability to transport 2DG.  
 Finally, while examining the monomeric GLUT1 structure is important to understanding 
ligand binding it cannot give a full understanding of transport behavior. This work uses transport 
deficient GLUT chimeras to examine both cis- and trans-allostery and the role that 
oligomerization plays. Utilizing this knowledge helps to develop a full model for the GLUT1 
mediated glucose transport cycle.  
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CHAPTER 2: 
Reconciling contradictory findings: Glucose transporter 1 (GLUT1) functions 
as an oligomer of allosteric, alternating access transporters 
 
This chapter was published in the Journal of Biological Chemistry in 2017, and can be found 
using the following reference: 
 
Lloyd, K., et al., Reconciling contradictory findings: Glucose transporter 1 (GLUT1) functions 
as an oligomer of allosteric, alternating access transporters. J Biol Chem, 2017. 
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Abstract 
Recent structural studies suggest that glucose transporter 1 (GLUT1)-mediated sugar transport is 
mediated by an alternating access transporter that successively presents exofacial (e2) and 
endofacial (e1) substrate-binding sites. Transport studies, however, indicate multiple, interacting 
(allosteric), and co-existent, exo- and endofacial GLUT1 ligand-binding sites. The present study 
asks whether these contradictory conclusions result from systematic analytical error or reveal a 
more fundamental relationship between transporter structure and function. Here, homology 
modeling supported the alternating access transporter model for sugar transport by confirming at 
least four GLUT1 conformations, the so-called outward, outward-occluded, inward-occluded, 
and inward GLUT1 conformations. Results from docking analysis suggested that outward and 
outward-occluded conformations present multiple β-D-glucose and maltose interaction sites, 
whereas inward-occluded and inward conformations present only a single β-D-glucose 
interaction site. Gln-282 contributed to sugar binding in all GLUT1 conformations via hydrogen 
bonding. Mutating Gln-282 to alanine (Q282A) doubled the KM(app) for 2-deoxy-D-glucose 
uptake, eliminated cis-allostery (stimulation of sugar uptake by subsaturating extracellular 
maltose) but not trans-allostery (uptake stimulation by subsaturating cytochalasin B). Cis-
allostery persisted, but trans-allostery was lost in an oligomerization-deficient GLUT1 variant in 
which we substituted membrane helix 9 with the equivalent GLUT3 sequence. Moreover, 
Q282A eliminated cis-allostery in the oligomerization variant. These findings reconcile 
contradictory conclusions from structural and transport studies by suggesting that GLUT1 is an 
oligomer of allosteric, alternating access transporters in which 1) cis-allostery is mediated by 
intra-subunit interactions and 2) trans-allostery requires inter-subunit interactions. 
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Introduction 
 Glucose plays a crucial role in mammalian energy metabolism serving as a preferred 
metabolic substrate in brain and exercising skeletal muscle (100). However, the molecular 
mechanism by which glucose enters and exits cells is the subject of considerable controversy 
(136). Blood brain barrier, glial and erythrocyte sugar transport are mediated by the transport 
protein GLUT1 (19). Recent structural studies suggest that GLUT1-mediated sugar transport is 
mediated by a carrier that alternately presents exofacial (e2) and endofacial (e1) substrate 
binding sites (77,131,133,134,142). Transport studies, on the other hand, demonstrate multiple, 
interacting, co-existent exo- and endofacial ligand binding sites and e1 ligand-induced sugar 
occlusion within GLUT1 (78-80,83,84,113,119,143,144). The present study asks whether these 
apparently contradictory conclusions are mutually exclusive and thus indicative of some form of 
systematic error in analysis or, rather, are revealing of a more fundamental relationship between 
transporter structure and function. 
 GLUT1 comprises 492 amino acids, is a member of the major facilitator superfamily 
(MFS) of proteins and shares the common MFS fold of 12 transmembrane domains, cytoplasmic 
N- and C-termini and a long, partially structured intracellular loop connecting membrane 
spanning helices 6 and 7 (124,145,146). GLUT1 has been crystalized in an inward open (e1 or 
endofacial) conformation (77). Additional members of the MFS family have been crystalized in 
outward open (e2 or exofacial) and outward (e2o) and inward (e1o) partially occluded 
conformations. These members include human GLUT3 (e2, e2o (134)), GLUT5 (e1, e2 (133)) 
and the bacterial xylose transporter XylE (e1, e1o, e2o (6,131)). Each structure supports the 
hypothesis that the sugar translocation pathway consists of eight amphipathic, membrane 
spanning α-helices (H1, H2, H4, H5, H7, H8, H10 and H11) coordinated by a scaffold of 4 
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hydrophobic α-helices (H3, H6, H9 and H12). The N- and C-terminal membrane-spanning α-
helices share a similar topology and are related by a two-fold symmetry (8). 
 Two competing hypotheses have been presented to explain glucose transporter behavior: 
the simple, alternating access carrier which sequentially presents mutually exclusive exofacial 
and endofacial substrate binding sites (124,145), or the fixed-site transporter with coexistent 
exofacial and endofacial sugar binding sites (143,147). Initial studies using purified GLUT1 
suggested that exofacial and endofacial inhibitors bind at mutually exclusive binding sites 
thereby supporting the simple carrier model (91,92). Erythrocyte sugar transport and ligand 
binding studies (78,79,83,113) and studies using non-reduced, purified transporter (79,83) 
suggest GLUT1 behaves like a fixed site transporter with interacting, cooperative binding sites.  
 Cell membrane resident GLUT1 forms non-covalent homodimers and tetramers 
(95,102,137,140). Purified, non-reduced GLUT1 forms a mixture of dimeric and tetrameric 
species while reduced purified GLUT1 is largely dimeric. GLUT1 and GLUT3 co-expressed in 
the same cells do not form heterocomplexes (139,140) but substitution of GLUT3 membrane 
spanning α-helix 9 (H9) into GLUT1 shifts the GLUT1 population from a tetrameric/dimeric 
mixture with high transport capacity to a dimeric population with reduced transport capacity 
suggesting H9 is involved in GLUT1 oligomerization. Conversely, substitution of GLUT1 H9 
into GLUT3 converts GLUT3 into a tetramer and increases its transport capacity to GLUT1 
levels confirming the pivotal role of H9 in determining GLUT quaternary structure and catalytic 
function (140).  
 Ligand binding studies with non-reduced and reduced GLUT1 provide further insights into 
the subunit organization of the transport complex (95). The sugar transport inhibitor cytochalasin 
B (CB) and intracellular sugar compete for binding at the GLUT1 endofacial sugar binding site 
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(148). Purified tetrameric GLUT1 binds 0.5 mol CB per mol GLUT1 while purified dimeric 
GLUT1 binds one mol CB per mol GLUT1 (95). This contradiction is explained by the 
suggestion (137) that each subunit of tetrameric GLUT1 undergoes the e2 ⇌ e1 catalytic cycle 
but, at any instant two subunits must present the e1 conformation and two must adopt the e2 
conformation. In dimeric GLUT1, each subunit is functionally unconstrained by its neighbor and 
free to adopt either the e1 or e2 conformation. Thus, both subunits of dimeric GLUT1 bind CB 
when [CB] is saturating.  
 This suggestion is reinforced by demonstrations of functional coupling between GLUT1 
ligand and substrate binding sites. Trans-allostery is observed when low concentrations of 
GLUT1 endofacial site inhibitors (e.g. forskolin or CB) increase the affinity of the external site 
for transported sugar (80). As inhibitor concentration is further increased, transport is inhibited. 
Exofacial cis-allostery is observed when extracellular maltose (a non-transportable disaccharide 
which binds at the exofacial sugar binding site), stimulates sugar uptake at low maltose 
concentrations but inhibits uptake as its concentration is raised (78). Endofacial cis-allostery is 
seen when endofacial ligand binding (e.g. forskolin) increases the affinity of GLUT1 for a 
second e1 ligand (e.g. CB, (80,84)). These findings suggest that GLUT1 presents multiple, co-
existent endo- and exofacial ligand binding sites and/or that oligomerization promotes subunit 
cooperativity. 
 This study interrogates crystal and homology-modeled GLUT1 structures to ask whether 
GLUT1 can present multiple substrate and ligand interaction sites. Then, using insights gained 
from this analysis, we mutagenize GLUT1 to examine its impact on cis-and trans-allostery. We 
conclude that exofacial cis-allostery is an intramolecular phenomenon resulting from cross-talk 
between multiple, co-existent ligand interaction sites present in the exofacial cavity of each 
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GLUT1 protein whereas trans-allostery and endofacial cis-allostery require ligand-induced 
subunit-subunit interactions. 
Materials and Methods 
Reagents 
 [3H]-2-deoxy-D-glucose ([3H]-2DG) was purchased from American Radiolabeled 
Chemicals (St. Louis, MO). Unlabeled 2DG, maltose, Cytochalasin B (CB) and phloretin were 
purchased from Sigma-Aldrich (St. Louis, MO). All primers were purchased from Integrated 
DNA Technologies. Herculase polymerase, XL1-Blue Competent cells, and QuikChange 
Multisite-directed Mutagenesis kits were obtained from Agilent Technologies. SuperSignal Pico 
West, NeutrAvidin Gel, micro-BCA kits, spin columns, and EZ-Link Sulfo-NHS-ss-Biotin were 
from Pierce. 
Solutions  
 Phosphate-buffered saline (PBS) comprised 140 mM NaCl, 10 mM Na2HPO4, 3.4 mM 
KCl, 1.84 mM KH2PO4, pH 7.3. Solubilization buffer comprised PBS medium with 0.5% Triton 
X-100 and 5 mM MgCl2. Stop solution comprised PBS-Mg medium plus CB (CB; 10 μM) and 
phloretin (100 μM). Sample buffer contained 0.125 M Tris-HCl (pH 6.8), 4% SDS, 20% 
glycerol, and 50 mM DTT. Transfer buffer comprised 12 mM Tris Base, 96 mM Glycine, 20% 
methanol. 
Antibodies 
 A custom-made (New England Peptide) affinity-purified goat polyclonal antibody (C-Ab) 
raised against a peptide corresponding to GLUT4 C-terminal residues 498-509 was used at 
1:10,000 dilution (86). Horseradish peroxidase-conjugated donkey anti-goat secondary antibody 
(Jackson ImmunoResearch) was used at 1:50,000 dilution. 
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Tissue Culture  
 HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL 
streptomycin in a 37 °C humidified 5% CO2 incubator as described previously (149). All 
experiments were performed with confluent cells. Plates were subcultured into 12-well plates at a 
ratio of 1:2-1:5 2-4 days prior to transfections. Passages 4-20 were used for all experiments. 
Mutagenesis 
 GLUT1-encoding cDNA was inserted into the EcoRV-NotI restriction sites of PCDNA 
3.1(+). As described previously (140), the C-terminal 13 amino acids of this GLUT1 construct 
are substituted using the C-terminal 13 amino acids of GLUT4 to facilitate detection of 
heterologously expressed GLUT1 against a low level background expression of endogenous 
GLUT1. Mutagenesis was as described previously (116) using QuikChange Multi-site-directed 
Mutagenesis kits and was verified by sequencing. The GLUT1 construct in which H9 is 
substituted with GLUT3 H9 sequence was described previously (140). 
Transient Transfection 
 Cells (70-90% confluence) were transfected with 2 µg (12 well plates) or 5 µg of DNA per 
well (6 well plates). Transfections were performed 36-48 hr prior to analysis of sugar uptake or 
protein expression. Sugar uptake and cell-surface biotinylation measurements were performed in 
tandem. GLUT1, GLUT3, GLUT1/GLUT3 chimeras tagged with a GLUT4-specific epitope and 
their associated mutations were constructed and heterologously expressed in HEK293 cells as 
described previously (116,140).  
Cell-Surface Expression Measurements 
 Three days post-transfection, 6-Well plates of HEK cells were washed twice with ice-cold 
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PBS and incubated on ice with ice-cold PBS containing 5 mM EZ-Link Sulfo-NHS-ss-Biotin for 
30 min with gentle rocking. Reactions were quenched by adjusting each well to 12.5 mM Trizma 
(Tris base). Cells were harvested, re-suspended in biotin lysis buffer, and lysates were bound to 
Neutravidin Gel in spin columns according to kit instructions. Protein was eluted from spin 
columns using reductant, the eluate protein concentration was determined 
spectrophotometrically. Normalized loads were analyzed by Western blotting. 
Western Blotting 
 GLUT1 expression in whole cell lysates and cell surface expression by biotinylation were 
analyzed by western blot as previously described (73). Total and isolated biotinylated proteins 
were normalized for total protein concentration by BCA and resolved by SDS-PAGE on a 10% 
NuPage gel in NuPage running buffer. Gels were transferred onto PVDF membranes blocked 
with 3% bovine serum albumin in PBS-T, probed with primary antibody overnight at 4°C, 
probed with secondary antibody for 1 hr at room temperature, and developed using SuperSignal 
Pico West Chemiluminescent substrate. Blots were imaged on a FujiFilm LAS-3000 and relative 
band densities were quantitated using ImageJ32 software. 
2-Deoxy-D-glucose Uptake 
 2-deoxy-D-glucose (2-DG) uptake was measured as described previously (140). Briefly, 
36-48 hr post transfections, confluent 12-well plates of HEK-293 cells were serum- and glucose-
starved for 2 hr at 37°C in FBS and penicillin/streptomycin-free DMEM lacking glucose. Cells 
were washed with 1.0 mL of DPBS-Mg at 37°C for 15 min, then exposed to 0.4 ml of [3H]2-DG 
uptake solution at various 2-DG concentrations (0.1 - 20 mM) for 5 min at 37°C. Uptake was 
stopped by addition of 1 ml of ice-cold stop solution. Cells were washed twice with ice-cold stop 
solution and lysed with Triton lysis buffer. Total protein content was analyzed in duplicate by 
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BCA. Each sample was counted in duplicate by liquid scintillation spectrometry. Each mutant 
was analyzed in triplicate on at least 3 separate occasions.  
 Cis- and trans-allostery experiments measured 0.1 mM 2-DG uptake in cells exposed to 
[maltose] or [CB] respectively. 
Homology Modeling 
 We modeled GLUT1 e2, e2-occluded and e1-occluded structures respectively using the 
human GLUT3 (4ZWC) structure (134) and the XylE e2-occluded (4GBZ) and e1-occluded 
(4JA3) structures (6,131). We removed ligands and used chain A as the template for each 
modeled structure. Sequence alignments were generated using ClustalX. Homology models were 
built using Modeller-9.9 and analyzed using PROCHECK. The GLUT1 e1 structure (4PYP (77)) 
was used directly. 
Cavity analysis 
 Cavities for ligand docking were calculated using the CastP server 
(http://sts.bioe.uic.edu/castp/) (150) and the grid was centered on the residues forming the cavity.  
Stochastic Docking 
 β-D-glucose, maltose and CB structures were obtained from ZINC 
(http://zinc.docking.org). The WZB117 structure was generated using the 3D structure generator 
Corina from Molecular Networks GmbH (http://www.molecular-networks.com). Docking was 
performed using the Schrodinger software suite. No restraints were used during the docking. The 
protein structure was preprocessed with the Protein Preparation Wizard, bond orders were 
assigned, hydrogens added and the H-bond network was optimized. The system was energy 
minimized using the OPLS 2005 force field. Ligand structures were prepared with the LigPrep 
module and the pKa of the ligands was calculated using the Epik module. Computational 
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docking was performed by the GLIDE module in standard-precision (SP) mode and default 
values for grid generation. Grids were mapped using CastP cavity analysis and ligand positions 
from the original crystal structures. 
Data analysis 
 Data analysis was undertaken using GraphPad Prism (version 7.0c, GraphPad Software, 
Inc.). Curve fitting was by non-linear regression using the following equations: 
1.  Concentration dependence of 2-deoxy-D-glucose uptake: 
  eqn 1 
where [S] is [2DG] and Vmax and Km(app) have the usual meaning. 
2.  Exofacial Cis-Allostery and Endofacial trans-allostery are expressed as normalized 2DG 
uptake which is described by 
  eqn 2 
where vi/vc is uptake in the presence of inhibitor divided by uptake in the absence of inhibitor, [I] 
is the concentration of cis- or trans-inhibitor and interpretation of constants is model dependent 
and described in (151). 
3.  When simple saturable inhibition of transport is observed, normalized 2DG uptake is 
described by 
  eqn 3 
where vi/vc is uptake in the presence of inhibitor divided by uptake in the absence of inhibitor, K1 
is uptake in the absence of inhibitor I, K2 is the difference between K1 and uptake in the presence 
of saturating [I] and K3 is KI(app) for uptake inhibition by I. 
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Results 
Homology Modeled GLUT1 structures 
 GLUT1 and GLUT3 structures have been described previously (77,134). The current study 
presents and interrogates three homology-modeled GLUT1 structures - the so-called outward, 
outward-occluded and inward-occluded conformations of GLUT1 plus the experimentally 
derived inward conformation of GLUT1 (4PYP (77); Figure 2.1). These conformations present a 
striking physical correspondence to the proposed kinetic intermediates in the alternating access 
carrier catalytic cycle named e2, e2o, e1o and e1 (99,100,111), argue strongly for sugar 
movements through a central translocation pore and are henceforth termed GLUT1-e2, GLUT1-
e2o, GLUT1-e1o and GLUT1-e1. 
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Figure 2.1: Homology-modeled GLUT1 conformations. A. GLUT1 is shown in cartoon 
representation normal to the bilayer plane (horizontal orange lines), membrane spanning α-
helices (H 2, 3, 4, 7, 11 and 12) are indicated, and locations of the interstitium and cytoplasm 
are highlighted. Four conformations are depicted: exofacial (GLUT1-e2), exofacial-occluded 
(GLUT1-e2o), endofacial-occluded (GLUT1-e1o) and endofacial (GLUT1-e1). B. A second 
depiction of GLUT1-e1 is shown along the bilayer normal from the cytoplasmic side. 
Membrane spanning α-helices (H1-12) are indicated. C. Representation of ligand-interaction 
cavities present in all 4 GLUT1 conformations shown normal to the bilayer plane. N- and C-
terminal halves (H1-6 and H7-12 respectively shown in gray in cartoon representation) of each 
conformation are indicated. Solvent-exposed residues in the ligand interaction cavities of each 
conformation are shown as surface maps colored cyan. Residues common to all 4 cavities are 
shown as surface maps colored red and include: N-terminal residues Gly-26, Thr-30 (of helix 
1), Gln-161, Ile-164, Val-165, and Ile-168 (of helix 5); C-terminal residues: Gln-282, Gln-283, 
Ile-287, Asn-288, Phe-291, Tyr-292 (of helix 7), Asn-317 (of helix 8), Phe-379, Trp-388 (of 
helix 10) and Asn-411, Trp-412 and Asn415 (of helix 11). 
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Docking analysis of GLUT1-substrate interactions  
 Docking analysis first requires the location of GLUT1 pockets of sufficient size to permit 
ligand entry and coordination. Cavity analysis of all 4 homology-modeled GLUT1 
conformations suggests the existence of a translocation pore that transitions from one contiguous 
with the interstitium but excluded from cytosol in GLUT1-e2 through intermediate, occluded 
cavity forms in GLUT1-e2o and GLUT1-e1o to a cavity contiguous with the cytosol but 
excluded from the interstitium in GLUT1-e1 (Figure 2.1). Translocation pore volume increases 
in the occluded state. Computed cavity volumes (Figure 2.1) are GLUT1-e2 = 2,850.8 Å3, 
GLUT1-e2o = 4,397.5 Å3, GLUT1-e1o = 3,029.4 Å3, and GLUT1-e1 = 2,845.9 Å3. For 
comparison, the molecular volume of β-D-glucose (β-D-Glc) based on its self-diffusion 
coefficient is 433 Å3 (152). Loop 6-7 was not included in cavity calculations for the GLUT1-e1 
conformation. The side chains of several residues line the cavities in all 4 conformations (Figure 
2.1C). 
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Figure 2.2: β-D-Glc docking to homology-modeled GLUT1 conformations. A. Each 
GLUT1 conformation is shown complexed with β-D-Glc (shown in red as a space-filling 
representation). The location of GLUT1 Q282 is shown in cyan in space-filling format. 
Conformation nomenclature is indicated beneath each structure where β-D-Glc is represented 
by the letter S and occluded β-D-Glc (by convention) by the letter S in parenthesis. B. β-D-Glc 
docking to GLUT1 conformations in which Glc is shown as a 2D structure, coordinating 
GLUT1 residues are shown as circles and are colored according to their properties 
(green=hydrophobic, cyan=polar, red=negative), GLUT1 backbone as green or blue ribbons, 
solvent exposed regions of β-D-Glc are indicated by gray-shaded circles and H-bonds shared 
between amino acid side chain amines, carbonyls or hydroxyls with β-D-Glc and their 
directionality are represented as red arrows. C. Alignment of XylE containing a co-crystallized 
β-D-Glc (4GBZ; (7); XyleE-e2o(S)) with homology-modeled GLUT1-e2o containing its 
docked β-D-Glc (GLUT1-e2o(S)). Both proteins are hidden to show the proximity of co-
crystallized and docked sugars. XylE-bound β-D-Glc lacks hydrogens and its carbons are 
colored yellow. GLUT1-bound β-D-Glc carbons are colored cyan. The black scale bar 
indicates the length of a single C-C bond (0.154 Å).   
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 GLIDE software was developed to optimize ligand docking to rigid protein structures using  
co-crystallized ligand-protein complexes as comparative standards (153,154). GlideScores for 
computed ligand/protein pairs are useful for selecting the best docked poses but can under- or 
over-estimate ∆G for binding by 2 kcal/mol (30-fold; (155)).  
 Transport studies show that β-D-Glc binding at the GLUT1 exofacial sugar binding site 
involves H-bonding to pyranose ring C1, C3 and C4 oxygens (74,75). Similarly, ligand binding 
at the endofacial sugar binding site involves H-bonding with OH groups at C3 and C4 in the 
pyranose ring and is inhibited by bulky substitutions at C6 (74). Docking analysis of β-D-Glc 
interactions with GLUT1-e2, GLUT1-e2o, GLUT1-e1o and GLUT1-e1 conformations is shown 
in Figures 2.2A and 2.2B. The illustrated interactions conform to the aforementioned 
stereospecificity of GLUT1-ligand binding. Gln-282 (Q282) is the one residue whose side chain 
interacts with β-D-Glc in all 4 GLUT1 conformations. Figure 2.2C shows the relative positions 
of β-D-Glc in the XylE-e2o-β-D-Glc co-crystal structure (131) and of β-D-Glc docked to the 
homology-modeled GLUT1-e2o structure following alignment of the two protein structures. The 
agreement is excellent and exceeds the resolution (2.9 Å) of the XyleE-e2o structure. 
Additional glucose interaction sites 
 β-D-Glc docking to GLUT1-e2 reveals additional potential interaction sites which we call 
intermediate and peripheral sites (Figure 2.3A). The intermediate site persists in GLUT1-e2o but 
not in e1o and e1 suggesting that an extra sugar (in addition to the core or transported sugar) is 
excluded in e1o and e1 states. If occupancy of the intermediate site modifies GLUT1 catalytic 
behavior, this could explain how extracellular sugar allosterically modulates sugar uptake. How 
it affects exit is more difficult to explain (78,80). β-D-Glc docking to GLUT1-e1o and GLUT1-
e1 (Figures 2.3C and 2.3D) suggests that each conformation presents a single interaction 
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envelope. This precludes simultaneous occupancy of endofacial conformations by two 
intracellular sugars. 
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Figure 2.3: GLUT1 presents additional β-D-Glc binding sites. GLUT1 is oriented as in 
Figure 1A. A. β-D-Glc (in red) docking to GLUT1-e2 reveals 3 potential sites termed 
peripheral, intermediate and core. Computed GlideScores (GS) for ligand binding: peripheral 
GS = -5.1 kcal/mol, intermediate GS = -5.1 kcal/mol, core GS = -4.9 kcal/mol. B. β-D-Glc (in 
red) docking to GLUT1-e2o reveals 2 potential sites termed peripheral and core. Computed GS 
for ligand binding: peripheral GS = -6.0 kcal/mol, core GS = -5.8 kcal/mol. C. β-D-Glc (in 
red) docking to GLUT1-e1o reveals 1 potential site with computed GS for ligand binding = -
5.1 kcal/mol. D. β-D-Glc (in red) docking to GLUT1-e1 Computed GS for ligand binding: 
core 1 GS = -5.4 kcal/mol. 
 
 
  
  
 52 
 Interpretation of KM(app) for transport is model-dependent and includes both binding and 
translocation rate constants (111). GlideScores for β-D-Glc interaction at these sites range from -
4.9 to -6 kcal/mol suggesting KD(app) for β-D-Glc binding of 18 - 135 µM.  KD(app) for β-D-Glc 
binding to GLUT1 is 0.5 mM (113). Computed KD(app) for xylose docking to each of the 8 known 
XylE structures ranges from 4 µM to 90 µM (136) yet KD(app) for xylose binding to XylE is 0.4 
mM (131). As previously discussed, GlideScores for computed ligand/protein can under- or 
over-estimate ∆G for binding by 2 kcal/mol (30-fold; (155)). 
Docking analysis of GLUT1-inhibitor interactions 
 Maltose and CB are non-transported inhibitors of GLUT1-mediated sugar transport acting 
at exofacial and endofacial sites respectively (83). Molecular docking of β-maltose to GLUT1-e2 
suggests two maltose interaction domains: 1) the core β-D-Glc site and, 2) an outer location 
comprising peripheral and intermediate β-D-Glc interaction sites (Figure 2.4A). These sites do 
not sterically clash suggesting that GLUT1-e2 can form a complex with 2 maltose molecules. 
GLUT1-e2o can also accommodate a core β-D-Glc or core β-maltose plus an outer β-maltose 
(Figure 2.4B). GlideScores for maltose interaction with core and outer sites range from -6.1 to -
3.4 kcal/mol corresponding to KD(app) ≈ 15 µM to 2 mM. Maltose stimulates then inhibits 
GLUT1-mediated sugar uptake with K0.5 of 32 µM and 3.2 mM respectively (78) indicating close 
agreement between GlideScores and KD(app) when the interfering exofacial ligand is non 
transportable. 
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Figure 2.4: Maltose binding to the exofacial conformation of GLUT1. GLUT1 is oriented 
as in Figure 1A. A. β-Maltose binding. Maltose (a disaccharide comprising two glucose units 
joined with an α(1→4) bond) can occupy two sites in GLUT1-e2: a site (shown in yellow) 
comprising the core β-D-Glc site and extending into additional space or a site (shown in green) 
comprising intermediate and peripheral β-D-Glc sites. β-D-Glc is indicated as a stick figure 
occupying its core site. GlideScores for Maltose binding core and intermediate sites are -6.1 
kcal/mol and -5.6 kcal/mol respectively. B. Maltose occupies two sites in GLUT1-e2o 
comprising core (yellow) and peripheral (green) sites. GlideScores for maltose binding at core 
and peripheral sites are -3.4 kcal/mol and -5.0 kcal/mol respectively. β-D-Glc is indicated as a 
stick figure occupying the core site. 
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 Docking analysis of CB - GLUT1-e1 interactions suggests two possible orientations for CB 
coordination (Figure 2.5). Each sterically clashes with the core, GLUT1-e1 β-D-Glc interaction 
envelope (Figure 2.5) thus explaining competition between CB and β-D-Glc for binding. 
GlideScores for CB interaction with GLUT1-e1 are consistent with KD(app) for CB binding of 0.1 
to 5 µM. KD(app) for CB binding to GLUT1 ranges from 150 - 180 nM (91,156)  
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Figure 2.5: CB interaction sites in GLUT1-e1. GLUT1 is oriented as in Figure 1A. CB 
adopts two overlapping coordinations in GLUT1-e1. These are shown as space-filling 
molecules in dark blue (CB site 1) and light blue (CB site 2). GS for CB binding to sites 1 and 
2 are -7.2 kcal/mol and -6.6 kcal/mol respectively. Both CB sites suggest steric hindrance with 
the core β-D-Glc binding site (shown as a space-filling molecule in red). 
 
 
  
 57 
 
Effects of inhibitors on sugar transport 
 The predicted involvement of Q282 in β-D-Glc coordination by all GLUT1 conformations 
suggests that this residue plays a central role in sugar transport. We therefore mutagenized Q282 
to alanine. The concentration dependence of the initial rate of 2-deoxy-D-glucose (2DG) uptake 
by HEK293 cells expressing wtGLUT1 or GLUT1 containing the Q282A mutation 
(GLUT1Q282A) is well approximated by Michaelis-Menten kinetics (Figure 2.6A). Vmax for net 
2DG uptake (wtGLUT1 = 3.18 x 10-12 ± 0.25 x 10-12 mol/µg protein/min) is unaffected by the 
Q282A mutation (Vmax = 3.38 x 10-12 ± 0.28 x 10-12 mol/µg protein/min). However, Km(app) for net 
sugar uptake by wtGLUT1 (0.89 ± 0.18 mM) is doubled in GLUT1Q282A (Km(app) = 1.59 ± 0.28 
mM). Cell-surface GLUT1 biotinylation studies confirm that HEK293 cells express similar 
levels of wtGLUT1 and GLUT1Q282A (Figure 2.6B). Replicate analysis (n = 5; Figure 2.6C) 
reveals that Km(app) is significantly increased in GLUT1Q282A (paired T-test, P = 0.0046) but Vmax 
is unchanged (P = 0.2036). 
 Two types of “allostery” have been described for GLUT1-mediated sugar import. Cis-
allostery obtains when extracellular inhibitors (e.g. maltose), stimulate sugar uptake at low 
concentrations but inhibit uptake at higher concentrations (78). Trans-allostery describes sugar 
uptake stimulation by subsaturating levels of endofacial inhibitors (e.g. CB, forskolin; (80)). 
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Figure 2.6: Sugar transport in HEK293 cells heterologously expressing wtGLUT1 or 
GLUT1Q282A. A. Michaelis-Menten kinetics of zero-trans 2-deoxy-D-glucose (2DG) uptake in 
cells expressing wtGLUT1 (●), or GLUT1Q282A (￮). 2DG uptake in µmol/µg cell protein/min is 
plotted versus [2DG] in mM. Each data point is the mean ± SEM of 3 or more duplicate 
measurements and is corrected for 2DG uptake in mock-transfected cells.  Curves were 
computed by nonlinear regression assuming Michaelis-Menten uptake kinetics (equation 1) 
and have the following constants: wtGLUT1 (●):Vmax = 3.2 ± 0.02 pmol/µg protein/min, 
Km(app) = 0.89 ± 0.18 mM, R2 = 0.884, standard error of regression = 0.31 pmol/µg 
protein/min; GLUT1Q282A (￮):Vmax = 3.4 ± 0.3 pmol/µg protein/min, Km(app) = 1.59 ± 0.28 mM, 
R2 = 0.926, standard error of regression = 0.24 pmol/µg protein/min. B. Cell surface 
expression of wtGLUT1 and GLUT1Q282A in HEK293 cells. The mobility of molecular weight 
markers is indicated at the left of the blot which shows GLUT1 levels present in biotinylated 
membrane proteins collected from untransfected (UTF), wtGLUT1-expressing (wt) and 
GLUT1Q282A (Q282A) expressing HEK293 cells. C. Km(app) but not Vmax for 2DG transport is 
affected in GLUT1Q282A. The results of 5 separate experiments are shown as scatter dot plots 
for both Km(app) and Vmax. Results are shown as mean ± SEM. Paired t-test analysis (dashed 
lines indicate paired measurements) indicates that Vmax is not significantly affected by the 
Q282A mutation (p = 0.2036) but that Km(app) increases 2-fold (p = 0.0046). 
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Cis-Allostery is eliminated in GLUT1Q282A 
 Subsaturating extracellular maltose (10 to 50 µM) stimulates wtGLUT1-mediated 2DG 
uptake (Figure 2.7A) but higher concentrations inhibit transport. Low concentrations of maltose 
are without effect on sugar uptake by GLUT1Q282A but higher concentrations inhibit transport 
(Figure 2.7A). 
Trans-Allostery persists in GLUT1Q282A 
 CB stimulates 2DG uptake at low concentrations (0.025 µM CB) in both wtGLUT1 and 
GLUT1Q282A but inhibits transport at higher concentrations (Figure 2.7B). 
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Figure 2.7: Cis- and trans-allostery in wtGLUT1 (●) and GLUT1Q282A (￮). A. Cis-
Allostery. Concentration dependence of maltose-modulation of 2DG influx. Normalized 2DG 
uptake (vi/vc) is plotted as a function of [Maltose] (mM) on a log scale. The curves drawn 
through the points (solid lines for wtGLUT1 (●) and dashed lines for GLUT1Q282A (￮)) were 
computed by nonlinear regression using equation 2 and have the following constants: 
wtGLUT1 (●) K1 = 0.0028, K2 = 0.31 mM-1; K3 = 0.197 mM-1, K4 = 1.62 mM-2, R2 = 0.582, 
standard error of regression = 0.147; GLUT1Q282A (￮) K1 = 0.028, K2 = 1.83 mM-1; K3 = 
1.911 mM-1, K4 = 1.62 mM-2, R2 = 0.582, standard error of regression = 0.147. B. Trans-
Allostery. Concentration dependence of CB-modulation of 2DG influx. Normalized 2DG 
uptake (vi/vc) is plotted as a function of [CB] (µM) on a log scale. The curves drawn through 
the points (solid lines for wtGLUT1 (●) and dashed lines for GLUT1Q282A (￮)) were computed 
by nonlinear regression using equation 2 and have the following constants: wtGLUT1 (●) K1 
= 0.0041 µM2, K2 = 0.073 µM; K3 = 2 x 10-12 µM, K4 = 1.64, R2 = 0.637, standard error of 
regression = 0.179; GLUT1Q282A (￮) K1 = 0.0050 µM2, K2 = 0.039 µM; K3 = 8.3 x 10-14 µM, 
K4 = 1.495, R2 = 0.849, standard error of regression = 0.067. 
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Cis- and trans-allostery in a GLUT1-oligomerization mutant. 
 GLUT1 forms a mixture of homo-tetramers and homo-dimers in red cell membranes and in 
CHO and HEK293 cells (102,140). GLUT1 tetramerization (but not sugar transport) is 
eliminated in a GLUT1/GLUT3 chimera in which GLUT1 membrane spanning helix 9 is 
substituted with GLUT3 membrane spanning helix 9 sequence (140). We used this 
tetramerization-deficient mutant (GLUT1(GLUT3-H9)) to ask whether cis- or trans-allostery require 
GLUT1 tetramerization.  
 Subsaturating levels of maltose stimulate both GLUT1- and GLUT1(GLUT3-H9)-mediated 
2DG uptake whereas higher concentration of maltose inhibit uptake (Figure 2.8A). Introduction 
of the Q282A mutation to the GLUT1(GLUT3-H9) background eliminates sugar uptake stimulation 
by subsaturating [maltose] (Figure 2.8A). 
 While cis-allostery persists in the oligomerization-deficient mutant, sub-saturating [CB] no 
longer stimulates 2DG uptake in GLUT1(GLUT3-H9) or GLUT1(GLUT3-H9)Q282A expressing HEK293 
cells (Figure 2.8B).  
 The effects of stimulating levels of maltose (10 and 50 µM) and CB (25 nM) on 2DG 
uptake in GLUT1, GLUT1Q282A, GLUT1(GLUT3-H9) and GLUT1(GLUT3-H9)Q282A are summarized in 
Figure 2.9. Stimulation by maltose but not by CB is eliminated in GLUT1Q282A. Stimulation by 
maltose but not by CB persists in GLUT1(GLUT3-H9) and all stimulations are lost in GLUT1(GLUT3-
H9)Q282A. 
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Figure 2.8: Cis- and trans-allostery in a GLUT1 oligomerization-deficient background. 
GLUT1(GLUT3-H9) and GLUT1(GLUT3-H9)Q282A  expressed in HEK293 cells were tested for their 
ability to mediate cis-and trans-allostery. A. Cis-Allostery. Concentration dependence of 
maltose-modulation of 2DG influx. Normalized 2DG uptake (vi/vc) is plotted versus [Maltose] 
(mM) on a log scale. The curves drawn through the points (solid lines for GLUT1(GLUT3-H9) and 
dashed lines for GLUT1(GLUT3-H9)Q282A) were computed by nonlinear regression using equation 
2 and have the following constants: GLUT1(GLUT3-H9) (●) K1 = 0.0022, K2 = 2.052 mM-1; K3 = 
1.707 mM-1, K4 = 1.72 mM-2, R2 = 0.656, standard error of regression = 0.137; GLUT1(GLUT3-
H9)Q282A (￮) K1 = 0.081, K2 = 0.63 mM-1; K3 = 0.626 mM-1, K4 = 1.528 mM-2, R2 = 0.747, 
standard error of regression = 0.080. B. Trans-Allostery. Concentration dependence of CB-
modulation of 2DG influx.  Normalized 2DG uptake (vi/vc) is plotted versus [CB] (µM) on a 
log scale. The curves drawn through the points (solid lines for GLUT1(GLUT3-H9) and dashed 
lines for GLUT1(GLUT3-H9)Q282A) were computed by nonlinear regression using equation 3 and 
have the following constants: GLUT1(GLUT3-H9) (●) K1 = 0.984 µM/s, K2 = 0.740 µM/s; K3 = 
0.138 µM, R2 = 0.963, standard error of regression = 0.058; GLUT1(GLUT3-H9)Q282A (￮) K1 = 
0.996 µM/s, K2 = 0.711 µM/s; K3 = 0.065 µM, R2 = 0.904, standard error of regression = 
0.093. 
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Figure 2.9: Scatter plots of the effects of maltose (10 and 50 µM) and CB (25 nM) on 0.1 
mM 2DG uptake in A GLUT1, B GLUT1Q282A, C GLUT1(GLUT3-H9) and D GLUT1(GLUT3-
H9)Q282A expressing cells. Normalized uptake (vi/vc) is plotted versus concentrations of maltose 
and CB applied during 2DG uptake measurements. Results are shown as the averages of paired 
replicates (n = 4) and mean ± SEM of multiple experiments (n ≥ 3). Data were examined by 
unpaired t-test analysis comparing the effect of treatment to no treatment (vi/vc = 1 as indicated 
by the dashed horizontal line) and the computed significance levels are indicated above the 
points for treatments resulting in P < 0.05. 
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Discussion 
 As more sugar transporter structures become available, the weight of evidence supporting 
the alternating access transporter model for sugar transport grows. Each study 
(6,8,77,131,133,157) has interpreted transporter structures in the context of this model 
(99,124,145) in which the transporter cycles between conformations presenting either an 
exofacial cavity to extracellular sugars or an endofacial cavity to cytoplasmic sugars. Sugar 
binding to exofacial (e2) or endofacial (e1) conformations promotes gating transitions which 
occlude the bound sugar from the interstitium (forming the e2o state) or from the cytoplasm 
(forming the e1o state). Occlusion triggers rigid body movements leading to e2o conversion to 
e1o and vice versa. The trans-gate then opens releasing bound sugar at the opposite side of the 
membrane. The catalytic cycle concludes via the reverse sequence of conformational changes 
with or without bound sugar as cargo. 
 This interpretation of the structural data has excited criticism (78-80,83,84,113,136,143) 
for 3 reasons: 1) We do not yet have crystal structures of each GLUT conformation complexed 
with a transported sugar; 2) Available sugar transport data demonstrate that GLUT1 
simultaneously presents exofacial and endofacial ligand binding sites; 3) Transport and ligand 
binding studies demonstrate that the transporter interacts with more than one exofacial ligand 
(e.g. β-D-Glc plus maltose) and more than one endofacial ligand (e.g. CB plus forskolin) at any 
instant. 
Ligand interaction sites 
 We therefore asked whether available crystal structures support the idea that e2 and e1 
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forms of GLUT1 can simultaneously bind multiple ligands in exo- or endofacial cavities. While 
a crystal structure for GLUT1-e1 is available (77), it was necessary to model GLUT1-e2, 
GLUT1-e2o and GLUT1-e1o structures using the human GLUT3 (4ZWC) structure (134) and 
the XylE e2-occluded and e1-occluded structures (6,131) respectively. 
 Molecular docking reveals that the GLUT1-e2 exofacial cavity presents 3 potential, non-
overlapping β-D-Glc interaction sites and two non-overlapping maltose interaction sites. β-D-Glc 
interaction envelopes are located at peripheral, intermediate and core locations within the 
exofacial cavity. One maltose interaction envelope overlaps with the core β-D-Glc interaction 
envelope and the second is more peripherally located in the exofacial cavity. Docking suggests 
that GLUT1-e2 can simultaneously accommodate core β-D-Glc and peripheral maltose. These 
three β-D-Glc sites may represent progressive steps in β-D-Glc binding or 3 co-existent 
interaction sites. The latter hypothesis is consistent with the observation that the transporter can 
bind extracellular maltose and transported sugar simultaneously (see (78) and this study). 
 We next asked if GLUT1-e1 or GLUT1-e2 simultaneously interact with endofacial and 
exofacial ligands. Molecular docking analysis indicates that this is highly improbable. Finally, 
we asked whether GLUT1-e1 interacts with more than one endofacial ligand simultaneously. 
GLUT1-e1 presents a single potential, CB interaction envelope which accommodates CB in 
either of 2 possible but mutually exclusive orientations. Both orientations sterically clash with 
the GLUT1-e1 β-D-Glc interaction envelope providing a rationale for competition between 
intracellular β-D-Glc and CB for binding to GLUT1 (92). CB interaction envelopes also 
sterically clash with the forskolin interaction envelope explaining competition between CB and 
forskolin for binding to GLUT1 (84). 
 
 69 
A model for allostery 
 Cis- and trans-allostery (sugar import stimulation at low [inhibitor] followed by inhibition 
at high [inhibitor]) require that GLUT1 must bind inhibitors at at least two sites. This is readily 
explicable for cis- (maltose-dependent) allostery because GLUT1-e2 presents 2 co-existent, 
exofacial maltose interaction sites and β-D-Glc competes with maltose for binding at both sites. 
Trans-(CB-dependent) allostery is more difficult to explain because GLUT1-e1 presents only 
one CB interaction site. We therefore conclude that each GLUT1 molecule is an alternating 
access transporter capable of exofacial cis-allostery but incapable of trans-allostery when 
catalyzing sugar import. How then do we explain trans-allostery? 
 Previous work (95,102,122,140,158-160) demonstrates that GLUT1 forms mixtures of 
dimeric and tetrameric GLUT1 complexes. When purifying RBC GLUT1, the ratio of 
dimeric:tetrameric GLUT1 is affected by cellular redox status with reducing conditions favoring 
the dimeric form (95,102). GLUT1 cysteines 347 and 421 may form mixed disulfides under non-
reducing conditions [95, 102] and GLUT1 transmembrane helix 9 contains GLUT1-specific 
sequence essential for tetramerization (140). Reduced, dimeric GLUT1 presents 1 CB binding 
site per GLUT1 molecule whereas nonreduced, tetrameric GLUT1 presents only 0.5 CB binding 
sites per GLUT1 molecule [95, 102]. Extracellular reductant inhibits RBC sugar import by 80-
90% [95, 102] and eliminates trans- but not cis-allostery (80). 
 The molecular mechanisms by which Q282 and membrane spanning helix 9 (TM9) 
promote cis- and trans-allostery respectively are unknown. However, our observations support 
the following model. Dimeric GLUT1 comprises two physically associated but functionally 
independent GLUT1 molecules. Each subunit displays cis- but not trans-allostery in net sugar 
uptake, binds 1 molecule of CB and, because transport is rate-limited by conformational changes 
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between unliganded e1 and e2 states (relaxation (99)), transport is characterized by a low kcat. 
Tetrameric GLUT1 comprises a noncovalent dimer of two associated and functionally coupled 
GLUT1 molecules. Intra-dimer subunit interactions produce a functional, anti-parallel 
arrangement of subunits. If one GLUT1 molecule presents an e2 conformation, its cognate 
partner in the dimer must present an e1 conformation and vice versa. When an e2 subunit of any 
dimer interacts with extracellular sugar to undergo the eS2 → eS1 conformational change, its 
cognate partner undergoes the e1 → e2 conformational change thereby coupling transport via 
one subunit to the regeneration of an e2 conformation in the cognate subunit, bypassing slow 
relaxation, and accelerating net sugar transport. Because only two subunits in tetrameric GLUT1 
can present the e1 conformation, the stoichiometry of CB binding is 0.5 mol CB per mol 
GLUT1. Each subunit functions as an allosteric alternating access transporter in import mode. 
Trans-allostery in sugar import obtains when one e1 subunit interacts with high affinity with an 
endofacial ligand (e.g. CB or forskolin). The dimer presenting this liganded e1 conformation is 
locked in an inhibited state but its occupancy is communicated to the adjacent dimer, increasing 
that dimer's affinity for extracellular β-D-Glc or kcat for transport. As the endofacial ligand 
concentration is raised, the remaining free e1 subunit in the adjacent dimer is occupied and both 
dimers are inhibited. Endofacial cis-allostery obtains when the affinity of an unliganded e1 
subunit in one dimer is increased by occupancy of the e1 subunit of the adjacent dimer.  
 In conclusion, GLUT1 functions as an oligomer of allosteric, alternating access 
transporters. Cis- and trans-allostery require intra- and inter-subunit interactions respectively. 
Each GLUT1 molecule appears to present a core, catalytic sugar binding site. The exofacial 
confomer of GLUT1 presents at least one and possibly two additional sugar interaction sites 
whose occupancy allosterically affects transport via the catalytic site. Trans-allostery requires at 
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least one subunit to bind an endofacial ligand and one to bind an extracellular, imported sugar. 
Preventing GLUT1-GLUT1 interactions in an oligomerization-deficient mutant, eliminates trans- 
but not cis-allostery. Mutating Gln-282 to alanine eliminates cis-allostery but not trans-allostery 
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CHAPTER 3: 
Kinetic basis of Cis- and Trans-Allostery in GLUT1-mediated sugar transport 
This chapter was published in the Journal of Membrane Biology in 2017, and can be found using 
the following reference: 
 
Lloyd, K., et al., Kinetic basis of Cis- and Trans-Allostery in GLUT1-mediated sugar transport. J 
Membr Biol, 2017. 
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Abstract 
A growing body of evidence demonstrates that GLUT1-mediated erythrocyte sugar transport is 
more complex than widely assumed and that contemporary interpretations of emergent GLUT1 
structural data are incompatible with the available transport and biochemical data. This study 
examines the kinetic basis of one such incompatibility -transport allostery - and in doing so 
suggests how the results of studies examining GLUT1 structure and function may be reconciled. 
Three-types of allostery are observed in GLUT1-mediated, human erythrocyte sugar transport: 1) 
Exofacial cis-allostery in which low concentrations of extracellular inhibitors stimulate sugar 
uptake while high concentrations inhibit transport; 2) Endofacial cis-allostery in which low 
concentrations of intracellular inhibitors enhance cytochalasin B binding to GLUT1 while high 
concentrations inhibit binding and, 3) Trans-allostery in which low concentrations of ligands 
acting at one cell surface stimulate ligand binding at or sugar transport from the other surface 
while high concentrations inhibit these processes. We consider several kinetic models to account 
for these phenomena. Our results show that an inhibitor can only stimulate then inhibit sugar 
uptake if: 1) the transporter binds 2 or more molecules of inhibitor; 2) high affinity binding to the 
first site stimulates transport and, 3) low affinity binding to the second site inhibits transport. 
Reviewing the available structural, transport and ligand binding data, we propose that exofacial 
cis-allostery results from cross-talk between multiple, co-existent ligand interaction sites present 
in the exofacial cavity of each GLUT1 protein whereas trans-allostery and endofacial cis-
allostery require ligand-induced subunit-subunit interactions. 
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Introduction 
 Human erythrocyte facilitative sugar transport is mediated by the sugar transport protein 
GLUT1 (18) (161)and displays three-types of allostery: 1) Exofacial cis-allostery in which low 
concentrations of extracellular maltose and WZB117 stimulate sugar uptake while high 
concentrations inhibit transport (78,149,162); 2) Endofacial cis-allostery in which low 
concentrations of intracellular inhibitors such as forskolin and related molecules enhance binding 
of the intracellular inhibitor cytochalasin to GLUT1 while high concentrations inhibit binding 
(80,84) and, 3) Trans-allostery in which low concentrations of ligands such as cytochalasin B or 
forskolin acting at one cell surface stimulate ligand binding at or sugar transport from the other 
surface while high concentrations inhibit these processes (80,118,149). These behaviors are 
incompatible with the predictions of the simple/alternating access (99,124,145) and the fixed site 
transporters (143,147) and are routinely ignored in discussions of emergent glucose transport 
structures (6,77,131,133) (but see (136,163)).  
 The present study considers several kinetic explanations for GLUT1 allostery. These 
models range from the simple, alternating access transporter (AAT, which alternately exposes an 
exofacial sugar binding site or an endofacial sugar binding site) and the fixed site transporter 
(FST, which simultaneously exposes exo-and endo-facial sugar binding sites) through 
progressively more complex variants of the AAT and FST presenting catalytic and allosteric 
ligand binding sites at either side of the membrane. We conclude that an exofacial or endofacial 
inhibitor can only stimulate then inhibit sugar uptake if: 1) the transporter binds 2 or more 
molecules of inhibitor at exofacial or endofacial binding sites respectively; 2) high affinity 
binding to the first site stimulates transport and, 3) low affinity binding to the second site inhibits 
transport. 
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 We then examine available structural, transport and biochemical evidence and propose: 1) 
that exofacial cis-allostery is an intramolecular phenomenon; 2) that trans-allostery and 
endofacial-cis allostery are intermolecular behaviors, and 3) that the available data may be 
reconciled by a model in which the transporter comprises an oligomer of interacting subunits in 
which each subunit is an allosteric alternating access transporter. 
Methods 
 Each model was schematized in King-Altman form and then analyzed assuming rapid-
equilibrium kinetics or when appropriate by the method of Cha (164,165). Sugar uptake was 
expressed as zero-trans sugar uptake (intracellular sugar is absent at zero-time) and cast as the 
ratio of uptake in the presence of inhibitor (vi) relative to uptake in the absence of inhibitor (vc), 
i.e. as  
𝑣𝑖
𝑣𝑐
. 
Analysis 
Tools 
In order to proceed with our analysis we must first consider some of the basic tools employed in 
studies of GLUT1-mediated sugar transport and ligand binding. These include: 
1. Cytochalasin B (CB) - an "e1" ligand (binds at the endofacial surface of GLUT1) 
(79,83,92). 
2. Maltose - an "e2" ligand (cell impermeant and binds at the exofacial surface of GLUT1) 
(78,83,118). 
3. β-D-Glucose (βGlc) and 3-O-methylglucose (3MG) - GLUT1 substrates that bind at both 
endofacial (e1) and exofacial (e2) binding sites (89,125). 
4. The human erythrocyte - a cell whose membrane contains approximately 500,000 copies of 
GLUT1 (166) and whose sugar transport properties have been studied exhaustively 
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(89,97,100,125,141). 
5. Purified and membrane-resident GLUT1 - exists in 2 forms of noncovalent oligomers: 
i) Dimeric GLUT1, isolated in the presence of reductant and binds 1 mol CB per mol GLUT1 
(95,102) 
ii) Tetrameric GLUT1, isolated in the absence of reductant and binds 0.5 mol CB per mol 
GLUT1 [95, 102]. 
6. Tetramerization-deficient GLUT1 mutants - GLUT1 forms in which membrane spanning 
helix 9 is substituted with GLUT3 membrane spanning helix 9 resulting in dissociation into 
GLUT1 dimers (140) and the loss of trans-allostery but retention of exofacial cis-allostery (162). 
Models 
We must then consider several models for sugar transport: 
1. The Simple Carrier: The transporter (or carrier, Figure 3.1A) is an alternating access 
transporter (AAT; (145)) alternately presenting e2 (external) and e1 (internal) substrate binding 
sites. Inhibitors bind competitively to e2 and/or e1. 
2. The Fixed Site Transporter (FST): The transporter (Figure 3.1B) presents sugar uptake 
and sugar exit sites simultaneously (147). Inhibitor binding at uptake and exit sites is competitive 
with sugar binding at the same sites.  
3. Intermolecular cis-allostery: The transporter is an FST but comprises a dimer of FSTs 
(Figure 3.2A). The occupancy state of one subunit affects the transport and ligand binding 
properties of adjacent subunits. 
4. Intramolecular cis-allostery: The transporter is an FST but additionally contains an 
exofacial allosteric activator site (Figure 3.2B) at which sugar or inhibitors compete for binding 
and whose occupancy activates transport (either via an affinity or catalytic effect). 
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5. Intramolecular trans-allostery 1: The transporter is an FST. An allosteric activator site 
that can bind sugar or inhibitors is present at the endofacial surface of each subunit (Figure 3.3A) 
and its occupancy activates transport (either via an affinity or catalytic effect) and enhances 
ligand binding at the exofacial site.  
6. Intramolecular trans-allostery 2: The transporter is an FST containing endofacial, 
mutually-exclusive, allosteric sites that can bind sugar or inhibitors (Figure 3.3B). High affinity 
occupancy of the first site activates transport. Low affinity occupancy of the second site inhibits 
transport. 
7. Intramolecular trans-allostery 3: The transporter is an FST containing two allosteric 
sites that can bind sugar or inhibitors (competitively) at the endofacial surface of each subunit 
(Figure 3.3C). High affinity occupancy of the first site activates transport. Low affinity 
occupancy of the second site inhibits transport. The low affinity site could also represent the 
endofacial sugar binding site.  
8. Intermolecular trans-allostery: The transporter is a dimer of dimers (a tetramer) of 
alternating access transporters in which each dimer presents an e2 subunit and an e1 subunit 
(Figure 3.4A). If an e1 subunit of a dimer undergoes the e1 to e2 conformational change, the 
adjacent e2 subunit within the same dimer must undergo the e2 to e1 conformational change. If 
one dimer contains an inhibitor in the e1 subunit, the dimer is locked in an inactive state. The 
occupancy states of any one dimer is communicated to the adjacent dimer.   
9. Exofacial, Allosteric Alternating Access Transporter: A simple carrier that contains an 
additional exofacial allosteric site at which sugars and inhibitors compete for binding (Figure 
3.4B). Occupancy of the allosteric site stimulates transport. 
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Figure 3.1: The Alternating Access Transporter (AAT) and the Fixed Site Transporter 
(FST). A. The AAT. The carrier alternates between conformations exposing an exofacial sugar 
binding site (e2) and an endofacial sugar binding site (e1). Extracellular inhibitor (L2) and 
extracellular sugar (S2) compete for binding to e2. intracellular inhibitor (L1) and intracellular 
sugar (S1) compete for binding to e1. Conformational changes between e2 and e1 are called 
"translocation" when sugar is bound and "relaxation" when no sugar is bound. B. The FST. 
The carrier, e, presents exofacial and endofacial sugar binding sites simultaneously. 
Extracellular sugar (S2) and inhibitor (L2) compete for binding at the exofacial site. 
Intracellular sugar (S1) and inhibitor (L1) compete for binding at the endofacial site. The 
carrier can form ternary complexes with intra- and extracellular sugars (S2.e.S1, intra- and 
extracellular inhibitors (L2.e.L1), or with sugars and inhibitors (L2.e.S1, S2.e.L1). 
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Figure 3.2: Models for cis-allostery A. Intermolecular cis-allostery The transporter is an 
FST but comprises a dimer of FSTs (Figure 3.2A). The occupancy state of one subunit affects 
the transport and ligand binding properties of adjacent subunits. Thus occupancy of subunit 1 
by an exofacial inhibitor to form L2.e traps that subunit in an inhibited state but increases the 
affinity of the adjacent subunit for extracellular sugar and/or accelerates the rate of transport 
via the adjacent subunit. B. Intramolecular cis-allostery. The transporter is an FST which 
additionally contains an exofacial allosteric activator site at which sugars or inhibitors compete 
for binding and whose occupancy activates transport (either via an affinity or catalytic effect). 
Thus L2.e.S2 transports faster or with higher affinity for substrate than does e.S2. 
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Figure 3.3: Intramolecular trans-allostery models. A. Model 1 The transporter is an FST. 
An allosteric activator site that can bind sugar or inhibitors is present at the endofacial surface 
of each subunit and, when occupied by ligand, activates transport (either via an affinity or 
catalytic effect) and enhances ligand binding at the exofacial site. B. Model 2 The transporter 
is an FST containing mutually-exclusive, endofacial, allosteric sites that can bind sugar or 
ligands. High affinity occupancy of the first site by an activating ligand (L1) activates 
transport. Low affinity occupancy of the second site by an inhibitory ligand (I1) inhibits 
transport. The transporter cannot be occupied by both activator and inhibitor simultaneously. 
C. Model 3 The transporter is an FST containing two allosteric sites that can bind sugar or 
inhibitors (competitively) at the endofacial surface of each subunit. High affinity occupancy of 
the first site by an activator (L1) activates transport. Low affinity occupancy of the second site 
by an inhibitory ligand (I1) inhibits transport. The transporter may be occupied by both 
activator and inhibitor simultaneously (forming L1.I1.e) and the net effect on transport 
depends on the relative potency of activator and inhibitor.  
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Figure 3.4: Trans-allostery Models A. Intermolecular trans-allostery The transporter is a 
dimer of dimers (a tetramer) of alternating access transporters in which each dimer must 
present subunits in opposite conformations (e.g. one subunit presents an e2 conformation and 
the second an e1 conformation or vice versa). If an e1 subunit of a dimer undergoes the e1 to 
e2 conformational change, the adjacent e2 subunit within the same dimer must undergo the e2 
to e1 conformational change. If a dimer contains an inhibitor in its e1 subunit (e.L1), that 
dimer is trapped in an inhibited state. If the adjacent dimer does not contain an inhibitory 
ligand (i.e. its e1 subunit is ligand-free), the occupancy state of the neighboring liganded dimer 
is communicated to the uninhibited dimer and transport of sugar via the e2 subunit is 
accelerated either via increased affinity of sugar binding or via increased translocation. B. 
Exofacial, Allosteric Alternating Access Transporter An AAT containing an additional 
exofacial allosteric site at which sugars and inhibitors compete for binding. Occupancy of the 
allosteric site (which may persist throughout the transport cycle) stimulates transport via the 
catalytic center. 
 
King-Altman Schema 
The King-Altman schema corresponding to each of these models are illustrated in Schema 1 
through 10 (Figure 3.5 - 10). 
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Figure 3.5: King-Altman representations of the AAT and FST. Scheme 1. The AAT. The 
carrier e isomerizes between exofacial (e2) and endofacial (e1) conformations. The 
dissociation constants for extracellular sugar and inhibitor binding to e2 are K2 and KI2 
respectively. The dissociation constants for intracellular sugar and inhibitor binding to e1 are 
K1 and KI1 respectively. First order relaxation rate constants are k-o and ko and first order 
translocation rate constants are k-1 and k1 Scheme 2. The FST. The carrier e exposes an 
exofacial site at which extracellular sugar (S2) and inhibitor (I2) compete for binding and an 
endofacial site at which intracellular sugar (S1) and inhibitor (I1) compete for binding. 
Dissociation constants for S2, I2, S1 and I1 binding are K2, KI2, K1 and KI1 respectively. 
Binding of I2 to e affects the dissociation constant for S1 binding by the cooperativity factor β 
and for I1 binding by the cooperativity factor δ. Binding of I1 to e affects the dissociation 
constant for S2 binding by the cooperativity factor γ. Binding of S2 to e affects the dissociation 
constant for S1 binding by the cooperativity factor α. kcat for net sugar import, net sugar export 
and for exchange transport are v21, v12 and ve respectively. 
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Figure 3.6: King-Altman representations of inter- and intramolecular cis-allostery. 
Scheme 3. Intermolecular cis-allostery GLUT1 is an FST but the transporter comprises a 
dimer of FSTs. Binding of extracellular inhibitor (I) or sugar (S) to subunit 1 is represented as 
an addition to the left of e. Binding of extracellular inhibitor (I) or sugar (S) to subunit 2 is 
represented as an addition to the right of e. Dissociation constants for I or S binding to either 
subunit are KI and KS respectively. Binding of S to either subunit affects the dissociation 
constants for S and I binding to the adjacent subunit by the cooperativity factors α and δ 
respectively. Binding of I to either subunit affects the dissociation constant for I binding to the 
adjacent subunit by the cooperativity factor π. kcat for transport by S.e and e.S is v. kcat for 
transport by S.e.I and I.e.S is γv. kcat for transport by S.e.S is 2φv.   Scheme 4. Intramolecular 
cis-allostery. GLUT1 is an FST which additionally contains an exofacial allosteric activator 
site at which sugars or inhibitors compete for binding and whose occupancy activates transport 
(either via an affinity or catalytic effect). Binding of inhibitor (I) or sugar (S) at the allosteric 
site is shown to the left of e. Binding of inhibitor (I) or sugar (S) at the catalytic center is 
shown to the right of e. Dissociation constants for I or S binding at the allosteric site are KII 
and KA respectively. Dissociation constants for I or S binding at the catalytic center are KI and 
KS respectively. Sugar binding at the allosteric site affects dissociation constants for S and I 
binding at the catalytic center by cooperativity factors α and Ω respectively. Inhibitor binding 
at the allosteric site affects dissociation constants for S and I binding at the catalytic center by 
cooperativity factors δ and π respectively. kcat for transport by e.S is v., for transport by I.e.S is 
γv and for transport by S.e.S is φv. 
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Figure 3.7: King-Altman representations of intramolecular trans-allostery. Scheme 5. 
Intramolecular trans-allostery model 1. GLUT1 is an FST which contains an allosteric site for 
intracellular ligand. Dissociation constants for binding of intracellular inhibitor (I) or 
extracellular sugar (S) are KI and KS respectively. Binding of S affects the dissociation 
constant for I binding by the cooperativity factor α and vice versa. kcat for transport by eS is v. 
kcat for transport by IeS is γv.   Scheme 6. Intramolecular trans-allostery model 2. GLUT1 is an 
FST containing mutually exclusive, endofacial, allosteric activator and inhibitor binding sites 
at which sugars or inhibitors compete for binding. Occupancy of the activator and inhibitory 
sites stimulates and inhibits transport respectively. Binding of activating ligand (I) is shown to 
the left of e (Ie) and of inhibitory ligand (I) to the right of e (eI). Binding of sugar (S) at the 
catalytic center is shown to the right of e. Dissociation constants for I binding at the activating 
and inhibitory sites are KA and Ki respectively. The dissociation constant for S binding at the 
catalytic center is KS. Sugar binding at its catalytic center affects dissociation constants for I 
binding at the activating and inhibitory sites by cooperativity factors δ and α respectively. kcat 
for transport by eS is v., for transport by IeS is δv. eIS is catalytically inactive. 
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Figure 3.8: King-Altman representations of intra- and inter-molecular trans-allostery. 
Scheme 7. GLUT1 is an FST containing two co-existent allosteric sites that competitively 
bind sugar (S) or inhibitors (I) at the endofacial surface of each subunit. High affinity 
occupancy of the first site (shown as binding to the left of e) activates transport. Low affinity 
occupancy of the second site (shown as binding to the right of e) inhibits transport. Binding of 
sugar (S) at the catalytic center is shown to the right of e. Dissociation constants for I binding 
at the activating and inhibitory sites are KA and Ki respectively. The dissociation constant for S 
binding at the catalytic center is KS. Sugar binding at its catalytic center affects dissociation 
constants for I binding at the activating and inhibitory sites by cooperativity factors δ and α 
respectively. I binding at the activating site affects the dissociation constant for I binding at the 
inhibitory site by cooperativity factor φ. The dissociation constant for I binding at the 
activating site in the eIS ternary complex is affected by the cooperativity factor σ. The 
dissociation constant for I binding at the inhibitory site in the IeS ternary complex is affected 
by the cooperativity factor λ. The dissociation constant for S binding at the catalytic center of 
the IeI ternary complex is affected by the cooperativity factor β. The rule of microscopic 
reversibility (45) requires that α σ = δ λ = φ β. kcat for transport by eS is v, for transport by IeS 
is δv and for transport by IeIS is πv. eIS is catalytically inactive. Scheme 8A. Inter-molecular 
trans-allostery. The transporter comprises a dimer of GLUT1 dimers. Each GLUT1 subunit is 
an AAT. Each dimer is independent of the other although subunit occupancy states are 
communicated across the dimer/dimer interface. Inhibitor L interacts only with e1 
conformations of GLUT1. When one e1 subunit of a dimer contains a bound inhibitor (L) its 
adjacent e2 partner within the dimer (termed the cognate subunit) is, like its liganded partner, 
locked and thus inactive. However, the occupancy state of e1L is transmitted to the adjacent 
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dimer and allows the e2 subunit of the adjacent dimer to bind S2 with higher affinity or to 
transport S2 (k-1) with greater speed. This scheme portrays intracellular ligand (L) and extra- 
and intracellular sugar (S2 and S1) binding to a single dimer in the tetrameric complex. First-
order translocation rate constants for sugar uptake and exit are k-1 and k1 respectively. First 
order translocation rate constants for relaxation are k-o and ko. Dissociation constants for S1, S2 
and L binding to the dimer are K1, K2 and KL respectively. S2 binding to the dimer affects the 
dissociation constants for S1 and L binding to the adjacent e1 subunit by the cooperativity 
factors α and β respectively. The law of microscopic reversibility requires the following: ko k-1 
K1 = k-o k1 K2. All other microscopic reversibility requirements derive from this specific 
relationship. 
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Figure 3.9: King-Altman representation of intermolecular trans-allostery. A. Scheme 8B. 
King-Altman representation of alternative model for intermolecular trans-allostery. The 
transporter comprises a dimer of GLUT1 dimers. Each GLUT1 subunit is an AAT. Each dimer 
is independent of the other although subunit occupancy states are communicated across the 
dimer/dimer interface. Each dimer adopts the e2.e1 or e1.e2 conformation. There are 4 possible 
configurations of unliganded tetramer (e2.e1|e2.e1, e2.e1|e1.e2, e1.e2|e2.e1 and e1.e2|e1.e2). The 
scheme in here illustrates only the e2.e1|e2.e1 conformation. The unliganded transporter 
(e2.e1|e2.e1) is depicted as _ _ | _ _ where each underscore represents an unliganded site. An e2 
site can become liganded with extracellular sugar S (e.g. S _ | _ _ or _ _ | S _ or S _ | S _) 
whereas the e1 site can become liganded with L (e.g. _ L | _ _ or _ _ | _ L or _ L | _ L ). Only 
dimers in which the cognate e1 subunit is not complexed with L are capable of transport. 
Dissociation constants for S and L binding are KS and KL respectively. The inset summarizes 
cooperative interactions. S biding to one dimer affects S binding to the adjacent dimer by the 
cooperativity constant α. L biding to one dimer affects L binding to the adjacent dimer by the 
cooperativity constant β. S and L biding to the same dimer is cooperative and described by the 
cooperativity constant δ. S and L biding to different dimers within the complex is cooperative 
and is described by the cooperativity constant γ. The factors p, q and r describe how kcat (v) for 
sugar uptake by the tetramer is affected when the tetramer contains: 1) 2 sugars, 2) a sugar in 1 
dimer plus an inhibitor in the adjacent dimer and 3) 2 sugars and one inhibitor respectively. B. 
Scheme 8C. A FST tetramer comprising a dimer of FST dimers. This transporter can bind up 
to 4 exofacial sugars (S) and 4 endofacial ligands (L). Exofacial cooperativity is shared within 
subunits of each dimer (binding of the first sugar affects KS for binding of the second by the 
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cooperativity factor α) and between dimers (binding of a sugar to one dimer affects KS for 
binding of a second sugar to a subunit in the adjacent dimer by the cooperativity factor θ. In a 
similar way, endofacial cooperativity is shared within subunits of each dimer (binding of the 
first ligand affects KL for binding of the second by the cooperativity factor β) and between 
dimers (binding of a ligand to one dimer affects KL for binding of a second ligand to a subunit 
in the second dimer by the cooperativity factor ψ. Finally, cooperativity may exist between 
endofacial and exofacial sites (trans-allostery) within the same subunit (γ) between subunits of 
the same dimer (δ) and between subunits in different dimers (π). 
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Figure 3.10: King-Altman representation of the exofacial allosteric AAT. Scheme 9A A 
simple carrier that contains an additional exofacial allosteric site at which sugars and inhibitors 
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compete for binding. Occupancy of the allosteric site stimulates transport. Ligand binding to 
the catalytic center is shown as an addition to the right of e. Ligand binding to the allosteric 
site is shown as an addition to the left of e. Dissociation constants for S1, S2 and I (exofacial 
inhibitor) binding to e are as described in Figure 5 (K1, K2 and Ki respectively). Intracellular 
inhibitor (L) binding to e1 is described the the dissociation constant KL. Dissociation constants 
for S2 and I binding to the exofacial allosteric site are KAS and KA respectively. Binding of I to 
the allosteric site affects the dissociation constant for S2 and I binding to the catalytic center of 
e2 by the cooperativity factors δ and γ respectively. Binding of S2 to the allosteric site affects 
the dissociation constant for S2 and I binding to the catalytic center of e2 by the cooperativity 
factors α and β respectively. When the allosteric site is occupied by S2 the relaxation rate 
constants (ko and k-o) become k2 and k-2 and the translocation rate constants (k1 and k-1) 
become k3 and k-3. Dissociation constants for L and S1 binding to Se1 are affected by the 
cooperativity factors π and α respectively. When the allosteric site is occupied by I the 
relaxation rate constants (ko and k-o) become k4 and k-4 and the translocation rate constants (k1 
and k-1) become k5 and k-5. Dissociation constants for L and S1 binding to Ie1 are affected by 
the cooperativity factors φ and δ respectively. The law of microscopic reversibility requires the 
following: K2 k-2 k3 = K1 k2 k-3 and K2 k-4 k5 = K1 k4 k-5.  Scheme 9B A simplified version of 
Scheme 9A according to the method of Cha. Scheme 9A is subdivided into 4 rapid equilibrium 
segments - A, B, C and D (see Scheme 9A). The components of segments A, B, C and D (that 
interchange with other segments via the indicated first order rate constants are described in the 
solution to Model 9. 
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Results 
 Both the alternating access transporter (model 1) and the fixed site transporter (model 2) 
have been analyzed previously (78,80,83,118,147,149,167) and neither can reproduce transport 
stimulation at low [inhibitor] followed by inhibition at higher [inhibitor] without significant 
modification. Only transport inhibition is possible with either of these models when inhibitors 
(cis or trans) are introduced (83). 
 Our general conclusion from the subsequent analyses we present below is that when the 
effect of inhibitor on transport is cast as the ratio of inhibited sugar uptake (vi) : control sugar 
uptake (vc) the equations that reproduce stimulation followed by inhibition take one of two 
general forms. In the absence of transbilayer sugar leakage (i.e. when non GLUT1-mediated 
sugar trans- bilayer diffusion is absent) 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+[𝐼]𝐶𝑜𝑛𝑠𝑡2
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡3+[𝐼]𝐶𝑜𝑛𝑠𝑡4)
 eqn 1 
Or, when non-specific leakage of sugar across the cell membrane is considered, 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡2+[𝐼])
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡3+[𝐼]𝐶𝑜𝑛𝑠𝑡4)
 eqn 2 
where the specific interpretation of Const1 - Const4 is model-dependent. An extension of 
equation 1 also results when the transporter can bind multiple ligands and transported sugars (see 
result for model 8C).  
Solutions for models 3 - 9 
Model 3 - Intermolecular cis-allostery 
Assuming rapid equilibrium kinetics, sugar uptake in the presence of extracellular inhibitors (vi) 
is given by 
𝑣𝑖
[𝑒]𝑡
=
2𝑣(
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝑆
2+𝛾
[𝐼][𝑆]
𝛿𝐾𝑆𝐾𝐼
)
(1+
2[𝑆]
𝐾𝑆
+
[𝑆]2
𝛼𝐾𝑆
2+
2[𝐼]
𝐾𝐼
+
[𝐼]2
𝜋𝐾𝐼
2+
2[𝐼][𝑆]
𝛿𝐾𝑆𝐾𝐼
)
  eqn 3 
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where [e]t is the concentration of membrane resident GLUT1, [S] and [I] are concentrations of 
extracellular transported sugar and transport inhibitor respectively and the remaining constants 
are as defined in Scheme 3. When inhibitors are absent, control uptake (vc) is given by  
𝑣𝑐
[𝑒]𝑡
=
2𝑣(
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝑆
2)
(1+
2[𝑆]
𝐾𝑆
+
[𝑆]2
𝛼𝐾𝑆
2)
 eqn 4 
Thus, the ratio of inhibited to control transport is given by: 
𝑣𝑖
𝑣𝑐
=
[𝐼]𝐶𝑜𝑛𝑠𝑡1+𝐶𝑜𝑛𝑠𝑡2
[𝐼](𝐶𝑜𝑛𝑠𝑡3+[𝐼]𝐶𝑜𝑛𝑠𝑡4)+𝐶𝑜𝑛𝑠𝑡2
 eqn 1 
Where the constants have the following solutions: 
𝐶𝑜𝑛𝑠𝑡1 = (1 +
2[𝑆]
𝐾𝑆
+
[𝑆]2
𝛼𝐾𝑆
2)(
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝑆
2)𝐶𝑜𝑛𝑠𝑡2 = (1 +
2[𝑆]
𝐾𝑆
+
[𝑆]2
𝛼𝐾𝑆
2)𝛾
[𝑆]
𝛿𝐾𝑆𝐾𝐼
 
𝐶𝑜𝑛𝑠𝑡3 =
2
𝐾𝐼
(1 +
[𝑆]
𝛿𝐾𝑆
)(
[𝑆]
𝐾𝑆
+ 𝜙
[𝑆]2
𝛼𝐾𝑆
2) 
𝐶𝑜𝑛𝑠𝑡4 =
(
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝑆
2)
𝜋𝐾𝐼
2  
 
This model successfully reproduces transport stimulation followed by transport inhibition as [I] 
is raised from 0 to saturating levels but seems unlikely given that cis-allostery persists in the 
GLUT1 tetramerization-null mutant (162). 
Model 4 - Intramolecular cis-allostery 
Assuming rapid equilibrium kinetics, sugar uptake in the presence of extracellular inhibitors (vi) 
is given by 
𝑣𝑖
[𝑒]𝑡
=
𝑣(
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝑆
2+𝛾
[𝐼][𝑆]
𝛿𝐾𝑆𝐾𝐼
)
(1+
[𝑆]
𝐾𝑆
+
[𝑆]
𝐾𝐴
+
[𝑆]2
𝛼𝐾𝐴𝐾𝑆
+
[𝐼]
𝐾𝐼
+
[𝐼]
𝐾𝐼𝐼
+
[𝐼]2
𝜋𝐾𝐼𝐾𝐼𝐼
+
[𝐼][𝑆]
𝛿𝐾𝑆𝐾𝐼𝐼
+
[𝐼][𝑆]
Ω𝐾𝐴𝐾𝐼
)
 eqn 5 
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where [e]t is the concentration of membrane resident GLUT1, [S] and [I] are concentrations of 
extracellular transported sugar and transport inhibitor respectively and the remaining constants 
are as defined in Scheme 4. When inhibitors are absent, control uptake (vc) is given by: 
𝑣𝑐
[𝑒]𝑡
=
𝑣(
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝑆
2)
(1+
[𝑆]
𝐾𝑆
+
[𝑆]
𝐾𝐴
+
[𝑆]2
𝛼𝐾𝐴𝐾𝑆
)
   eqn 6 
Thus the ratio of inhibited to control transport is given by: 
𝑣𝑖
𝑣𝑐
=
[𝐼]𝐶𝑜𝑛𝑠𝑡1+𝐶𝑜𝑛𝑠𝑡2
[𝐼](𝐶𝑜𝑛𝑠𝑡3+[𝐼]𝐶𝑜𝑛𝑠𝑡4)+𝐶𝑜𝑛𝑠𝑡2
 eqn 1 
Where the constants have the following solutions: 
𝐶𝑜𝑛𝑠𝑡1 = (1 + [𝑆] (
1
𝐾𝑆
+
1
𝐾𝐴
+
[𝑆]
𝛼𝐾𝐴𝐾𝑆
))(
[𝑆]
𝐾𝑆
+ 𝜙
[𝑆]2
𝛼𝐾𝐴𝐾𝑆
) 
𝐶𝑜𝑛𝑠𝑡2 = (1 + [𝑆] (
1
𝐾𝑆
+
1
𝐾𝐴
+
[𝑆]
𝛼𝐾𝐴𝐾𝑆
))𝛾
[𝑆]
𝛿𝐾𝑆𝐾𝐼𝐼
 
𝐶𝑜𝑛𝑠𝑡3 = (
[𝑆]
Ω𝐾𝐴𝐾𝐼
+
[𝑆]
𝛿𝐾𝑆𝐾𝐼𝐼
+
1
𝐾𝐼
+
1
𝐾𝐼𝐼
) (
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝐴𝐾𝑆
) 
𝐶𝑜𝑛𝑠𝑡4 =
(
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝐴𝐾𝑆
)
𝜋𝐾𝐼𝐾𝐼𝐼
  
 This reproduces transport stimulation followed by transport inhibition as [I] is raised from 
0 to saturating levels (the equation is of the correct form) and is consistent with the finding that 
the exofacial cavity presents 3 sugar binding sites - peripheral (P), intermediate (I) and core (C) 
(149,162). The core site is proposed to be catalytic and the peripheral and intermediate are 
thought to be allosteric (maltose, WZB117 and other molecules can occupy P+I and I+C; 
(78,149,162). 
Model 5 - Intramolecular trans-allostery 1 
Assuming rapid equilibrium kinetics, uptake (vi) in the presence of intracellular inhibitors (I) is 
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given by: 
𝑣𝑖
[𝑒]𝑡
=
𝑣(
[𝑆]
𝐾𝑆
+𝛾
[𝐼][𝑆]
𝛼𝐾𝑆𝐾𝐼
)
(1+
[𝑆]
𝐾𝑆
+
[𝐼]
𝐾𝐼
+
[𝐼][𝑆]
𝛼𝐾𝑆𝐾𝐼
)
  eqn 7 
where [e]t is the concentration of membrane resident GLUT1, [S] and [I] are concentrations of 
extracellular transported sugar and intracellular transport inhibitor respectively and the remaining 
constants are as defined in Scheme 5. When inhibitors are absent, control uptake (vc) is given by: 
𝑣𝑐
[𝑒]𝑡
=
𝑣(
[𝑆]
𝐾𝑆
)
(1+
[𝑆]
𝐾𝑆
)
   eqn 8 
Thus the ratio of inhibited to control transport is given by: 
𝑣𝑖
𝑣𝑐
=
[𝐼]𝐶𝑜𝑛𝑠𝑡1+𝐶𝑜𝑛𝑠𝑡2
[𝐼]𝐶𝑜𝑛𝑠𝑡3+𝐶𝑜𝑛𝑠𝑡2
  eqn 9 
Where the constants have the following solutions: 
𝐶𝑜𝑛𝑠𝑡1 =
𝛾
𝐾𝐼
(1 +
[𝑆]
𝛼𝐾𝑆
) 
𝐶𝑜𝑛𝑠𝑡2 = 1 +
[𝑆]
𝐾𝑆
 
𝐶𝑜𝑛𝑠𝑡3 =
1
K𝐼
(1 +
[𝑆]
𝛼𝐾𝑆
) 
Equation 9 can only produce transport inhibition (γ < 1) or stimulation (γ > 1) thus this model is 
rejected.  
Model 6 - Intramolecular trans-allostery 2 
Assuming rapid equilibrium kinetics, sugar uptake (vi) in the presence of intracellular inhibitors 
is given by: 
𝑣𝑖
[𝑒]𝑡
=
𝑣(
[𝑆]
𝐾𝑆
+𝛾
[𝐼][𝑆]
𝛿𝐾𝑆𝐾𝐼
)
(1+
[𝑆]
𝐾𝑆
+
[𝐼]
𝐾𝐼
+
[𝐼]
𝐾𝐴
+
[𝐼][𝑆]
𝐾𝑆
(
1
𝛼𝐾𝐼
+
1
𝛿𝐾𝐴
))
  eqn 10 
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where [e]t is the concentration of membrane resident GLUT1, [S] and [I] are concentrations of 
extracellular transported sugar and transport inhibitor respectively and the remaining constants 
are as defined in Scheme 6. When inhibitors are absent, control uptake (vc) is given by  
𝑣𝑐
[𝑒]𝑡
=
𝑣(
[𝑆]
𝐾𝑆
)
(1+
[𝑆]
𝐾𝑆
)
   eqn 11 
Thus the ratio of inhibited to control transport is given by: 
𝑣𝑖
𝑣𝑐
=
[𝐼]𝐶𝑜𝑛𝑠𝑡1+𝐶𝑜𝑛𝑠𝑡2
[𝐼]𝐶𝑜𝑛𝑠𝑡3+𝐶𝑜𝑛𝑠𝑡2
  eqn 9 
Where the constants have the following solutions: 
𝐶𝑜𝑛𝑠𝑡1 =
𝛾
𝛿𝐾𝐴
(1 +
[𝑆]
𝐾𝑆
) 
𝐶𝑜𝑛𝑠𝑡2 = 1 +
[𝑆]
𝐾𝑆
 
𝐶𝑜𝑛𝑠𝑡3 =
1
𝐾𝐼
+
1
𝐾𝐴
+
[𝑆]
𝐾𝑆
(
1
𝛼𝐾𝐼
+
1
𝛿𝐾𝐴
) 
As with Model 5, Model 6 can only produce transport inhibition (γ < 1) or stimulation (γ > 1) 
thus this model is rejected. 
Model 7 - Intramolecular trans-allostery 3 
Assuming rapid equilibrium kinetics, sugar uptake (vi) in the presence of intracellular inhibitors 
(I) is given by:  
𝑣𝑖
[𝑒]𝑡
=
𝑣(
[𝑆]
𝐾𝑆
+𝛾
[𝐼][𝑆]
𝛿𝐾𝑆𝐾𝐴
+𝜋
[𝐼]2[𝑆]
𝛿𝛾𝐾𝑆𝐾𝐴𝐾𝑆𝐾𝐼
)
(1+
[𝑆]
𝐾𝑆
+
[𝐼]
𝐾𝐼
+
[𝐼]
𝐾𝐴
+
[𝐼]2
𝜙K𝐼𝐾𝐴
+
[𝐼][𝑆]
𝐾𝑆
(
1
𝛼K𝐼
+
1
𝛿K𝐴
)+
[𝐼]2[𝑆]
𝛿𝜆𝐾𝑆𝐾𝐴𝐾𝐼
)
  eqn 12 
where [e]t is the concentration of membrane resident GLUT1, [S] and [I] are concentrations of 
extracellular transported sugar and intracellular transport inhibitor respectively and the remaining 
constants are as defined in Scheme 7. When inhibitors are absent, control uptake (vc) is given by  
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𝑣𝑐
[𝑒]𝑡
=
𝑣[𝑆]
𝐾𝑆+[𝑆]
   
Thus the ratio of inhibited to control transport is given by: 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡2+[𝐼]𝐶𝑜𝑛𝑠𝑡3)
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡4+[𝐼]𝐶𝑜𝑛𝑠𝑡5)
 eqn 1.1 
Where the constants have the following solutions: 
𝐶𝑜𝑛𝑠𝑡1 = 𝛼𝛿𝛾𝜆𝜙𝐾𝐴𝐾𝐼(𝐾𝑆 + [𝑆]) 
𝐶𝑜𝑛𝑠𝑡2 = 𝛼𝛾𝜆𝜙𝐾𝐼(𝐾𝑆 + [𝑆]) 
𝐶𝑜𝑛𝑠𝑡3 = 𝛼𝜋𝜙(𝐾𝑆 + [𝑆]) 
𝐶𝑜𝑛𝑠𝑡4 = 𝛼𝛿𝜆𝜙𝐾𝑆{(𝐾𝐴 +𝐾𝐼) + 𝜆𝜙[𝑆](𝛿K𝐴 + 𝛼𝐾𝐼)} 
𝐶𝑜𝑛𝑠𝑡5 = 𝛼(𝛿𝛾𝐾𝑆 + 𝜙[𝑆]) 
When π = 0, 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+[𝐼]𝐶𝑜𝑛𝑠𝑡2
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡4+[𝐼]𝐶𝑜𝑛𝑠𝑡5)
  eqn 1 
These equations (eqns 1 and 1.1) take the correct form (eqn 1) to permit transport stimulation 
followed by transport inhibition as [I] is raised from subsaturating to saturating levels. This 
model seems unlikely, however, because dimeric GLUT1 binds 1 mol CB per mol GLUT1 while 
tetrameric GLUT1 binds 0.5 mol CB per mol GLUT1 (95,102). The binding capacity of this 
carrier would be 2 mol CB per mol GLUT1. 
Model 8 - Intermolecular trans-allostery  
In this model, the transporter comprises a dimer of GLUT1 dimers. Each dimer is essentially 
independent of the other although subunit occupancy states are communicated across the 
dimer/dimer interface. When one e1 subunit of a dimer contains a bound inhibitor (L) its 
adjacent e2 partner within the dimer (termed the cognate subunit) is, like its liganded partner, 
locked and thus inactive. However, the occupancy state of e1L is transmitted to the adjacent 
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dimer and allows the e2 subunit of the adjacent dimer to bind S2 with higher affinity or to 
transport S2 (k-1) with greater speed.  
This model is more challenging to solve. The probability of dimer 1 or 2 having S2 bound in a 
catalytically active form is given by 
𝑃𝑆2 =
𝑆2
𝐾2
𝐷𝐴
where𝐷𝐴 = 1 +
[𝑆1]
𝐾1
+
[𝑆2]
𝐾2
+
[𝑆1][𝑆2]
𝛼𝐾1𝐾2
+
[𝐿]
𝐾𝐿
+
[𝐿][𝑆2]
𝛽𝐾𝐿𝐾2
 
The probability of dimer 1 or 2 having S1 plus S2 bound in a catalytically active form is given 
by: 
𝑃𝑆𝑆 =
[𝑆1][𝑆2]
𝛼𝐾1𝐾2
𝐷𝐴
 
The probability of dimer 1 or 2 having L bound is given by 
𝑃𝐿 =
[𝐿]
𝐾𝐿
+
[𝐿][𝑆2]
𝛽𝐾𝐿𝐾2
𝐷𝐴
 
And the probably of either being free of ligand is 1-PL. 
Assuming only transport rates are affected (not affinity at this point) 
𝑣21 = 𝑣𝑖 = (1 − 𝑃𝐿)(𝑘−1𝑃𝑆2 + 𝑘𝑒𝑃𝑆𝑆) + 𝑃𝐿(𝑘−1
∗ 𝑃𝑆2 + 𝑘𝑒
∗𝑃𝑆𝑆) 
where
𝑘−1
∗
𝑘−1
and
𝑘𝑒
∗
𝑘𝑒
> 1 = 𝛾 
When S1 = 0 
𝑃𝐿 =
[𝐿]
𝐾𝐿
+
[𝐿][𝑆2]
𝛽𝐾𝐿𝐾2
1 +
[𝑆2]
𝐾2
+
[𝐿]
𝐾𝐿
+
[𝐿][𝑆2]
𝛽𝐾𝐿𝐾2
and1 − 𝑃𝐿 =
1 +
[𝑆2]
𝐾2
1 +
[𝑆2]
𝐾2
+
[𝐿]
𝐾𝐿
+
[𝐿][𝑆2]
𝛽𝐾𝐿𝐾2
; 𝑃𝑆2
=
[𝑆2]
𝐾2
1 +
[𝑆2]
𝐾2
+
[𝐿]
𝐾𝐿
+
[𝐿][𝑆2]
𝛽𝐾𝐿𝐾2
; 𝑃𝑆𝑆 = 0 
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𝑣𝑐 =
𝑘−1
[𝑆2]
𝐾2
1 +
[𝑆2]
𝐾2
; 𝑣𝑖 =
(1 +
[𝑆2]
𝐾2
)𝑘−1
[𝑆2]
𝐾2
+
[𝐿]
𝐾𝐿
(1 +
[𝑆2]
𝛽𝐾2
)𝛾𝑘−1
[𝑆2]
𝐾2
𝐷𝐴𝐷𝐴
 
𝑣𝑖
𝑣𝑐
=
[(1 +
[𝑆2]
𝐾2
)𝑘−1
[𝑆2]
𝐾2
+
[𝐿]
𝐾𝐿
(1 +
[𝑆2]
𝛽𝐾2
)𝛾𝑘−1
[𝑆2]
𝐾2
] (1 +
[𝑆2]
𝐾2
)
𝐷𝐴𝐷𝐴𝑘−1
[𝑆2]
𝐾2
 
𝑣𝑖
𝑣𝑐
=
(1+𝛾
[𝐿]
𝐾𝐿
+
2[𝑆2]
𝐾2
+𝛾
[𝐿][𝑆2]
𝐾𝐿𝐾2
+𝛾
[𝐿][𝑆2]
𝛽𝐾𝐿𝐾2
+
[𝑆2]
2
𝐾2
2 +𝛾
[𝐿][𝑆2]
2
𝛽𝐾𝐿𝐾2
2 )
(1+
[𝐿]
𝐾𝐿
+
[𝑆2]
𝐾2
+
[𝐿][𝑆2]
𝛽𝐾𝐿𝐾2
)
2  eqn 13 
𝑣𝑖
𝑣𝑐
=
𝛽𝐾𝐿(𝐾2+[𝑆2])(𝛾[𝐿][𝑆2]+𝛽(𝐾2(𝐾𝐿+𝛾[𝐿])+𝐾𝐿[𝑆2]))
(𝛽(𝐾2(𝐾𝐿+[𝐿])+𝛽𝐾𝐿[𝑆2]+[𝐿][𝑆2])2
 eqn 14 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+[𝐿]𝐶𝑜𝑛𝑠𝑡2
𝐶𝑜𝑛𝑠𝑡1+[𝐿](𝐶𝑜𝑛𝑠𝑡3+[𝐿]𝐶𝑜𝑛𝑠𝑡4)
  eqn 1.1 
where 
    𝐶𝑜𝑛𝑠𝑡1 = 𝛽
2𝐾𝐿
2(𝐾2 + [𝑆2])
2 
   𝐶𝑜𝑛𝑠𝑡2 = 𝛽𝛾𝐾𝐿(𝐾2 + [𝑆2])(𝛽𝐾𝐿 + [𝑆2]) 
   𝐶𝑜𝑛𝑠𝑡3 = 2𝛽𝐾𝐿(𝐾2 + [𝑆2])(𝛽𝐾2 + [𝑆2]) 
    𝐶𝑜𝑛𝑠𝑡4 = (𝛽𝐾2 + [𝑆2])
2 
Equation 1.1 is analogous to eqn 1 thereby permitting transport stimulation followed by transport 
inhibition as [L] is raised from subsaturating to saturating levels. 
A variant of this scheme (Scheme 8B) is shown in Figure 3.9A. Here the tetramer is shown as a 
dimer of dimers in which each subunit is an AAT but where each dimer adopts the e2.e1 or e1.e2 
conformation. There are 4 possible configurations of unliganded tetramer (e2.e1|e2.e1, e2.e1|e1.e2, 
e1.e2|e2.e1 and e1.e2|e1.e2). The scheme in Figure 3.9 illustrates only the e2.e1|e2.e1 conformation. 
It should be noted, however, that this represents only one half cycle of AAT-mediated transport 
(we assume rapid equilibrium kinetics to simplify the analysis). 
Assuming rapid equilibrium, uptake in the absence of intracellular inhibitor, L, is given by: 
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𝑣𝑐 =
2𝑣[𝑆]
𝐾𝑆
+
2𝑝𝑣[𝑆]2
𝛼𝐾𝑆
2
1+
2[𝑆]
𝐾𝑆
+
[𝑆]2
𝛼𝐾𝑆
2
  
and uptake in the presence of intracellular inhibitor L is described by 
𝑣𝑖
=
2𝑣[𝑆]
𝐾𝑆
+
2𝑝𝑣[𝑆]2
𝛼𝐾𝑆
2 +
2𝑞𝑣[𝐿][𝑆]
𝛾𝐾𝐿𝐾𝑆
+
2𝑟𝑣[𝐿][𝑆]2
𝛼𝛿𝛾𝐾𝐿𝐾𝑆
2
1 + 2
[𝑆]
𝐾𝑆
+
[𝑆]2
𝛼𝐾𝑆
2 + 2
[𝐿]
𝐾𝐿
+
[𝐿]2
𝛽𝐾𝐿
2 + 2
[𝐿][𝑆]
𝛾𝐾𝐿𝐾𝑆
+ 2
[𝐿][𝑆]
𝛿𝐾𝐿𝐾𝑆
+ 2
[𝐿]2[𝑆]
𝛽𝛿𝛾𝐾𝐿
2𝐾𝑆
+ 2
[𝐿][𝑆]2
𝛼𝛿𝛾𝐾𝐿𝐾𝑆
2 +
[𝐿]2[𝑆]2
𝛼𝛽𝛿2𝛾2𝐾𝐿
2𝐾𝑆
𝐿
 
Thus vi/vc is: 
 
𝑣𝑖
𝑣𝑐
=
(
2𝑣[𝑆]
𝐾𝑆
+
2𝑝𝑣[𝑆]2
𝛼𝐾𝑆
2 +
2𝑞𝑣[𝐿][𝑆]
𝛾𝐾𝐿𝐾𝑆
+
2𝑟𝑣[𝐿][𝑆]2
𝛼𝛿𝛾𝐾𝐿𝐾𝑆
2 ) (1 +
2[𝑆]
𝐾𝑆
+
[𝑆]2
𝛼𝐾𝑆
2)
(1 + 2
[𝑆]
𝐾𝑆
+
[𝑆]2
𝛼𝐾𝑆
2 + 2
[𝐿]
𝐾𝐿
+
[𝐿]2
𝛽𝐾𝐿
2 + 2
[𝐿][𝑆]
𝛾𝐾𝐿𝐾𝑆
+ 2
[𝐿][𝑆]
𝛿𝐾𝐿𝐾𝑆
+ 2
[𝐿]2[𝑆]
𝛽𝛿𝛾𝐾𝐿
2𝐾𝑆
+ 2
[𝐿][𝑆]2
𝛼𝛿𝛾𝐾𝐿𝐾𝑆
2 +
[𝐿]2[𝑆]2
𝛼𝛽𝛿2𝛾2𝐾𝐿
2𝐾𝑆
𝐿) (
2𝑣[𝑆]
𝐾𝑆
+
2𝑝𝑣[𝑆]2
𝛼𝐾𝑆
2 )
 
 
which reduces to 
𝑣𝑖
𝑣𝑐
=
𝛽𝛿𝛾𝐾𝐿(𝛼𝐾𝑆{𝐾𝑆 + 2[𝑆]} + [𝑆]
2)(𝛼𝛿𝐾𝑆{𝛾𝐾𝐿 + [𝐿]𝑞} + [𝑆]{𝛿𝛾𝐾𝐿𝑝 + [𝐿]𝑟})
(𝛼𝐾𝑆 + 𝑝[𝑆])(𝛼𝛿𝛾𝐾𝑆(𝛽𝐾𝐿(𝛿{𝛾𝐾𝐿𝐾𝑆 + 2𝛾𝐾𝐿[𝑆] + 2𝛾𝐾𝑆[𝐿] + 2[𝐿][𝑆]} + 2𝛾[𝐿][𝑆]) + [𝐿]2{𝛿𝛾𝐾𝑆 + 2[𝑆]}) + [𝑆]2(𝛽𝛿𝛾𝐾𝐿{𝛿𝛾𝐾𝐿 + 2[𝐿]} + [𝐿]2)
 
and subsequently to the form of equation 1  
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+𝐶𝑜𝑛𝑠𝑡2[𝐿]
𝐶𝑜𝑛𝑠𝑡1+[𝐿](𝐶𝑜𝑛𝑠𝑡3+[𝐿]𝐶𝑜𝑛𝑠𝑡4)
 eqn 1 
where:     
𝐶𝑜𝑛𝑠𝑡1 = 𝛽𝛿
2𝛾2𝐾𝐿
2(𝛼𝐾𝑆 + 𝑝[𝑆])([𝑆]
2 + 𝛼𝐾𝑆{𝐾𝑆 + 2[𝑆]}) 
 
𝐶𝑜𝑛𝑠𝑡2 = 𝛽𝛿𝛾𝐾𝐿(𝛼𝛿𝐾𝑆𝑞 + 𝑟[𝑆])([𝑆]
2 + 𝛼𝐾𝑆{𝐾𝑆 + 2[𝑆]}) 
 
𝐶𝑜𝑛𝑠𝑡3 = 2𝛽𝛿𝛾𝐾𝐿(𝛼𝐾𝑆 + 𝑝[𝑆])([𝑆]
2 + 𝛼𝐾𝑆(𝛾[𝑆] + 𝛿{𝛾𝐾𝑆 + [𝑆]})) 
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𝐶𝑜𝑛𝑠𝑡4 = (𝛼𝐾𝑆 + 𝑝[𝑆])([𝑆]
2 + 𝛼𝛿𝛾𝐾𝑆{𝛿𝛾𝐾𝑆 + 2[𝑆]}) 
 
If the trans-action of L is to increase VMAX for net sugar uptake, the parameters q and r > 1 while 
the cooperativity factors α, β, δ and γ = 1. If the trans-action of L is to increase affinity for 
substrate in net sugar uptake, the parameters q = r = 1 while the cooperativity factors δ and γ = < 
1. This model allows for endofacial cis-allostery when β < 1. 
 As described, this model is also kinetically equivalent to a dimer of FSTs. While we think 
the latter model is inappropriate because trans-allostery is lost when GLUT1 forms only dimers 
(162), this model could be expanded to allow for a tetramer of FSTs in which trans-allostery 
requires cooperative interactions from all 4 subunits. Such a model (Scheme 8C) is shown in 
Figure 3.9B. This transporter can bind up to 4 exofacial sugars (S) and 4 endofacial ligands (L). 
Exofacial cooperativity is shared within subunits of each dimer (binding of the first sugar affects 
KS for binding of the second by the cooperativity factor α) and between dimers (binding of a 
sugar to one dimer affects KS for binding of a second sugar to a subunit in the second dimer by 
the cooperativity factor θ. In a similar way, endofacial cooperativity is shared within subunits of 
each dimer (binding of the first ligand affects KL for binding of the second by the cooperativity 
factor β) and between dimers (binding of a ligand to one dimer affects KL for binding of a second 
ligand to a subunit in the second dimer by the cooperativity factor ψ. Finally, cooperativity could 
be expressed between endofacial and exofacial sites (trans-allostery) in the same subunit (γ) 
between subunits of the same dimer (δ) and between subunits in different dimers (π).  Since 
trans-allostery and endofacial cis allostery are absent in dimeric GLUT1, this eliminates a role 
for trans-cooperativity factors ∂ and γ) and trans-allostery must (according to this model) be 
strongly dependent on cooperativity factor π. The endofacial cis-allostery constant ψ must be 
 110 
restored to unity in dimeric GLUT1.  
 Capable of binding up to 8 ligands simultaneously, this transporter complex can exist in as 
many as 256 (28) different liganded states and the solution is correspondingly complex. 
Measuring uptake of extracellular sugar, S, in the absence of intracellular sugar but in the 
presence of endofacial ligand, L, and assuming that any individual subunit complexed with L is 
catalytically inactive, the ratio vi/vc is given by: 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+𝐿(𝐶𝑜𝑛𝑠𝑡2+𝐿(𝐶𝑜𝑛𝑠𝑡3+𝐿))
𝐶𝑜𝑛𝑠𝑡1+𝐿(𝐶𝑜𝑛𝑠𝑡4+𝐿(𝐶𝑜𝑛𝑠𝑡5+𝐿(𝐶𝑜𝑛𝑠𝑡6+𝐿𝐶𝑜𝑛𝑠𝑡7)))
 eqn 1.2 
where: 
Const1 =
𝛽𝜓2𝛿3𝛾3𝐾𝐿
3𝜋6{𝑆3 + 3𝛼𝐾𝑆𝑆
2𝜃2 + 𝛼2𝐾𝑆
3𝜃4 + 𝛼𝐾𝑆
2𝑆𝜃3(2𝛼 + 𝜃)}
𝑆3 + 𝛼𝛾𝐾𝑆𝜋(2𝛿 + 𝜋)𝑆2𝜃2 + 𝛼2𝜓𝛿2𝛾3𝐾𝑆
3𝜋4𝜃4 + 𝛼𝛿𝛾2𝐾𝑆
2𝜋2𝑆𝜃3(2𝛼𝜋 + 𝛿𝜃)
 
Const2 = 
𝛽𝜓2𝛿2𝛾2𝜋4𝐾𝐿
2 (
𝛼2𝛾𝜋𝜃4(2𝛿 + 𝜋)𝐾𝑆
3 + 𝛼𝜃3(2𝛼𝜋(𝛿 + 2𝛾)𝐾𝑆
2𝑆
+𝜃(2𝛿𝛾 + 𝜋2)) + 𝛼𝜃2(2𝛿 + 3𝛾 + 4𝜋)𝐾𝑆𝑆
2 + 3𝑆3
)
𝛼2𝜓𝛿2𝛾3𝜋4𝜃4𝐾𝑆
3 + 𝛼𝛿𝛾2𝜋2𝜃3(2𝛼𝜋 + 𝛿𝜃)𝐾𝑆
2𝑆 + 𝛼𝛾𝜋𝜃2(2𝛿 + 𝜋)𝐾𝑆𝑆2 + 𝑆3
 
𝐶𝑜𝑛𝑠𝑡3 = 
𝜓𝛿𝛾𝐾𝐿𝜋
2 (
(2𝛽 + 𝜓)𝑆3 + 𝛼𝜃2(2𝛽(𝛿 + 2𝛾)𝜋 + 𝜓(2𝛿𝛾 + 𝜋2))𝐾𝑆𝑆
2
+2𝛼2𝛽𝛾(2𝛿 + 𝛾)𝜋2𝜃3𝐾𝑆
2𝑆 + 𝛼𝛿𝛾𝐾𝑆
2(𝛼𝛾𝐾𝑆𝜋
2(𝜓𝛿 + 2𝛽𝜋) + (𝜓𝛿𝛾 + (𝛽 + 𝜓)𝜋2)𝑆)𝜃4
)
𝑆3 + 𝛼𝛾𝐾𝑆𝜋(2𝛿 + 𝜋)𝑆2𝜃2 + 𝛼2𝜓𝛿2𝛾3𝐾𝑆
3𝜋4𝜃4 + 𝛼𝛿𝛾2𝐾𝑆
2𝜋2𝑆𝜃3(2𝛼𝜋 + 𝛿𝜃)
 
𝐶𝑜𝑛𝑠𝑡4 = 
4𝛽𝜓2𝛿2𝛾2𝐾𝐿
2𝜋4
(𝑆3 + 3𝛼𝐾𝑆𝑆
2𝜃2 + 𝛼2𝐾𝑆
3𝜃4 + 𝛼𝐾𝑆
2𝑆𝜃3(2𝛼 + 𝜃))
(𝑆4 + 𝛼𝐾𝑆(𝛿 + 𝛾 + 2𝜋)𝑆
3𝜃2 + 𝛼2𝛿𝛾𝐾𝑆
4𝜋2𝜃4 + 𝛼2𝐾𝑆
3𝜋(𝛾𝜋 + 𝛿(2𝛾 + 𝜋))𝑆𝜃4 + 𝛼𝐾𝑆
2𝑆2𝜃3(2𝛼(𝛿 + 𝛾)𝜋 + (𝛿𝛾 + 𝜋2)𝜃))
(𝑆4 + 4𝛼𝐾𝑆𝑆
3𝜃2 + 𝛼2𝐾𝑆
4𝜃4 + 4𝛼2𝐾𝑆
3𝑆𝜃4 + 2𝛼𝐾𝑆
2𝑆2𝜃3(2𝛼 + 𝜏))(𝑆3 + 𝛼𝛾𝐾𝑆𝜋(2𝛿 + 𝜋)𝑆
2𝜃2 + 𝛼2𝜓𝛿2𝛾3𝐾𝑆
3𝜋4𝜃4 + 𝛼𝛿𝛾2𝐾𝑆
2𝜋2𝑆𝜃3(2𝛼𝜋 + 𝛿𝜃))
 
 
𝐶𝑜𝑛𝑠𝑡5 = 
2𝜓𝛿𝛾𝐾𝑙𝐿𝜋
2
(
(2𝛽 + 𝜓)𝑆4+ 2𝛼𝐾𝑆(2𝛽(𝛿 + 𝛾)𝜋 + 𝜓(𝛿𝛾 + 𝜋
2))𝑆3𝜃2+ 2𝛼2𝛽(𝛿2+ 4𝛿𝛾 + 𝛾2)𝐾𝑆
2𝜋2𝑆2𝜃3+ 𝛼𝐾𝑆
2((2𝛽𝛿𝛾𝜋2 +𝜓(𝛿𝛾 + 𝜋2)2)𝑆2
+𝛼𝛿𝛾𝐾𝑆𝜋
2((2𝛽 + 𝜓)𝛿𝛾𝐾𝑆𝜋
2 + 2(𝜓𝛿𝛾 + 2𝛽𝛾𝜋 + (𝜓 + 2𝛿)𝜋2)𝑆))𝜃4
) (𝑆3+ 3𝛼𝐾𝑆𝑆
2𝜃2+ 𝛼2𝐾𝑆
3𝜃4+ 𝛼𝐾𝑆
2𝑆𝜃3(2𝛼 + 𝜃))
(𝑆4 + 4𝛼𝐾𝑆𝑆3𝜃2+ 4𝛼2𝐾𝑆
2𝑆2𝜃3+ 𝛼𝐾𝑆
2(2𝑆2+ 𝛼𝐾𝑆(𝐾𝑆 + 4𝑆))𝜃4)
(𝑆3 + 𝛼𝛾𝐾𝑆𝜋(2𝛿 + 𝜋)𝑆2𝜃2+ 𝛼2𝜓𝛿2𝛾3𝐾𝑆
3𝜋4𝜃4+ 𝛼𝛿𝛾2𝐾𝑆
2𝜋2𝑆𝜃3(2𝛼𝜋 + 𝛿𝜃))
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𝐶𝑜𝑛𝑠𝑡6 =
4𝜓(𝑆4 + 𝛼𝜋𝐾𝑆𝑆
2(𝜓2𝛿𝛾𝜋3𝐾𝑆 + 𝜃
2(2𝛿𝛾 + (𝛿 + 𝛾)𝜋)𝑆)+ 2𝛼2𝛿𝛾(𝛿 + 𝛾)𝜋3𝜃3𝐾𝑆
2𝑆2 + 𝛼𝛿2𝛾2𝜋2𝐾𝑆
2(𝑆2 + 𝛼𝜓𝜋2𝐾𝑆(𝛿𝛾𝐾𝑆𝜋
2 + (𝛿 + 𝛾 + 2𝜋)𝑆))𝜃4)
(𝑆3+ 3𝛼𝜃2𝐾𝑆𝑆
2+ 𝛼2𝜃4𝐾𝑆
3 + 𝛼𝜃3(2𝛼 + 𝜃)𝐾𝑆
2𝑆)
(𝑆4 + 4𝛼𝐾𝑆𝑆3𝜃2+ 4𝛼2𝐾𝑆
2𝑆2𝜃3+ 𝛼𝜃4𝐾𝑆
2(2𝑆2 + 𝛼𝐾𝑆(𝐾𝑆 + 4𝑆)))
(𝑆3+ 𝛼𝛾𝜋𝜃2(2𝛿 + 𝜋)𝐾𝑆𝑆2+ 𝛼2𝜓𝛿2𝛾3𝜋4𝜃4𝐾𝑆
3 + 𝛼𝛿𝛾2𝜋2𝜃3(2𝛼𝜋 + 𝛿𝜃)𝐾𝑆
2𝑆)
 
𝐶𝑜𝑛𝑠𝑡7 =
(𝑆3+ 3𝛼𝐾𝑆𝑆
2𝜃2 + 𝛼2𝐾𝑆
3𝜃4 + 𝛼𝐾𝑆
2𝑆𝜃3(2𝛼 + 𝜃))
(𝑆4 + 4𝛼𝛿𝛾𝐾𝑆𝜋
2𝑆3𝜃2 + 𝛼2𝜓2𝛿4𝛾4𝐾𝑆
4𝜋8𝜃4 + 4𝛼𝛿3𝛾4𝐾𝑆
3𝜋6𝑆𝜃4+ 2𝛼𝛿2𝛾2𝐾𝑆
2𝜋4𝑆2𝜃3(2𝛼 + 𝜃))
𝛽𝜓2𝛿𝛾𝐾𝐿𝜋2(𝑆4 + 4𝛼𝐾𝑆𝑆3𝜃2 + 4𝛼2𝐾𝑆
2𝑆2𝜃3+ 𝛼𝐾𝑆
2(2𝑆2+ 𝛼𝐾𝑆(𝐾𝑆 + 4𝑆))𝜃4)
(𝑆3+ 𝛼𝛾𝐾𝑆𝜋(2𝛿 + 𝜋)𝑆2𝜃2 + 𝛼2𝜓𝛿2𝛾3𝐾𝑆
3𝜋4𝜃4+ 𝛼𝛿𝛾2𝐾𝑆
2𝜋2𝑆𝜃3(2𝛼𝜋 + 𝛿𝜃))
 
 
 This model allows for trans-allostery (stimulation of sugar uptake by endofacial ligand 
(e.g. CB) when all allostery constants are set to unity but ∂ (trans allostery between S and L 
binding sites in neighboring subunits of each dimer) or π (trans allostery between S and L 
binding sites in subunits of neighboring dimers) are <1. Since trans-allostery is lost in dimeric 
GLUT1, we assume that ∂ =1 and that π is the dominant trans-cooperativity constant in this 
model. 
Model 9 - Exofacial, Allosteric Alternating Access Transporter 
 This is a standard alternating access transporter with the proviso that the e2 conformation 
presents 2 binding sites - an allosteric site which can be occupied by sugar or inhibitor and a 
catalytic site which can be occupied by sugar or inhibitor. Occupancy of the allosteric site can 
stimulate or inhibit transport and affect the affinity of the catalytic site in both e1 and e2 for 
substrate or inhibitor. Occupancy of the allosteric site and its effects persist through the e2 to e1 
conformational change. However, S or I can only dissociate from the allosteric site in the e2 
conformation.  
 This model is more challenging to solve. Assuming segments A, B, C and D of scheme 9 
(Figure 3.10; for simplicity, only one of the 4 subunits is illustrated) are in rapid equilibrium, we 
can define the following: 
f-1 is fraction of A existing as eS2 
f-o is fraction of A existing as e2 
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f-2 is fraction of A existing as Se2 
f-3 is fraction of A existing as SeS2 
f-4 is fraction of A existing as Ie2 
f-5 is fraction of A existing as IeS2 
 
f1 is fraction of B existing as eS1 
fo is fraction of B existing as e1 
 
f4 is fraction of C existing as Ie1 
f5 is fraction of C existing as IeS1 
 
f2 is fraction of D existing as Se1 
f3 is fraction of D existing as SeS1 
 
The King-Altman figure reduces to Scheme 9B and uptake 
𝑣21
𝑒𝑡𝑜𝑡𝑎𝑙
=
(𝑓−1𝑘−1 + 𝑓−3𝑘−3 + 𝑓−5𝑘−5)𝐴
𝐴 + 𝐵 + 𝐶 + 𝐷
 
 
𝑣21
𝑒𝑡𝑜𝑡𝑎𝑙
=
(𝑘−3
[𝑆2]
2
𝛼𝐾2𝐾𝐴𝑆
+ 𝑘−1
[𝑆2]
𝐾2
+ 𝑘−5
[𝐼][𝑆2]
𝛿𝐾2𝐾𝐴
)(𝑘4 + 𝑘5
[𝑆1]
𝛿𝐾1
) (𝑘2 + 𝑘3
[𝑆1]
𝛼𝐾1
) (𝑘𝑜 + 𝑘1
[𝑆1]
𝐾1
)
(
(𝑘4 + 𝑘5
[𝑆1]
𝛿𝐾1
)(𝑘2 + 𝑘3
[𝑆1]
𝛼𝐾1
) (𝑘𝑜 + 𝑘1
[𝑆1]
𝐾1
) 𝐷𝐴 + (𝑘4 + 𝑘5
[𝑆1]
𝛿𝐾1
) (𝑘2 + 𝑘3
[𝑆1]
𝛼𝐾1
) (𝑘−𝑜 + 𝑘−1
[𝑆1]
𝛿𝐾1
)𝐷𝐵
+(𝑘𝑜 + 𝑘1
[𝑆1]
𝐾1
) (𝑘−4
[𝐼]
𝐾𝐴
+ 𝑘−5
[𝐼][𝑆2]
𝛿𝐾𝐴𝐾2
) (𝑘2 + 𝑘3
[𝑆1]
𝛼𝐾1
)𝐷𝐶 + (𝑘4 + 𝑘5
[𝑆1]
𝛿𝐾1
)(𝑘𝑜 + 𝑘1
[𝑆1]
𝐾1
) (𝑘−2
[𝑆2]
𝐾𝐴𝑆
+ 𝑘3
[𝑆2]
2
𝛼𝐾2𝐾𝐴𝑆
)𝐷𝐷
)
 
 
where 
𝐷𝐴 = 1 +
[𝑆2]
𝐾2
+
[𝐼]
𝐾𝑖
+
[𝐼]
𝐾𝐴
+
[𝑆2]
𝐾𝐴𝑆
+
[𝑆2][𝐼]
𝛽𝐾𝐴𝑆𝐾𝑖
+
[𝑆2]
2
𝛼𝐾𝐴𝑆𝐾2
+
[𝑆2][𝐼]
𝛿𝐾𝐴𝐾2
+
[𝐼]2
𝛾𝐾𝐴𝐾𝑖
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𝐷𝐵 = 1 +
[𝑆1]
𝐾1
+
[𝐿]
𝐾𝐿
 
𝐷𝐶 = 1 +
[𝑆1]
𝛿𝐾1
+
[𝐿]
𝜙𝐾𝐿
 
𝐷𝐷 = 1 +
[𝑆1]
𝛼𝐾1
+
[𝐿]
𝜋𝐾𝐿
 
 
 
When S1 = L = I = 0 
𝑣21
𝑒𝑡𝑜𝑡𝑎𝑙
= 𝑣𝑐 =
[𝑆2]𝑘𝑜𝑘2𝑘4(𝛼𝐾𝐴𝑆𝑘−1 + [𝑆2]𝑘−3)
[𝑆2]2𝑘𝑜𝑘4(𝑘2 + 𝑘−3) + [𝑆2](𝑘𝑜𝑘2𝛼𝐾2 + 𝑘2𝛼𝐾𝐴𝑆(𝑘−1 + 𝑘𝑜) + 𝑘𝑜𝑘−2𝑘4𝛼𝐾2)
+𝑘𝑜𝑘2𝑘−4𝛼𝐾2𝐾𝐴𝑆 + 𝑘2𝑘4𝛼𝐾2𝐾𝐴𝑆(𝑘𝑜 + 𝑘−𝑜)
 
=
[𝑆2](𝐶𝑜𝑛𝑠𝑡2 + [𝑆2])
𝐶𝑜𝑛𝑠𝑡1 + [𝑆2](𝐶𝑜𝑛𝑠𝑡3 + [𝑆2]𝐶𝑜𝑛𝑠𝑡4)
 
where 
   𝐶𝑜𝑛𝑠𝑡1 =
𝛼𝐾2𝐾𝐴𝑆(𝑘𝑜𝑘−4+𝑘4(𝑘𝑜+𝑘−𝑜))
𝑘𝑜𝑘−3𝑘4
 
     𝐶𝑜𝑛𝑠𝑡2 =
𝛼𝑘1𝑘−1𝐾𝐴𝑆
𝑘2𝑘−3
 
   𝐶𝑜𝑛𝑠𝑡3 =
𝛼(𝑘𝑜𝑘−2𝑘4𝐾2+𝑘2(𝑘𝑜𝐾2+𝐾𝐴𝑆(𝑘𝑜+𝑘−1)))
𝑘𝑜𝑘2𝑘−3𝑘4
 
     𝐶𝑜𝑛𝑠𝑡4 =
1
𝑘2
+
1
𝑘−3
 
When S1 = I = 0 but L > 0 
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𝑣21
𝑒𝑡𝑜𝑡𝑎𝑙
= 𝑣𝑖
=
[𝑆2]𝑘𝑜𝑘2𝑘4 (
𝑘−1
𝐾2
+ [𝑆2]
𝑘−3
𝛼𝐾2𝐾𝐴𝑆
)
𝑘𝑜𝑘2𝑘−4 (1 +
[𝐿]
𝐾𝐿
) + 𝑘2𝑘4 (1 +
[𝐿]
𝐾𝐿
(𝑘−𝑜 +
𝑘−1[𝑆2]
𝐾2
)) + 𝑘𝑜𝑘2𝑘4 (1 +
[𝑆2]
𝐾2
+
[𝑆2]
𝐾𝐴𝑆
+
[𝑆2]2
𝛼𝐾2𝐾𝐴𝑆
)
+𝑘𝑜𝑘4 (1 +
[𝐿]
𝜋𝐾𝐿
) (
𝑘2[𝑆2]
𝐾𝐴𝑆
+
𝑘−3[𝑆2]2
𝛼𝐾2𝐾𝐴𝑆
)
 
Thus 
𝑣𝑖
𝑣𝑐
=
[𝑆2]𝑘𝑜𝑘2𝑘4 (
𝑘−1
𝐾2
+ [𝑆2]
𝑘−3
𝛼𝐾2𝐾𝐴𝑆
)
([𝑆2 ]
2
𝑘𝑜𝑘4(𝑘2 + 𝑘−3) + [𝑆2](𝑘𝑜𝑘2𝛼𝐾2 + 𝑘2𝛼𝐾𝐴𝑆(𝑘−1 + 𝑘𝑜) + 𝑘𝑜𝑘−2𝑘4𝛼𝐾2) + 𝑘𝑜𝑘2𝑘−4𝛼𝐾2𝐾𝐴𝑆 + 𝑘2𝑘4𝛼𝐾2𝐾𝐴𝑆(𝑘𝑜 + 𝑘−𝑜))
[𝑆2]𝑘𝑜𝑘2𝑘4(𝛼𝐾𝐴𝑆𝑘−1 + [𝑆2]𝑘−3)
(𝑘𝑜𝑘2𝑘−4 (1 +
[𝐿]
𝐾𝐿
) + 𝑘2𝑘4(1 +
[𝐿]
𝐾𝐿
(𝑘−𝑜 +
𝑘−1[𝑆2]
𝐾2
)) + 𝑘𝑜𝑘2𝑘4 (1 +
[𝑆2]
𝐾2
+
[𝑆2]
𝐾𝐴𝑆
+
[𝑆2]
2
𝛼𝐾2𝐾𝐴𝑆
) + 𝑘𝑜𝑘4 (1 +
[𝐿]
𝜋𝐾𝐿
) (
𝑘2[𝑆2]
𝐾𝐴𝑆
+
𝑘−3[𝑆2]
2
𝛼𝐾2𝐾𝐴𝑆
))
 
 
Expanding terms then gathering around L terms yields the following: 
𝑣𝑖
𝑣𝑐
=
𝑅1 + [𝑆2](𝑅2 + [𝑆]2)
𝑅1 + [𝑆2](𝑅2 + [𝑆2] + [𝐿]{𝑅3 + [𝑆2]𝑅4}[𝑆2]) + [𝐿]𝑅5
 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1
𝐶𝑜𝑛𝑠𝑡1+[𝐿]𝐶𝑜𝑛𝑠𝑡2
  eqn 15 
where 
𝐶𝑜𝑛𝑠𝑡1 = 𝑅1 + [𝑆2](𝑅2 + [𝑆2]) 
=
𝛼𝑘2𝐾2𝐾𝐴𝑆(𝑘𝑜𝑘−4 + 𝑘4(𝑘𝑜 + 𝑘−𝑜))
𝑘𝑜𝑘4(𝑘2 + 𝑘−3)
+ [𝑆2] (
𝛼(𝑘−1𝑘2𝐾𝐴𝑆 + 𝑘𝑜𝑘2(𝐾2 +𝐾𝐴𝑆) + 𝑘𝑜𝑘−2𝐾2)
𝑘𝑜(𝑘2 + 𝑘−3)
+ [𝑆2]) 
𝐶𝑜𝑛𝑠𝑡2 = 𝑅5 + [𝑆2]{𝑅3 + [𝑆2]𝑅4} 
=
𝛼𝐾2𝐾𝐴𝑆(𝑘𝑜𝑘2𝑘−4 +𝜙𝑘−𝑜𝑘2𝑘4)
𝜙𝑘𝑜𝑘4𝐾𝐿(𝑘2 + 𝑘−3)
+ [𝑆2] (
𝛼(𝑘𝑜𝑘−2𝐾2 + 𝜋𝑘−1𝑘2𝐾𝐴𝑆)
𝜋𝑘𝑜𝐾𝐿(𝑘2 + 𝑘−3)
+ [𝑆2]
𝑘−3
𝜋𝐾𝐿(𝑘2 + 𝑘−3)
) 
Finally, let’s consider that S1 = L = 0 but I > 0. Under these conditions: 
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𝑣21
𝑒𝑡𝑜𝑡𝑎𝑙
= 𝑣𝑖 =
𝑘𝑜𝑘2𝑘4 (𝑘−1
[𝑆2]
𝐾2
+ 𝑘−5
[𝐼][𝑆2]
𝛿𝐾2𝐾𝐴
+ 𝑘−3
[𝑆2]
2
𝛼𝐾2𝐾𝐴𝑆
)
𝑘2𝑘4 (𝑘−𝑜 + 𝑘−1
[𝑆2]
𝐾2
) + 𝑘𝑜𝑘2 (𝑘−4 + 𝑘−5
[𝐼][𝑆2]
𝛿𝐾2𝐾𝐴
)
+𝑘𝑜𝑘2𝑘4 (1 +
[𝐼]
𝐾𝐴
+
[𝐼]
𝐾𝑖
+
[𝐼]2
𝛾𝐾𝑖𝐾𝐴
+
[𝑆2]
𝐾2
+
[𝐼][𝑆2]
𝛿𝐾2𝐾𝐴
+
[𝑆2]
𝐾𝐴𝑆
+
[𝐼][𝑆2]
𝛽𝐾𝐴𝑆𝐾𝑖
+
[𝑆2]2
𝛼𝐾2𝐾𝐴𝑆
)
+𝑘𝑜𝑘4 (𝑘−2
[𝑆2]
𝐾𝐴𝑆
+ 𝑘−3
[𝑆2]2
𝛼𝐾2𝐾𝐴𝑆
)
 
Dividing by vc expanding then gathering terms around I, we obtain: 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+[𝐼]𝐶𝑜𝑛𝑠𝑡2
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡3+[𝐼]𝐶𝑜𝑛𝑠𝑡4)
  eqn 1 
where 
𝐶𝑜𝑛𝑠𝑡1 = 𝛼
2𝛽𝛾2𝛿𝑘−1𝑘2𝐾2𝐾𝐴𝐾𝐴𝑆
2 𝐾𝑖(𝑘𝑜𝑘−4 + 𝑘4(𝑘𝑜 + 𝑘−𝑜))
+ [𝑆2] (𝛼𝛽𝛾𝛿𝐾𝐴𝐾𝐴𝑆𝐾𝑖 (𝛼𝑘−1𝑘4(𝑘−1𝑘2𝐾𝐴𝑆 + 𝑘𝑜𝑘2(𝐾2 + 𝐾𝐴𝑆) + 𝑘𝑜𝑘−2𝐾2)
+ 𝑘2𝑘−3𝐾2(𝑘𝑜𝑘−4 + 𝑘4(𝑘𝑜 + 𝑘−𝑜))))
+ [𝑆2] (𝛼𝛽𝛾𝛿𝑘4𝐾𝐴𝐾𝑖 (𝑘𝑜𝑘−3(𝑘−1𝐾𝐴𝑆 + 𝑘−2𝐾2)
+ 𝑘2(𝑘−1𝑘−3𝐾𝐴𝑆 + 𝑘𝑜𝑘−3𝐾2 + 𝑘𝑜𝐾𝐴𝑆(𝑘−1 + 𝑘−3))))
+ [𝑆2](𝛽𝛾𝛿𝑘𝑜𝑘−3𝑘4𝐾𝐴𝐾𝑖(𝑘2 + 𝑘−3)) 
𝐶𝑜𝑛𝑠𝑡2 = 𝛼
2𝛽𝛾𝑘2𝑘−5𝐾2𝐾𝐴𝑆
2 𝐾𝑖(𝑘𝑜𝑘−4 + 𝑘4(𝑘𝑜 + 𝑘−𝑜))
+ [𝑆2] (𝛼
2𝛽𝛾𝑘4𝑘−5𝐾𝐴𝑆𝐾𝑖(𝑘−1𝑘2𝐾𝐴𝑆 + 𝑘𝑜𝑘2(𝐾2 +𝐾𝐴𝑆) + 𝑘𝑜𝑘−2𝐾2)
+ [𝑆2](𝛼𝛽𝛾𝑘𝑜𝑘4𝑘−5𝐾𝐴𝑆𝐾𝑖(𝑘2 + 𝑘−3))) 
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𝐶𝑜𝑛𝑠𝑡3 = 𝛼
2𝛽𝛾𝛿𝑘𝑜𝑘−1𝑘2𝑘4𝐾2𝐾𝐴𝑆
2 (𝐾𝐴 + 𝐾𝑖)
+ [𝑆2] (𝛼𝛾𝑘𝑜𝑘2𝐾𝐴𝑆 (𝛽𝛿𝑘−3𝑘4𝐾2(𝐾𝐴 + 𝐾𝑖)
+ 𝛼𝑘−1(𝛿𝑘4𝐾2𝐾𝐴 + 𝛽𝐾𝐴𝑆𝐾𝑖(𝑘4 + 𝑘−5)))
+ [𝑆2] (𝛼𝛾𝑘𝑜𝑘2𝑘−3(𝛿𝑘4𝐾2𝐾𝐴 + 𝛽𝐾𝐴𝑆𝐾𝑖(𝑘4 + 𝑘−5)))) 
𝐶𝑜𝑛𝑠𝑡4 = 𝛼
2𝛽𝛿𝑘𝑜𝑘−1𝑘2𝑘4𝐾2𝐾𝐴𝑆
2 + [𝑆2](𝛼𝛽𝛿𝑘𝑜𝑘2𝑘−3𝑘4𝐾2𝐾𝐴𝑆) 
 
 This model explains why exofacial cis-allostery persists in the TM9 (tetramerization-null) 
mutant (162) and in dimeric GLUT1 (80) and allows for allosteric stimulation of sugar uptake by 
the transport substrate. The model also explains sugar occlusion in the presence of CB (119). The 
model does not allow for intramolecular, endofacial trans-allostery because the equation for the 
effect of L on uptake takes the form 
 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1
𝐶𝑜𝑛𝑠𝑡1+[𝐿]𝐶𝑜𝑛𝑠𝑡2
 
Consideration of non-specific transport 
 We occasionally observe a component of transport (typically measured as uptake of 
radiolabeled sugar) that is neither inhibited by saturating concentrations of inhibitors (e.g. 
cytochalasin B or forskolin) nor by saturating concentrations of sugars (e.g. D-glucose or 3-O-
methylglucose) (168). This could represent protein-independent, trans-bilayer diffusion or non-
specific association with the cell surface or with plasticware used in transport determinations. 
Such non-specific "transport" is well-described as 
𝑣 = 𝑘[𝑆] eqn 16 
where k is a first order rate constant which is insensitive to inhibitor. We examine the effect of 
inclusion of non-specific transport in our analyses by reviewing its impact on Model 4 - 
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intramolecular cis-allostery. 
Assuming rapid equilibrium kinetics, sugar uptake in the presence of extracellular inhibitors (vi) 
is given by: 
𝑣𝑖
[𝑒]𝑡
= 𝑘[𝑆] +
𝑣 (
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝑆
2 + 𝛾
[𝐼][𝑆]
𝛿𝐾𝑆𝐾𝐼𝐼
)
(1 +
[𝑆]
𝐾𝑆
+
[𝑆]
𝐾𝐴
+
[𝑆]2
𝛼𝐾𝐴𝐾𝑆
+
[𝐼]
𝐾𝐼
+
[𝐼]
𝐾𝐼𝐼
+
[𝐼]2
𝜋𝐾𝐼𝐾𝐼𝐼
+
[𝐼][𝑆]
𝛿𝐾𝑆𝐾𝐼𝐼
+
[𝐼][𝑆]
Ω𝐾𝐴𝐾𝐼
)
 
           eqn 17 
where [e]t is the concentration of membrane resident GLUT1, [S] and [I] are concentrations of 
extracellular transported sugar and transport inhibitor respectively and the remaining constants 
are as defined in Scheme 4. When inhibitors are absent, control uptake (vc) is given by: 
𝑣𝑐
[𝑒]𝑡
= 𝑘[𝑆] +
𝑣(
[𝑆]
𝐾𝑆
+𝜙
[𝑆]2
𝛼𝐾𝑆
2)
(1+
[𝑆]
𝐾𝑆
+
[𝑆]
𝐾𝐴
+
[𝑆]2
𝛼𝐾𝐴𝐾𝑆
)
  eqn 18 
 
𝑣𝑖
𝑣𝑐
=
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡2+[𝐼])
𝐶𝑜𝑛𝑠𝑡1+[𝐼](𝐶𝑜𝑛𝑠𝑡3+[𝐼]𝐶𝑜𝑛𝑠𝑡4)
 eqn 2 
where: 
𝐶𝑜𝑛𝑠𝑡1 =
𝐾𝐼𝐾𝐼𝐼𝜋(𝛼{𝑘⟨𝐾𝑆[𝑆] + 𝐾𝐴(𝐾𝑆 + [𝑆])⟩ + 𝐾𝐴𝑣} + [𝑆](𝑘[𝑆] + 𝜙𝑣))
𝛼𝑘𝐾𝐴𝐾𝑆
 
𝐶𝑜𝑛𝑠𝑡2 =
𝜋(𝛿𝑘Ω𝐾𝐴{𝐾𝐼 +𝐾𝐼𝐼} + 𝐾𝐼𝐼[𝑆] + Ω𝐾𝐴𝐾𝐼{𝑘[𝑆] + 𝛾𝑣})
𝛿𝑘Ω𝐾𝐴𝐾𝑆
 
 
𝐶𝑜𝑛𝑠𝑡3
=
𝜋(𝛼{𝑘⟨𝐾𝐴(𝐾𝑆 + [𝑆]) + 𝐾𝑆[𝑆]⟩ + 𝐾𝐴𝑣} + [𝑆](𝑘[𝑆] + 𝜙𝑣))(𝛿𝐾𝑆{𝐾𝐴Ω(𝐾𝐼 +𝐾𝐼𝐼) + 𝐾𝐼𝐼[𝑆]} + 𝐾𝐴𝐾𝐼Ω[𝑆])
𝛿𝑘Ω𝐾𝐴𝐾𝑆(𝛼⟨𝐾𝐴(𝐾𝑆 + [𝑆]) + 𝐾𝑆[𝑆]⟩ + [𝑆]2)
 
𝐶𝑜𝑛𝑠𝑡4 =
𝛼(𝑘{𝐾𝑆[𝑆] + 𝐾𝐴(𝐾𝑆 + [𝑆])} + 𝐾𝐴𝑣) + [𝑆](𝑘[𝑆] + 𝜙𝑣)
𝑘([𝑆]2 + 𝛼{𝐾𝑆[𝑆] + 𝐾𝐴⟨𝐾𝑆 + [𝑆]⟩})
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Behavior of Models 
 Models 1, 2, 3, 5, 6 and 7 were eliminated in the Results section either because the 
resulting equations cannot reproduce the transport behavior (Models 1, 2, 5, 6) or because the 
available biochemical evidence (ligand binding) is incompatible with the model's predictions 
(Models 3 and 7). This leaves models 4, 8 and 9 for consideration. Because each of the 
remaining models is described by a common set of equations, we consider the simplest models 
for cis-allostery (Model 4) and trans-allostery (Model 8B) although the general conclusions for 
Models 4 and 8B are also applicable to Models 9 and 8A/8C respectively. 
 Figure 3.11A (intramolecular cis-allostery - the affinity affect) illustrates how 
subsaturating levels of extracellular maltose stimulate GLUT1-mediated 3-O-methylglucose 
uptake in human erythrocytes then, as extracellular maltose levels increase, how sugar uptake is 
inhibited. This was modeled simply as two binding sites for maltose - a high affinity allosteric 
site whose occupancy reduces KD(app) for 3-O-methylglucose binding to the catalytic center by 
the factor δ and a lower affinity catalytic site at which maltose and 3-O-methylglucose compete 
for binding. At low [maltose], the allosteric site is occupied reducing KD(app) for transport and 
thus stimulating sub-saturated transport. As [maltose] is further increased, maltose and 3-O-
methylglucose compete for binding to the catalytic site and transport is inhibited. Using 
parameters that are consistent with previously published affinity constants for 3-O-
methylglucose and maltose (3–5), Figure 3.11A (intramolecular cis-allostery - the affinity affect) 
illustrates that reducing δ from 1 to 0.7 produces a 1.4-fold increase in transport that peaks at 
approximately 50 µM maltose followed by robust transport inhibition with an IC50 of 
approximately 5 mM. Conversely, we can model the same effect by eliminating any affect of 
high affinity maltose binding on 3-O-methylglucose binding (δ is fixed at 1) but progressively 
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increasing γ from 1 to 1.4. (Figure 3.11B Intramolecular cis-allostery the kcat effect). This 
increases kcat for transport thereby stimulating transport until [maltose] is increased sufficiently 
to compete with 3-O-methylglucose for binding at the catalytic center. 
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Figure 3.11: A. Intramolecular cis-allostery - the affinity affect. Subsaturating levels of 
extracellular maltose stimulate GLUT1-mediated 3-O-methylglucose uptake in human 
erythrocytes then, as extracellular maltose levels increase, sugar uptake is inhibited. Ordinate: 
vi/vc. Abscissa: [Maltose] in mM (note the log scale). Equation 1 from Model 4 was used to 
simulate these data.  The following constants were used: [S] = 0.1 mM, KS = 1 mM, KA = 0.05 
mM, KI = 2 mM, KII = 0.001 mM, α = Ω = γ = π = φ = 1, δ is varied (see legend). These 
parameters result in the following: Const1 = 0.99, Const2 (varies from 330 mM-1 to 464.8 mM-1 
with increasing δ), Const3 (varies from 330.45 to 342.7 mM-1with increasing δ), Const4 = 150 
mM-2. Curves were computed by nonlinear regression using equation 1. B. Intramolecular cis-
allostery - the kcat affect. As in Figure 11 A but now δ = 1 and  γ is varied (see legend). These 
parameters result in the following: Const1 = 0.99, Const2 (varies from 330 mM-1 to 462 mM-1 
with increasing γ), Const3 = 330.45 mM-1, Const4 = 150 mM-2. Curves were computed by 
nonlinear regression using equation 1.  
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 Figure 3.12 (intermolecular trans-allostery) illustrates how subsaturating levels of 
cytochalasin B (CB, a ligand that readily crosses the cell membrane to act at an endofacial site on 
GLUT1 (162,169)) first stimulate GLUT1-mediated 3-O-methylglucose uptake in human 
erythrocytes then, as CB levels increase, how sugar uptake is inhibited (149,162). This was 
modeled assuming a dimer of GLUT1 dimers. Each dimer is independent of its neighbor 
although subunit occupancy states are communicated across the dimer/dimer interface. When 
one e1 subunit of a dimer contains a bound inhibitor (L or CB) its cognate e2 partner (the 
adjacent subunit in the same dimer) like its liganded partner, is locked and thus inactive. 
However the occupancy state of e1.L is transmitted to the adjacent dimer and allows the e2 
subunit of the adjacent dimer to bind S2 with higher affinity (by the factor γ) or to transport S2 
with greater efficiency (by the factor p). Figures 3.12A and B illustrate how varying either γ (the 
affinity effect) or p (the kcat effect) affect transport. At low [CB], the probability of only 1 e1 
subunit of the tetramer being occupied is high, causing transport via the remaining CB-free 
dimer to become activated by the factor γ. As [CB] is further increased, the second dimer 
becomes complexed with CB and transport is inhibited. Using parameters that are consistent with 
previously published affinity constants for 3-O-methylglucose and CB (78,149,162), Figure 3.12 
illustrates how reducing γ from 1 to 0.175 (Figure 3.12A) or increasing p from 1 to 4.25 (Figure 
3.12B) reproduce the 1.3-fold increase in transport that peaks at approximately 25 nM CB 
followed by robust transport inhibition with an IC50 of approximately 100 - 150 nM. 
Equation 2 obtains when not all transport is inhibited by saturating inhibitors and thus allows for 
the possibility of non-specific, non-protein-mediated or inhibitor-insensitive sugar transport - a 
phenomenon that is often observed experimentally (168). Under these circumstances vi/vc does 
not approach 100% inhibition even at saturating [inhibitor]. 
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Figure 3.12: A. Intermolecular trans-allostery - the affinity affect. Subsaturating levels of 
intracellular cytochalasin B stimulate GLUT1-mediated 3-O-methylglucose uptake in human 
erythrocytes then, as cytochalasin B levels increase, sugar uptake is inhibited. Ordinate: vi/vc. 
Abscissa: [cytochalasin B] in µM (note the log scale). Equation 1 from Model 8B was used to 
simulate these data.  The following constants were used: [S] = 100 µM, K2 = 1000 µM, KL = 
0.14 µM, α = β = δ = p = q = r = 1, γ is varied (see legend). These parameters result in the 
following: Const1 falls from 2.61 x 107 to 7.99 x 105 µM4 with decreasing γ, Const2 falls from 
1.86 x 108 to 3.26 x 107 µM3 with decreasing γ, Const3 falls from 3.73 x 108 to 1.63 x 107 µM3 
with decreasing γ, Const4 falls from 1.33 x 109 to 8.32 x 107 µM2 with decreasing γ. Curves 
were computed by nonlinear regression using equation 1. B. Intermolecular trans-allostery - 
the kcat affect. Subsaturating levels of intracellular cytochalasin B stimulate GLUT1-mediated 
3-O-methylglucose uptake in human erythrocytes then, as cytochalasin B levels increase, sugar 
uptake is inhibited. Ordinate: vi/vc. Abscissa: [cytochalasin B] in µM (note the log scale). 
Equation 1 from Model 8B was used to simulate these data.  The following constants were 
used: [S] = 100 µM, K2 = 1000 µM, KL = 0.14 µM, α = β = δ = γ = p = r = 1, q is varied (see 
legend). These parameters result in the following: Const1 = 2.61 x 107 µM4, Const2 increases 
from 1.86 x 108 to 7.37 x 108 µM3 with increasing q, Const3 = 3.73 x 108 µM3, Const4 = 1.33 x 
109 µM2. Curves were computed by nonlinear regression using equation 1.  
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Limitations of the analysis 
 While these considerations support the elimination of models 1, 2, 3, 5, 6 and 7, the 
remaining models are kinetically indistinguishable. These include model 4 (a fixed site 
transporter), model 8 (variations of oligomers of alternating access transporters or fixed site 
transporters) and model 9 (an oligomer of allosteric alternating access transporters). As 
presented, these analyses do not discriminate between alternating access and fixed site 
transporter models. Other approaches are necessary to accomplish this (79,83,167) and when 
applied, support the hypothesis that GLUT1 functions as an allosteric fixed site transporter 
(although they do not consider the possibility that a fixed site transporter could be an oligomeric 
complex of interacting, alternating access transporters). In the present study, discrimination 
between models 4, 8 and 9 relies on prior analysis of GLUT1 cytochalasin B binding 
stoichiometry. This could introduce interpretive problems for two reasons: 1) GLUT1 
cytochalasin B binding is also influenced by ATP; 2) The stoichiometry of cytochalasin B 
binding to GLUT1 monomers, dimers and tetramers may be difficult to measure accurately if 
GLUT1 affinity for cytochalasin B is affected by its oligomeric state. 
 Previous studies from this laboratory (78,80,86,87,118,170) have shown that GLUT1 is a 
nucleotide binding protein, that ATP binding at an endofacial site increases the affinity of the 
exofacial site for sugars but reduces Vmax for sugar uptake, reduces cooperativity in cytochalasin 
B binding to GLUT1 but increases the affinity of the high affinity site for cytochalasin B. Other 
studies have shown that steroidal ligands (171,172), caffeine and AMP (85) inhibit ATP binding 
to GLUT1 thereby altering the kinetics of glucose transport and cytochalasin B binding. It is 
possible therefore that activation of glucose influx at low cytochalasin B concentrations results 
from a complex interplay between cytochalasin B and nucleotide binding to GLUT1. We think 
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this unlikely for three reasons: 1) Cytochalasin B and ATP binding to GLUT1 are positively 
cooperative - cytochalasin B binding at low [cytochalasin B] is enhanced by ATP and ATP 
binding at subsaturating [ATP] is enhanced by cytochalasin B (80); 2) Low concentrations of 
extracellular maltose trans-activate cytochalasin B binding to red cell ghosts in the presence and 
absence of intracellular ATP (78). Sub-saturating [cytochalasin B] stimulates sugar uptake in 
both ATP-containing and in ATP-free red cell ghosts [78]. These results indicate that trans-
allostery is not ATP-dependent but may be modulated by ATP.  
 The question of GLUT1 cytochalasin B binding stoichiometry is more difficult to address 
when cells typically express a mixture of GLUT1 monomers, dimers and tetramers (140). What 
is clear, however is that cis-allostery persists but trans-allostery is lost in both reduced (dimeric) 
and recombinant, tetramerization-deficient GLUT1 (80,162). Trans-allostery thus requires 
intermolecular interactions while cis-allostery may be dependent on intramolecular interactions. 
Detailed analysis by Cunningham and Naftalin (163) of the homology-modeled GLUT1 structure 
and the T295M GLUT1 deficiency mutation led to the important insight that GLUT1 presents 
twin glucose entry ports at its external surface which converge on a common catalytic vestibule 
containing a high affinity glucose binding site. Maltose binding to one entry port could, 
therefore, increase glucose affinity at the other port and thereby stimulate glucose entry into the 
catalytic vestibule. Cunningham and Naftalin further noted that the T295M GLUT1 deficiency 
mutation exhibits high temperature sensitivity and proposed a rationale for this behavior 
(impaired glucose exchange between intramolecular “vestibules” at low temperatures; (163)). 
Our own studies also suggest the presence of 2 exofacial sugar binding sites that converge on a 
catalytic site (149,162) and thus support the Cunningham and Naftalin model. Studies of the 
temperature-dependence of cis-allostery in the T295M GLUT1 deficiency mutation may allow 
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further review of their model and the roles of the entry ports in cis-allostery. 
Conclusions 
 GLUT1 allostery is explained only by models in which multiple exofacial ligand and 
multiple endofacial ligand binding sites co-exist. At least one exofacial site and one endofacial 
site must also correspond to the catalytic site. The endofacial ligand binding properties of 
GLUT1 (92,102) and molecular docking studies (85,135,149,162)indicating 1 or fewer 
cytochalasin B binding sites per GLUT1 molecule eliminate the possibility that more than one e1 
ligand can bind to each GLUT1 molecule. This conclusion, in conjunction with the observation 
that multiple e1 ligand binding sites per transporter are required to explain the transport 
behavior, suggests that the transporter must comprise an oligomer of interacting GLUT1 
proteins. Each subunit (protein) could function as an AAT or an FST. The X-ray crystallography 
data (6,77,131,133,162) suggest: 1) each GLUT1 molecule is an AAT not FST; 2) the exofacial 
conformation of GLUT1 presents multiple ligand binding sites; 3) the allosteric endofacial site 
corresponds to the catalytic site in an adjacent e1 subunit. Previous studies have shown that 
forskolin-stimulated cytochalasin B binding to GLUT1 is abolished in dimeric (reduced) GLUT1 
(80) suggesting that endofacial cis-allostery requires tetrameric GLUT1 and that the endofacial 
allosteric site is contributed by an adjacent subunit not by the subunit to which ligand binding is 
measured. If, correct, this behavior (loss of endofacial cis-allostery) should be recapitulated with 
the TM9 (tetramerization-deficient) mutant, confirming that exofacial cis-allostery is an 
intramolecular phenomenon but endofacial cis-allostery is intermolecular. 
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Chapter 4: 
Small Molecule Interactions with GLUT1 
 
Parts of this chapter was published in the American Journal of Physiology-Cell Physiology in 
2015, the Journal of Biological Chemistry in 2016 and 2017, and can be found using the 
following references: 
 
Sage, J., et al., Caffeine inhibits glucose transport by binding at the GLUT1 nucleotide-binding 
site. Am J Physiol Cell Physiol, 2015. 308: p. C827-C834 
 
Ojelabi, O., et al., WZB117 inhibits GLUT1-mediated sugar transport by binding reversibly at 
the exofacial sugar binding site. J Biol Chem, 2016. 291: p. 26762-26772. 
 
Lloyd, K., et al., Reconciling contradictory findings: Glucose transporter 1 (GLUT1) functions 
as an oligomer of allosteric, alternating access transporters. J Biol Chem, 2017. 
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Abstract 
 The human glucose transporter GLUT1 interacts with and its activity is modulated by a 
wide variety of ligands. These ligands can bind at the exofacial and/or endofacial surfaces of the 
transporter. Recent advances in the structural biology of membrane proteins and the 
crystallization of GLUT1 and GLUT3 in inward and outward facing conformations, respectively, 
now permit examination of potential ligand binding sites through computational docking. Using 
computational docking software, we have examined the potential substrate binding pockets for 
both endofacial and exofacial ligands in order to explore GLUT1 structural determinants of 
ligand binding affinity and cooperativity. 
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Introduction 
 GLUTs comprise the mammalian family of sugar transporters that mediates rapid 
equilibration of sugars into or out of the cell. The GLUT family of transporters has several 
different primary substrates including glucose, galactose, fructose, and myoinositol (100). 
GLUT1, the first glucose transporter isoform to be identified, purified ex vivo, reconstituted, and 
cloned rapidly transports glucose across the cell membrane in all cell types but, most importantly 
in humans, red blood cells and at the blood brain barrier (17-19). In addition to its role as the 
glucose transporter, GLUT1 also transports dehydroascorbic acid and galactose at lower 
efficiencies (173,174).  
 The pioneers of the field very quickly proposed that GLUT1-glucose interactions involve 
hydrogen bonding between amino acid side chains and glucose hydroxyl groups. Replacement of 
an interacting hydroxyl by a hydrogen atom or inversion of a hydroxyl (e.g. as in the C4 epimer 
of D-glucose, galactose), it was reasoned, would decrease the affinity of GLUT1 for the sugar, 
assuming that all other groups on the sugar continued to interact with GLUT1. In practice, 
substitution of the sugar hydroxyls with either hydrogen or R-groups has a strong effect on the 
ability of the modified ligand to inhibit sugar transport suggesting requirements for spatial 
compatibility and hydrogen bonding. Replacement of the hydrogen with an R-group at hydroxyls 
2, 3, and 4 of glucose decreases affinity of ligand binding at the exofacial, e2 site while 
replacement at hydroxyls 1 and 6 does not (74,75). Similarly, when measuring ligand 
interactions at the endofacial or e1 binding site, replacement of hydroxyl 6 with a hydrogen 
decreases the ligand’s ability to inhibit sugar transport but affinity is rescued by fluorine 
suggesting hydrogen bonding between GLUT1 and the hydroxyl on C6 [74, 75]. Replacement of 
hydroxyl 1 with an R-group does not affect the ligand’s ability to inhibit sugar transport 
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suggesting that C1 of the hexose is oriented towards cytoplasmic bulk solvent rather than the 
interior of GLUT1 and thus can tolerate bulky substitutions at C1 [74, 75].  By contrast, 
replacement of hydroxyl 6 with an R-group prevents ligand binding at the endofacial site.  
 GLUT1 also interacts with other non-transportable sugars. Glucose transport is inhibited by 
interaction with maltose, ethylidene glucose and other glucose analogs (79,80). Increasing the 
size of the sugar (number of hexose units) increases KI(app) for sugar transport inhibition (78). In 
addition, both maltose and maltotriose, accelerate sugar transport when applied at low 
concentrations, but inhibit transport at higher concentrations [78]. 
 Unlike normal differentiated cells which use mitochondrial oxidative phosphorylation to 
sustain cellular function, most cancer cells use anaerobic metabolism to generate the ATP and 
biomass required for cellular processes and proliferation (50). This has prompted several groups 
to propose that suppressing anaerobic metabolism may offer an effective anti-cancer strategy. 
Three approaches have been used to limit glycolysis in cancer cells: glucose deprivation in vitro, 
in vitro and in vivo use of glycolysis inhibitors and use of glucose transport inhibitors both in 
vitro and in vivo, with all three approaches resulting in cell death (175-178). GLUT1 is 
upregulated in tumors (179). Several molecules have been developed as inhibitors of GLUT1 
mediated glucose transport including WZB117 (2-fluoro-6-(m-hydroxybenzoloxy)phenyl m-
hydroxybenzoate), and two compounds from Bayer pharmaceuticals: BAY-588 and BAY-876 
(180,181).  
 A second class of molecules investigated for their effects on cancer tissue are the 
flavonoids a large class of polyphenolic secondary metabolites found in green tea and red wine. 
Several studies have shown that quercetin, epigallocatechin gallate (EGCG) and epicatechin 
gallate (ECG), flavonoids present in both red wine and green tea, inhibit GLUT1 mediated 
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glucose transport [81,82]. Glucose transport inhibition by these compounds may explain their 
reported protections against cancer, cardiovascular disease, and diabetes associated with red 
wine and green tea consumption. 
 GLUT1 mediated sugar transport is also inhibited by families of structurally diverse small 
molecules which affect the kinetics of transport in different ways. Cytochalasin B is a mycotoxin 
that binds at the endofacial surface of GLUT1 and functions as a competitive inhibitor of 
exchange and net sugar efflux and as a noncompetitive inhibitor of net sugar uptake (182). 
Additionally, low concentrations of CB stimulate sugar uptake while increasing concentrations 
inhibit uptake. Similarly, forskolin, a diterpene is a competitive inhibitor of CB binding and 
exchange transport while acting as a noncompetitive inhibitor of net sugar uptake (183). 
Interestingly forskolin and forskolin derivatives have different effects on CB binding, ranging 
from, competitive inhibition, stimulation at low concentrations and followed by inhibition at high 
concentrations, and stimulation at all concentrations (84).  
 GLUT1 is allosterically inhibited by ATP, which binds at a single, ATPase-null nucleotide 
binding site. ATP binding leads to a conformational change that involves the cytoplasmic C-
terminus and the large intracellular loop 6-7 resulting in a decrease in both Km and Vmax for zero-
trans sugar uptake characteristic of uncompetitive inhibition, an increase in Km for net exit 
(characteristic of competitive inhibition of exit) and a reduction in Km for exchange transport 
(characteristic of mixed-type inhibition) (86,87,184,185). Caffeine, a methylxanthine, binds to 
GLUT1 and acts as a competitive inhibitor of ATP inhibition of GLUT1 mediated glucose 
transport (85). Interestingly caffeine acts as a competitive inhibitor of CB binding while ATP 
does not [85]. 
 Utilizing our knowledge of the sidedness of action of different GLUT1 inhibitors, the 
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GLUT1 e1 crystal structure(s), and homology models of GLUT1 based upon the GLUT3 e2 
crystal structure in combination with the known structures of GLUT1 ligands and molecular 
docking analysis may permit definition of the determinants of GLUT1-ligand interactions. 
Integrating this understanding with experimentally determined binding and inhibition constants 
may then allow us to determine the regions of the GLUTs involved in ligand binding and how it 
is that multiple ligands can complex with one subunit of GLUT1 to modify transport in such 
diverse ways. 
Experimental Procedures 
Homology Modeling 
 We modeled GLUT1 e2, e2-occluded and e1-occluded structures respectively using the 
human GLUT3 (4ZWC) structure (134) and the XylE e2-occluded (4GBZ) and e1-occluded 
(4JA3) structures (6,131). We removed ligands and used chain A as the template for each 
modeled structure. Sequence alignments were generated using ClustalX. Homology models were 
built using Modeller-9.9 and analyzed using PROCHECK. The GLUT1 e1 structure (4PYP (77)) 
was used directly. 
Cavity analysis 
 Cavities for ligand docking were calculated using the CastP server 
(http://sts.bioe.uic.edu/castp/) [150] and the grid was centered on the residues forming the 
cavity.  
Stochastic Docking 
 β-D-Glucose, maltose, maltotriose, maltotetraose, caffeine, ATP, quercetin, EGCG, ECG, 
forskolin(s) and cytochalasin(s) structures were obtained from ZINC (http://zinc.docking.org). 
The WZB117, BAY-588, and BAY-876 structures were generated using the 3D structure 
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generator Corina from Molecular Networks GmbH (http://www.molecular-networks.com). 
Docking was performed using the Schrodinger software suite. No restraints were used during the 
docking. The protein structure was preprocessed with the Protein Preparation Wizard, bond 
orders were assigned, hydrogens added and the H-bond network was optimized. The system was 
energy minimized using the OPLS 2005 force field. Ligand structures were prepared with the 
LigPrep module and the pKa of the ligands was calculated using the Epik module. 
Computational docking was performed by the GLIDE module in standard-precision (SP) mode 
and default values for grid generation. Grids were mapped using CastP cavity analysis and ligand 
positions from the original crystal structures. Up to 32 poses were generated for each ligand.  
Results 
Homology Modeled GLUT1 structures 
 GLUT1 and GLUT3 structures have been described previously (77,134). The current study 
presents and interrogates e2 homology-modeled GLUT1 structure and e1 GLUT1 crystal 
structure(s).  
GLUT1 Central Hydrophilic Cavity 
 The GLUT1 translocation pore is described in chapter 2. The hydrophilic cavity of GLUT1 
complexed with CB, pdb code 5EQI, (3294.9, Å3) is larger than the cavity of GLUT1 pdb code 
4PYP (2854.9 Å3 (Figure 4.1)). 
 135 
 
Figure 4.1: GLUT1 e1 structures with the translocation cavity. GLUT1 is shown as a 
cartoon representation. The amino acids lining the inward open translocation cavity are shown 
as red spheres. 4PYP, the GLUT1 structure complexed with a glycodetergent is shown in A, 
with a cavity volume of 2854.9 Å3. Shown in panel B is 5EQI, GLUT1 complexed with CB, 
with a cavity volume of 3294.9 Å3. 
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Glucose Interaction Sites 
 GLUT1 β-D-glucose interaction sites are described in chapter 2. 
GLUT1 Ligands 
GLUT1 ligands have been characterized based upon their interaction at exofacial (e2) or 
endofacial (e1) binding sites. Figures 4.2 and 4.3 show the chemical structures of exofacial and 
endofacial that were docked to GLUT1. 
 
Figure 4.2: Chemical structures of exofacial ligands. The chemical structures of the e2 
ligands maltose, maltotriose, maltotetraose, WZB117, ECG, EGCG, and quercetin. 
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Figure 4.3: Chemical structures of endofacial ligands. The chemical structures of the e1 
ligands FSK, 6A-FSK, 7DEA-FSK, 7FPA-FSK, cytochalasins (CA, CB, CC, CD, CE, CH, CJ) 
ATP, Caffeine, BAY-588, and BAY-876.  
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ATP Docking to the GLUT1 e1 Conformation 
 Thirty different poses of ATP, caffeine, and CB interaction with GLUT1 were generated to 
examine their interactions with the GLUT1 e1 conformation. From these, the highest affinity 
conformation is shown for ATP, caffeine, and CB, respectively (Figure 4.4). However, ATP and 
caffeine compete for binding to GLUT1, suggesting that ATP and caffeine share identical or 
overlapping binding sites [85]. Caffeine is also a competitive inhibitor of CB binding to GLUT1 
but CB and ATP binding are not mutually exclusive (85). This suggests that if competitive 
inhibition is achieved through steric overlap then the caffeine binding site bridges the CB and 
ATP binding sites. ATP and caffeine were also docked to the 5EQI structure (Figure 4.5). The 
ligand (CB) was removed and the CastP cavity map was used to generate the grid. CB inhibition 
studies with caffeine and ATP show that caffeine competitively inhibits CB binding but ATP 
does not, suggesting that while ATP and caffeine share a common binding site, the caffeine 
binding site overlaps with CB while ATP does not. We therefore searched the docked positions 
of ATP, caffeine, and CB to find conformations where ATP and caffeine xanthine rings overlap 
while the methyl groups of caffeine overlap with the docked CB position (Figure 4.6). The CB 
pose was chosen that does not overlap with the ATP pose but does with the caffeine pose. All 
positions of ATP docked to the 5EQI structure overlap with the CB ligand present in the crystal 
structure. (Figure 4.6).   
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Figure 4.4: Docking of ATP (A, B), caffeine (C, D), and CB (E, F) to the GLUT1 e1 
structure, 4PYP. All docked poses are shown in panels A, C, and E for ATP (30), caffeine 
(27), and CB (29) respectively. The highest affinity pose is shown in panels B, D, and F for 
ATP, caffeine, and CB respectively. Panel G shows the highest affinity poses for ATP 
(yellow), caffeine (red), and CB (green) together. 
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Figure 4.5: Docking of ATP (A, B), caffeine (C, D), and CB (E, F) to the GLUT1 e1 
structure, 5EQI. All docked poses are shown in panels A, C, and E for ATP (30), caffeine 
(30), and CB (26) respectively. The highest affinity pose is shown in panels B, D, and F for 
ATP, caffeine, and CB respectively. Panel G shows the highest affinity poses for ATP 
(yellow), caffeine (red), and CB (green) together. 
 
 
  
 141 
 
Figure 4.6: ATP, Caffeine, and CB docked to e1 conformations. A.) Docking poses of ATP 
(yellow), caffeine (red) and CB (green) to the 4PYP crystal structure, with caffeine and the 
ATP xanthine groups occupying the same site. The caffeine methyl group overlaps with CB 
while ATP does not overlap with CB. B.) Docking of ATP to the 5EQI GLUT1 crystal 
structure. ATP positions are shown as sticks in rainbow colors. CB is shown as green spheres 
in the position it occupies in the crystal structure. 
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GLUT1 e1 Inhibitor docking to 4PYP 
 Cytochalasin and forskolin derivatives bind to the e1 conformation of GLUT1. The binding 
of cytochalasins to GLUT1 has been characterized by inhibition of CB binding and reveals that 
multiple cytochalasin binding sites coexist in the transporter complex. The size of the 
macrocyclic ring of the cytochalasin does not always affect KD(app) for binding of the first ligand 
but decreasing the size of the ring increases the impact (negative cooperativity) on binding of the 
second cytochalasin (84). This is reflected in the different docking positions for cytochalasin 
docking to the 4PYP structure (Figure 4.7).  
 The cytochalasins exercise both homo- and hetero-cooperativity such that the binding of 
one cytochalasin can either stimulate or inhibit the binding of a second identical or nonidentical 
cytochalasin respectively. Cytochalasins with highly negative homo-cooperativity bind near the 
glucose “core” binding site (e.g. CC) while cytochalasins with moderately negative homo-
cooperativity and positive hetero-cooperativity in relation to CB do not bind as deeply in the e1 
cavity (e.g. CA). As with the cytochalasins, the forskolins also display experimental negative 
homo-cooperativity with positive homo-cooperativity and bind near the “core” binding site 
(Figure 4.8).  
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Figure 4.7: Docking of Cytochalasins to the GLUT1 e1 structure, 4PYP. Docking of CA 
(A, B), CB (C, D), CC (E, F), CD (G, H), CE (I, J), CH (K, L), and CJ (M, N) to the GLUT1 
e1 structure, 4PYP. All docked poses of CA (27), CB (29), CC (30), CD (27), CE (28), CH 
(29), and CJ (30) are shown in panels A, C, E, G, I, K, and M, respectively. The highest 
affinity pose of each of these ligands is shown by: CA (B), CB (D), CC (F), CD (H), CE (J), 
CH (L), and CJ (N). Each of the highest affinity poses are shown in panel O with CA (red), 
CB (green), CC (blue), CD (yellow), CE (magenta), CH (cyan), and CJ (orange). 
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Figure 4.8: Docking positions of FSK and forskolin derivatives to the GLUT1 e1 
structure, 4PYP. Docking of FSK (A, B) and the forskolin derivatives 6A-FSK (C, D) 7DeA-
FSK (E, F) and 7FPA-FSK (G, H) to the GLUT1 e1 structure, 4PYP. All docking poses are 
shown in panels A, C, E, and G for FSK (26), 6A-FSK (26), 7DeA-FSK (26), and 7FPA-FSK 
(16), respectively. The highest affinity pose(s) are shown in panels B, D, F, and H for FSK, 
6A-FSK, 7DeA-FSK, and 7FPA-FSK, respectively. Panel I shows the highest affinity poses 
for each forskolin, FSK (red), 6A-FSK (green), 7DeA-FSK (blue), and 7FPA-FSK (cyan).  
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GLUT1 e1 Drugs 
 Transport studies with the potential anti-cancer drugs BAY-588 and BAY-876 suggest that 
both interact with GLUT1 by non-competitively inhibiting sugar uptake and competitively 
inhibiting sugar exit. This suggest that BAY interacts with GLUT1 at the endofacial face or 
interacts only with the e1 conformation of GLUT1. KI(app) for BAY-876 inhibition of transport is 
almost 50-fold lower than KI(app) for BAY-588 inhibition of GLUT1 suggesting that replacement 
of the nitrile group with a tert-butyl group on the benzene ring severely decreases affinity (Figure 
4.9).  
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Figure 4.9: Docking positions of BAY-876 and BAY-588 to the GLUT1 e1 structure, 
4PYP. BAY-876 (A, B) and BAY-588 (C, D) to the GLUT1 e1 structure, 4PYP. All docking 
poses are shown in panels A and C for BAY-876 (27) and BAY-588 (30), respectively. The 
highest affinity position is shown in panel B for BAY-876. Panel D shows a middle affinity 
docked pose of BAY-588 that matches the pose of the highest affinity BAY-876. Panel E 
shows BAY-876 (magenta) and BAY-588 (green) in one structure.  
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GLUT1 e1 Inhibitor docking to 5EQI 
 The GLUT1 crystal structure pdb code 5EQI is a structure of GLUT1 complexed with a 
CB molecule. In this structure, the CB molecule forms a hydrogen-bond with W388 and is 
complexed in the core interaction region (Figure 4.10) (135). While in silico docking of CB to 
5EQI (using the CB ligand to generate the docking grid) does produce a complex in which the 
docked CB overlaps with the observed CB binding site in the crystal structure, the docked 
position(s) of CB do not precisely match the crystal structure (Figure 4.10). Additionally, none 
of the docked conformations form an H-Bond with W388. GLIDE uses the position of the ligand 
in the structure to generate the three-dimensional search space, but does not specify coordinating 
residues. This amino acid (W388) is considered crucial for CB binding because its mutagenesis 
to alanine in X. laevis oocytes decreases GLUT1 photolabeling by CB significantly (186). 
Similarly, Docking of CB to 5EQI using the hydrophilic cavity rather than the co-crystalized 
ligand for grid generation produces CB poses that do not align with the co-crystalized CB. 
Docking of other cytochalasins to 5EQI was undertaken using either ligand replacement (Figure 
4.11) or cavity maps (Figure 4.12) for grid generation. The ligand replacement methodology 
places the cytochalasin molecule deeper in the translocation cavity.  
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Figure 4.10: Docking of CB to 5EQI using ligand replacement for grid generation. Panel 
A shows a 2D interaction map of CB co-crystalized with GLUT1 (5EQI). Panel B shows co-
crystalized CB as spheres (orange) with the poses of docked CB as rainbow sticks. 
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Figure 4.11: Docking of Cytochalasins to the GLUT1 e1 structure, 5EQI. Docking of CA 
(A, B), CB (C, D), CC (E, F), CD (G, H), CE (I, J), CH (K, L), and CJ (M, N) to the GLUT1 
e1 structure, 5EQI using co-crystalized CB for grid generation through ligand replacement. All 
docked poses of CA (29), CB (26), CC (30), CD (28), CE (27), CH (29), and CJ (30) are 
shown in panels A, C, E, G, I, K, and M, respectively. The highest affinity position of each of 
these ligands is shown by: CA (B), CB (D), CC (F), CD (H), CE (J), CH (L), and CJ (N). Each 
of the highest affinity poses are shown in panel O with CA (red), CB (green), CC (blue), CD 
(yellow), CE (magenta), CH (cyan), and CJ (orange). 
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Figure 4.12: Docking of Cytochalasins to the GLUT1 e1 structure, 5EQI. Docking of CA 
(A, B), CB (C, D), CC (E, F), CD (G, H), CE (I, J), CH (K, L), and CJ (M, N) to the GLUT1 
e1 structure, 5EQI using the hydrophilic cavity for grid generation. All docked poses of CA 
(29), CB (26), CC (30), CD (28), CE (27), CH (29), and CJ (30) are shown in panels A, C, E, 
G, I, K, and M, respectively. The highest affinity pose of each of these ligands is shown by: 
CA (B), CB (D), CC (F), CD (H), CE (J), CH (L), and CJ (N). Each of the highest affinity 
poses are shown in panel O with CA (red), CB (green), CC (blue), CD (yellow), CE 
(magenta), CH (cyan), and CJ (orange). 
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GLUT1 e2 Sugars 
 GLUT1 interacts with, does not transport and is inhibited by several sugars at its external 
face. The oligosaccharides maltose, maltotriose, and maltotetraose, formed by the concatenation 
of multiple glucose molecules all bind to and inhibit GLUT1 mediated transport (78). The 
strength of inhibition/binding decreases as the size of the oligosaccharide increases [78]. The 
sugars all bind at the “core” glucose binding site. (Figure 4.13) 
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Figure 4.13: Docking positions of maltose, maltotriose, and maltotetraose to the 
homology modeled GLUT1 e2 structure. Maltose (A, B), maltotriose (C, D), and 
maltotetraose (E, F) to the homology modeled GLUT1 e2 structure. All docking poses are 
shown in panels A, C, and E for maltose (30), maltotriose (30), and maltotetraose (30), 
respectively. The highest affinity pose is shown in panel B, D, and F for maltose, maltotriose, 
and maltotetraose, respectively. Panel G shows the highest affinity pose for maltose (blue), 
maltotriose (orange), and maltotetraose (magenta) in one structure. 
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GLUT1 e2 inhibitors 
 In addition to the sugar molecules, GLUT1 is inhibited by the flavonoids: ECG, EGCG, 
and quercetin. These inhibitors appear to interact with the exofacial ligand binding sites of 
GLUT1. Docking analysis reveals that all three flavonoids interact with the core β-D-glucose 
interaction site and that increasing the size of the ligand leads to additional interactions with the 
N-terminal half of GLUT1 (Figure 4.14). GLUT1 is also inhibited by the potential cancer 
therapeutic WZB117 which binds to the exofacial conformation of GLUT1. The highest affinity 
position interacts with the core and intermediate β-D-glucose sites. Alternative poses interact 
with the core and peripheral β-D-glucose sites or intermediate and peripheral β-D-glucose sites 
(Figure 4.15). 
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Figure 4.14: Docking of WZB117 (rainbows) to the homology modeled GLUT1 e2 
structure. Panel A shows all poses of WZB117 (32). Panel B shows the highest affinity pose 
of WZB117 in red. 
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Figure 4.15: Docking positions of quercetin, ECG, and EGCG to the homology modeled 
GLUT1 e2 structure. Quercetin (A, B), ECG (C, D), and EGCG (E, F) to the homology 
modeled GLUT1 e2 structure. All docking poses are shown in panels A, C, and E for quercetin 
(30), ECG (30), and EGCG (30), respectively. The highest affinity pose is shown in panel B, 
D, and F for quercetin, ECG, and EGCG, respectively. Panel G shows the highest affinity 
poses for quercetin (red), ECG (blue), and EGCG (cyan) in one structure.  
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Discussion 
 Comparisons of the docking of cytochalasins to 5EQI and 4PYP demonstrate one of the 
main caveats to molecular docking to static structures. The docking analysis requires grid 
generation for the compound to encompass the binding site, accurate prediction of the ligand’s 
positional, conformational and configurational space (pose) and scoring of the ligand:protein 
interaction. Additionally, the interaction is based on a static structure of a highly dynamic 
protein. While, docking of CB to the 5EQI structure faithfully reproduces the binding region it 
does not reproduce the ligand pose seen in the crystal structure (Figure 4.10). While, the docked 
ligand may not match the crystallographic position of the ligand, evaluating all of the potential 
conformations can generate a map of the binding pocket and testable hypothesis for amino acids 
involved in conferring affinity and specificity. Additionally, as demonstrated with β-D-glucose 
docking in chapter 2, it is necessary to incorporate biochemical data into the evaluation of the 
binding sites and docking poses.  
 The e1 conformation of GLUT1 has been crystalized with both glyco-detergent (4PYP), 
and CB (5EQI) in the transport pore (77,135). Molecular docking was undertaken with these 
structures by using the ligand as a guide molecule, in the case of 5EQI, and by choosing a grid 
based upon the residues lining the translocation pore with both 5EQI and 4PYP. Differences in 
docking between the conformations can be attributed to the change in pore size, change in 
ligand, or changes in the docking grid size due to the more specific grid localization using CB. 
 Cytochalasins were docked to both 4PYP and 5EQI. Analysis of CB docking to the 4PYP 
structure suggests important roles for residues in helices 4, 5, and 10 including W388 
hypothesized to interact with CB (Figure 4.16) [186]. Similarly, the interaction map with CA 
follows a very similar pattern in side chain interactions, but a decrease in potential hydrogen 
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bonds resulting from the change from a hydroxyl to a ketone group in the macrocyclic ring, 
possibly explaining the decreased affinity seen with CA compared to CB CC, CJ and CE all have 
very high negative homo-cooperatively when compared to CB suggesting that binding of any of 
these ligands prevents binding of a second ligand. Examination of the interaction maps for CC, 
CE, CJ, suggest increased interactions in helices 1, 7, 8 and 11 suggesting that binding at this site 
may affect binding of a second cytochalasin molecule. Since GLUT1 e1 cannot dock two 
cytochalasins simultaneously, this must mean that binding one molecule of CC, CE, or CJ, 
affects binding of a second molecule to adjacent GLUT1-e1 conformers in the oligomeric 
complex. Docking to the 5EQI site utilized co-crystalized CB for grid generation. This CB 
docking analysis suggests interactions with residues in the glucose binding core (Q282, Q283, 
chapter 2) and in TMs 4, 5, 10 and 11 (Figure 4.17). Elimination of tryptophan in helices 10 and 
11 (W388 and W412) eliminates CB photolabeling of GLUT1 suggesting these residues are 
important for CB binding [186]. Additionally, the presence of CB in the glucose binding core 
suggests that CB induced sugar occlusion must involve additional GLUT1 subunits in the 
oligomeric complex because this seems extremely unlikely to occur in individual monomers 
(119). Docking of additional cytochalasins to GLUT1 assumes that all of the cytochalasins bind 
at the same general site. CJ has the highest affinity and additional interactions with H2 and H7 
and to N415 relative to CB. CE and CH have similar affinities to CB. CE has a similar docking 
interaction profile to CB with the main differences being decreased interactions at H11 (G408, 
W412). CH is also characterized by decreased interactions at H11 (G408, W412) but increased 
interactions in helices 5, 7, 8, and 10. CA has a slight increase in affinity and a decrease in 
potential hydrogen bonding resulting from the replacement of the hydroxyl group with a ketone. 
Of the cytochalasins examined, CC and CD have the lowest affinity for GLUT1 and increased 
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interactions with residues H8 (N317 and N321) in comparison to the other cytochalasins 
suggesting that the introduced acetyl group interacts with these residues. CB was also docked to 
the e2 structure with high affinity (GlideScore = -7.059) demonstrating the necessity of 
combining experimental determinations of ligand sidedness with computational modeling. 
 
Figure 4.16: Quantitation of amino acid interactions with cytochalasins. CB (A), CA (B), 
CC (C), and CD (D), CE (E), CH (F), CJ (G) to the GLUT1 e1 structure 4PYP. Percentages 
are normalized to number of docking poses generated. 
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Figure 4.17: Quantitation of amino acid interactions with cytochalasins. CB (A), CA (B), 
CC (C), and CD (D), CE (E), CH (F), CJ (G) to the GLUT1 e1 structure 5EQI. Percentages are 
normalized to number of docking poses generated. 
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 Forskolin and forskolin derivatives were only docked to the 4PYP structure.  
The forskolin binding pocket is characterized by interactions with H4 (T137), H5 (H160, Q161, 
I164), H7 (Q282, Q283, I287, N288) and H10 (F379, E380, G384, P385, W388) with potential 
hydrogen bonding to Q282 and W388 (Figure 4.18). Changing the ester group to an alcohol 
(7DeA-FSK) leads to an increase in both the calculated and experimentally determined affinity 
compared to forskolin and adds residues N288 and F291 to the potential binding pocket while 
increasing the hydrogen bonding potential in H10 (E380, W388) and H2 (H160, Q161). Adding 
a large benzyl fluoride group (7FPA-FSK) to the ester leads to an increase in affinity compared 
to forskolin while increasing potential interactions with helices 2, and 11 and decreasing 
interactions with H7. 7FPA-FSK also has fewer potential hydrogen bonds than forskolin. 
Converting a hydroxyl to an ester (6A-FSK) significantly decreases interactions with H7 while 
increasing interactions with H4 compared to forskolin. Potential hydrogen bonding to H160 is 
increased relative to forskolin. Docking of BAY-588 and BAY-876 to the cavity follows similar 
binding patterns. However, BAY-588 has more side chain interactions in helices 4 and 5 (Figure 
4.17). Additionally, BAY-876 has potential hydrogen bonding via its cyano group with Q283 
and N288. This is not observed in docked BAY-588 and may account for the increased affinity 
observed in BAY-876 compared to BAY-588. Calculated KD for the highest affinity poses of 
suggests BAY-876 (KD = 0.764 µM) has ~2-fold higher affinity than BAY-588 (KD = 1.23 µM). 
However, when the highest affinity BAY-876 pose is matched to a BAY-588 (KD = 7.85 µM) 
pose the change in calculated KD is 10-fold (Table 4.1).  
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Figure 4.18: Quantitation of amino acid interactions with forskolins. Forskolin (A), 
7DEA-FSK (B), 7FPA-FSK (C), and 6A-FSK (D) to the GLUT1 e1 structure 4PYP. 
Percentages are normalized to number of docking poses generated. 
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Figure 4.19: Quantitation of amino acid interactions with BAY588 and BAY876 to the 
GLUT1 e1 structure 4PYP. BAY588 (A) and BAY876 (B) Percentages are normalized to 
number of docking poses generated. 
 
 ATP and caffeine were docked to both the 5EQI structure and the 4PYP structure. Docking 
of ATP and caffeine to 4PYP suggests potential interactions with helices 5, 7, 10 and 11 (Figure 
4.20). When compared to ATP, caffeine has fewer interactions with helices 5 and 10 suggesting 
that the methylxanthine ring is interacting with residues in helices 4 (T137), 7 (Q282, Q283, 
I287, N288), 10 (F379, W388) and 11 (N411, W412, N415). Additionally, GLUT1 helices 8 and 
9 (residues 301-364) were identified as ATP interacting domains when photolabeled with  
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8-Azido[γ-32P]ATP (184). Docking studies suggest that potential interaction sites with ATP in 
this conformation are at N317 and T321. ATP has a similar binding profile when docked to the 
5EQI structure with additional potential interactions in helices 1, 2, and 8 and fewer potential 
interactions in H5. Caffeine follows the same pattern in both 4PYP and 5EQI with only an 
increase in potential interactions with N317 and fewer interactions with T137. 
 
Figure 4.20: Quantitation of amino acid interactions with ATP and Caffeine to GLUT1 
e1 structures. ATP to the GLUT1 e1 structures 4PYP (A) and 5EQI (B). Quantitation of 
amino acid interactions with caffeine to the GLUT1 e1 structures 4PYP (C) and 5EQI (D). 
Percentages are normalized to number of docking poses generated. 
 
 164 
 
 Maltose appears to bind to GLUT1 through potential H-bonding to Q282, Q283, N317, 
N380 and N415. Increasing the number of hexoses in the oligosaccharide leads to an increase in 
inhibition constant for GLUT1 mediated glucose transport, and a decrease in affinity for the 
oligosaccharide [78]. Examination of all of the docked poses suggests that when the size of the 
oligosaccharide increases there is a decrease in side chain interaction with H8 and H10 and an 
increase in interactions with helices 1, 2, and 11 (Figure 4.21). Additionally, potential hydrogen 
bonding is increased to residues in the N-terminal half of GLUT1 and decreases in the C-
terminal half.  
 The high affinity of WZB117-GLUT1 interactions can be attributed to the large number of 
hydrogen bonds made including potential interactions with Q161, Q282, Q283, and N415. The 
substrate binding pocket can be defined most strongly with residues T30, F72, S73, I168, I287, 
F291, F379, and N415. (Figure 4.22). Quercetin and ECG have KI(app) of ~ 2µM while EGCG 
has lower affinity with KI(app) of 10 µM. Comparison of docking does poses does not explain the 
differences in affinity for ECG and EGCG (Figure 4.23).  
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Figure 4.21: Quantitation of amino acid interactions with maltose, maltotriose, and 
maltotetraose to the homology modeled e2 structure. Maltose (A), maltotriose (B), and 
maltotetraose (C). Percentages are normalized to number of docking poses generated. 
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Figure 4.22: Quantitation of amino acid interactions with WZB117 to the homology 
modeled e2 structure. Percentages are normalized to number of docking poses generated. 
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Figure 4.23: Quantitation of amino acid interactions with quercetin, ECG, and EGCG to 
the homology modeled GLUT1 e2 structure. Quercetin (A), ECG (B), and EGCG (C). 
Percentages are normalized to number of docking poses generated. 
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 GLIDE software was developed to optimize ligand docking to rigid protein structures using 
co-crystallized ligand complexes as comparative standards(153,154). GlideScores for computed 
docking poses are useful for selecting the best docked poses but can under- or over-estimate ΔG 
by 2 kcal/mol (30-fold) (155). Interpretation of KI(app) for transport and ligand binding is 
extremely model-dependent and includes both binding, transport (catalytic), and allosteric 
constants. Comparisons between computed GlideScores and calculated affinity constants are 
summarized in Table 4.1. The WZB-117 pose best matches GlideScore with experimental 
affinity. When comparing similar compounds (BAY, FSK compounds) the relative affinities of 
the molecules matches without the calculated and experimental affinities being equal. 
Alternatively, the calculated affinities do not match the experimental affinities for the 
cytochalasins docked to either 5EQI or 4PYP, suggesting that determining cytochalasin affinity 
for GLUT1 less well predicted by GlideScore. 
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Table 4.1: Summary of Docked Ligands. Sidedness and experimental KI(app) for EGCG, 
ECG, Quercetin, BAY-588, and BAY-876 were determined by Ogooluwa Ojelabi and are 
unpublished. The GlideScore of the highest scoring pose were used for calculating KD. 
 
  
  
Ligand Sidedness Affinity GlideScore  
kcal/mol 4PYP
GlideScore  
kcal/mol 5EQI
GlideScore  
kcal/mol e2
Calculated  
KD µM 4PYP
Calculated  
KD µM 5EQI
Calculated  
KD µM e2
ATP e1 KD(app) = 0.6-2 mM  [86] -7.192 -6.252 - 5.27 25.82 -
Caffeine e1 KI(app) = 0.91 ± 0.34 mM  
[85]
-6.917 -6.645
- 
8.39 13.29 -
Bay588 e1 KI(app) = 581.55 nM -8.054 -
- 1.23 - -
Bay876 e1 KI(app) = 13.15 nM -8.335 -
- 
0.76 - -
Cytochalasin 
B
e1 KD(app)  = 98 ± 8.5 nM 
[84]
-7.174 -7.607 -7.059 5.44 2.62 6.60
Cytochalasin 
A
e1 KI(app) = 815 ± 96 nM [84] -6.163 -7.589
- 30.01 2.70 -
Cytochalasin 
C
e1 KI(app) = 1591 ± 431 nM 
[84]
-8.048 -8.413
- 
1.24 1.87 -
Cytochalasin 
D
e1 KI(app) = 1969 ± 98 nM 
[84]
-6.482 -7.805 - 17.50 0.67 -
Cytochalasin 
E
e1 KI(app) = 99 ± 8 nM [84] -6.64 -6.968
- 
13.40 7.70 -
Cytochalasin 
H
e1 KI(app) = 98 ± 3 nM [84] -6.304 -7.163
- 23.64 5.54 -
Cytochalasin J e1 KI(app) = 12 ± 3 nM [84] -8.979 -8.929
- 0.26 0.28 -
Forskolin e1 KD(app) = 3282 ± 960 nM 
[84]
-5.93 - 
- 
44.48 - -
6AFSK e1 KI(app) = 949 ± 164 nM 
[84]
-5.982 - - 40.74 - -
7FPAFSK e1 KI(app) = 142 ± 78 nM [84] -6.228 -
- 
26.88 - -
7DeAFSK e1 KI(app) = 2 ± 2 nM [84] -7.5 -
- 
3.13 - -
Maltose e2 KD(app) = 29.3 µM [78] - - -6.215 - - 27.48
Maltotriose e2 KD(app) = 32.2 µM [78] - - -6.472 - - 17.80
Maltotetraose e2 KD(app) = 128 µM [78] - - -6.972 - - 7.65
WZB117 e2 KI(app) = 0.233 ± 0.042 µM 
[149]
- - -8.647 - - 0.45
EGCG e2 KI(app) = 9.563 ± 1.80 µM - - -8.428 - - 0.65
ECG e2 KI(app) = 1.902 ± 0.315 µM - - -8.274 - - 0.84
Quercetin e2 KI(app) = 1.476 ± 0.337 µM - - -7.51 - - 3.08
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 In conclusion, molecular docking analysis is a useful tool for understanding the structural 
components of GLUT1 involved in ligand binding and glucose transport. It can be used to 
develop testable hypotheses of side chain interactions involved in ligand binding (chapter 2) and 
to explain biological phenomena (e.g. CB occlusion of glucose in GLUT1, changes in affinity of 
forskolin ligands based on side-chain interactions). Molecular docking can be used to predict 
interacting residues and binding pockets for similar ligands. However, differences in docking 
poses obtained using similar or even the same crystal structures demonstrate the necessity for 
undertaking biochemical experimentation to verify the interactions predicted by docking 
analysis. Similarly, incorporation of experimental knowledge into side-chain pose predictions 
(e.g. as with β-D-glucose, chapter 2) greatly improves the reliability of predictions. 
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Chapter 5: 
Analysis of GLUT1 Transmembrane Domain Glycines 
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Abstract 
GLUT1 catalyzes rapid, equilibrative glucose transport across the cell membrane. Kinetic and 
ligand binding studies have led to the development of multiple models for explaining GLUT1 
mediated glucose transport. The alternating access carrier model proposes that the transporter 
alternately presents sugar import and export sites. Recent developments in membrane protein 
crystallography and the crystallization of GLUT1 and GLUT3 in inward and outward open 
conformations appear to confirm the alternating access carrier hypothesis. Understanding the 
transition between inward and outward open conformations would help to bridge the gap 
between kinetic and structural analyses. Transitions between the inward and outward 
conformations suggest that the N-terminal half of the protein is a rigid body while the C-terminal 
half of GLUT1 is a more dynamic structure. The N-terminal half of GLUT1 contains multiple 
GXXXG motifs which are hypothesized to enhance packing in trans-membrane alpha helices. 
Additionally, GLUT1 has highly dynamic glycine residues, possibly existing as hinges 
regulating the transition between inward and outward conformations. Combining this structural 
modeling with glycine-to-alanine mutagenesis suggests that several membrane-resident glycine 
residues play significant roles in GLUT1-mediated transport as either hinge glycines or GXXXG 
motifs.  
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Introduction 
 Glucose serves as the preferred metabolic substrate in brain and exercising skeletal muscle. 
Understanding the mechanism by which glucose enters and exits cells is critical to developing a 
further understanding of energy metabolism. Two families of proteins mediate glucose uptake 
into cells: the GLUTs and the SGLTs. SGLTs are active transporters that utilize an inwardly 
directed Na electrochemical gradient to couple net uphill glucose transport to downhill Na 
transport while the GLUTs are passive transporters that carry sugar down a concentration 
gradient only (13). The GLUTs are divided into three classes based upon tissue distribution and 
substrate specificity (100). GLUT1, a class I transporter, is a ubiquitously expressed glucose 
transporter and, in humans, is the primary glucose transporter in the blood brain barrier, glia and 
erythrocytes (187).  
 GLUT1 makes up 10-20% of the integral membrane content of erythrocytes where it is the 
only expressed glucose transporter (52). The availability of red cells combined with their high 
GLUT1 content, uniformity of cell size and surface area has resulted in a wealth of detailed 
kinetic analyses of GLUT1 mediated sugar transport and ligand binding (141). Recent structural 
studies of GLUTs suggest that the protein acts as an alternating access transporter, presenting 
either an inward open, e1, or outward open, e2 binding site at any time but not both sites 
simultaneously (77,134,135).  
 However, structural studies cannot fully explain the kinetic behavior of the transporter 
which functions as if it simultaneously presents multiple exofacial and endofacial substrate 
binding sites (79,83,113,120,122). A more detailed understanding of the physical basis of 
transitions between the GLUT1 e1 and e2 conformations could provide further insight into the 
transport cycle. To that end, identification of conformationally dynamic residues in the 
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transmembrane alpha helices and exploration of their roles by mutagenesis could be an intriguing 
path of research.  
 Due to its lack of a side chain, glycine is a unique amino acid that introduces 
conformational flexibility into the backbone of a protein. Wide scale genome analysis of 
membrane resident proteins shows that glycine is frequently found in transmembrane helices, 
including in conserved positions (188,189). Different studies have shown glycine(s) fulfilling 
both structural and functional roles in membrane transport proteins. Glycine residues have been 
shown to function as a gating hinge in potassium channels (190,191). Introduction of glycine into 
lactose permease can confer conformational flexibility (192), and a conserved glycine in GAT-1 
is involved in conformational transition during its transport cycle (193). By contrast, glycine-
rich-motifs in transmembrane domains have been shown to enhance packing and 
oligomerization, such as the GXXXG and GXXXXXXG motifs (194-196).  
 GLUT1 contains 41 (8.3% of total amino acids) glycine residues with 31 (9.2% of 
transmembrane domain resident amino acids) residing in transmembrane regions. Eight glycines, 
six in transmembrane regions, are 100% conserved across the 14 members of the GLUT family. 
GLUT1 structure can be divided into two symmetrical halves with the halves separated by a 
large intracellular loop. These halves are thought to have arisen through a gene duplication event 
(197,198). GLUT1 contains 6 GXXXG packing motifs (H1 (2), H2, H4 (2), H5) and 2 
GXXXXXXG packing motifs (H1, H4). Interestingly while the first half of GLUT1 contains 8 
packing motifs, the second half which contains the oligomerization domain H9 does not contain 
any packing motifs. To analyze the conformationally dynamic residues we mutated glycine with 
Δ dihedral angles (phi/psi > 20°) to alanine. Additionally, we mutated the GXXXG domains and 
all glycine residues that are 100% conserved to alanine. 
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 Our results identify several membrane-resident glycine residues that support GLUT1-
mediated catalysis either by serving as hinge glycines or through their role as helix-stabilization 
GXXXG motifs. 
Experimental Procedures 
Reagents 
 [3H]-2-deoxy-D-glucose ([3H]-2DG) was purchased from American Radiolabeled 
Chemicals (St. Louis, MO). HEK-293 cells were purchased from ATCC. DPBS, DMEM, 
carbenicillin, Lipofectamine 2000, NuPage BisTris gels and MES buffer were obtained from Life 
Technologies. Unlabeled 2DG, Maltose, Cytochalasin B (CB), and phloretin were purchased 
from Sigma-Aldrich (St. Louis, MO). All primers were purchased from Integrated DNA 
Technologies. HiSpeed Maxi Kits were from Qiagen. QuikChange Multisite-directed 
Mutagenesis kits were obtained from Agilent. PVDF membranes were obtained from 
ThermoFisher. Bovine serum albumim was from American Bioanalytical. Protease inhibitor 
mixture tablets were from Roche Applied Science. SuperSignal Pico West, NeutrAvidin Gel, 
micro-BCA kits, spin columns, and EZ-Link Sulfo-NHS-ss-Biotin were from Pierce.  
Solutions  
 Solubilization buffer comprised PBS medium with 0.5% Triton X-100 and 5 mM MgCl2. 
Stop solution comprised ice-cold PBS-Mg medium plus CB (CB; 10 μM) and phloretin (100 
μM). Sample buffer contained 0.125 M Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, and 50 mM 
DTT. Transfer buffer comprised 12 mM Tris base, 96 mM glycine, 20% methanol. 
Antibodies 
 A goat polyclonal antibody anti-GLUT4 C-terminal residues 480–492 (Santa Cruz G1416) 
was used at 1:10,000 dilution as described previously (86). Horseradish peroxidase-conjugated 
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donkey anti-goat secondary antibody (Jackson ImmunoResearch) was used at 1:50,000 dilution. 
Tissue Culture  
 HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL 
streptomycin in a 37 °C humidified 5% CO2 incubator as described previously (149). All 
experiments were performed with confluent cells. Plates were subcultured into 12-well plates at a 
ratio of 1:2-1:5 2-4 days prior to transfections. Passages 4-20 were used for all experiments. 
Mutagenesis 
 GLUT1-encoding cDNA was inserted into the EcoRV-NotI restriction sites of PCDNA 
3.1(+). As described previously (140), the C-terminal 13 amino acids of this GLUT1 construct 
are substituted using the C-terminal 13 amino acids of GLUT4 to facilitate detection of 
heterologously expressed GLUT1 against a low level background expression of endogenous 
GLUT1. Mutagenesis was as described previously (116) using QuikChange Multi-site-directed 
Mutagenesis kits and was verified by sequencing. The GLUT1 construct in which H9 is 
substituted with GLUT3 H9 sequence was described previously (140). 
Transient Transfection 
 Cells (70-90% confluence) were transfected with 2 µg (12 well plates) or 5 µg of DNA per 
well (6 well plates). Transfections were performed 36-48 hr prior to analysis of sugar uptake or 
protein expression. Sugar uptake and cell-surface biotinylation measurements were performed in 
tandem. GLUT1 and GLUT1 glycine mutations GLUT c4 DNA heterologous expression in 
HEK293 cells was as described previously (116,140).  
Cell-Surface Expression Measurements 
 Three days post-transfection, 6-Well plates of HEK cells were washed twice with ice-cold 
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PBS and incubated on ice with ice-cold PBS containing 5 mM EZ-Link Sulfo-NHS-ss-Biotin for 
30 min with gentle rocking. Reactions were quenched by adjusting each well to 12.5 mM Trizma 
(Tris base). Cells were harvested, re-suspended in biotin lysis buffer, and lysates were bound to 
Neutravidin Gel in spin columns according to kit instructions. Protein was eluted from spin 
columns using reductant, the eluate protein concentration was determined 
spectrophotometrically. Normalized loads were analyzed by Western blotting. 
Western Blotting 
 GLUT1 expression in whole cell lysates and cell surface expression by biotinylation were 
analyzed by western blot as previously described (73). Total and isolated biotinylated proteins 
were normalized for total protein concentration by BCA and resolved by SDS-PAGE on a 10% 
NuPage gel in NuPage running buffer. Gels were transferred onto PVDF membranes blocked 
with 3% bovine serum albumin in PBS-T, probed with primary antibody overnight at 4 °C, 
probed with secondary antibody for 1 hr at room temperature, and developed using SuperSignal 
Pico West Chemiluminescent substrate. Blots were imaged on a FujiFilm LAS-3000 and relative 
band densities were quantitated using ImageJ32 software. 
2-deoxy-D-glucose Uptake 
 2-deoxy-D-glucose (2-DG) uptake was measured as described previously (140). Briefly, 
36-48 hr post transfections, confluent 12-well plates of HEK-293 cells were serum- and glucose-
starved for 2 hr at 37 °C in FBS and penicillin/streptomycin-free DMEM lacking glucose. Cells 
were washed with 1.0 mL of DPBS-Mg at 37 °C for 15 min, then exposed to 0.4 ml of [3H]2-DG 
uptake solution at various 2-DG concentrations (0.1 - 20 mM) for 5 min at 37°C. Uptake was 
stopped by addition of 1 ml of ice-cold stop solution. Cells were washed twice with ice-cold stop 
solution and lysed with Triton lysis buffer. Total protein content was analyzed in duplicate by 
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BCA. Each sample was counted in duplicate by liquid scintillation spectrometry. Each mutant 
was analyzed in triplicate on at least 3 separate occasions.  
Homology Modeling 
 We modeled GLUT1 e2 open using the human GLUT3 (4ZWC) structure. We removed 
ligands and used chain A as the template for each modeled structure. Sequence alignments were 
generated using ClustalX. Homology models were built using Modeller-9.9 and analyzed using 
PROCHECK. The GLUT1 e1 structure (4PYP (77)) was used directly. 
Results 
Homology Modeled GLUT1 structures 
 GLUT1 and GLUT3 structures have been described previously (77,134). The current study 
presents and interrogates the e2 open homology-modeled GLUT1 structure and the e1 open 
GLUT1 crystal structure. A compelling argument can be made for the alternating access model 
for facilitative sugar transport simply from inspection of the outward and inward conformations 
of GLUT1 (Figure 5.1). These conformations suggest a striking physical correspondence to the 
proposed kinetic intermediates of the alternating access carrier’s catalytic cycle named e2 and e1 
(99,124,145), argue strongly for sugar movements through a central translocation pore and are 
henceforth termed GLUT1-e2, and GLUT1-e1. The transporters exist as a 12 transmembrane 
(TM) domain protein where the first 6 TMs of the N-terminal half are separated from the C-
terminal half by a large intracellular loop. Analysis of conformational changes between the e2 
and e1 conformations suggest the N-terminal half exists as a rigid body while the C-terminal half 
is more dynamic.  
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Figure 5.1: GLUT1 e2 and e1 structures. Transmembrane domains are colored such that the 
pore forming TMs 1, 4, 7, and 10 are pink, and 2, 5, 8, 11 are blue. The scaffold TMs 3, 6, 9, 
and 12 are green.  
 
 
  
e2 e1
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Backbone Dynamics in Transmembrane Domains 
 Amino acids in alpha helices have (Φ/Ψ) angles of (-64 ± 7º, -41 ± 7º). However, glycine 
due to its lack of a side chain does not generally follow these constraints and can be more 
conformationally dynamic. Analysis of the Δ(Φ/Ψ) between the e2 and e1 open conformations of 
GLUT1 suggests highly dynamic alpha-helical regions between the outward and inward open 
conformations (Figure 5.2). 
GLUT Sequence Analysis 
 The GLUTs are divided into three classes based upon sequence alignments: class I: 
GLUT1-4, GLUT14; class II GLUT5, 7, 9, and 11, and class III, GLUT6, 8, 10, 12, and 13. 
Sequence alignments show varying degrees of glycine conservation across the 14 GLUTs 
ranging from 7% to 100% conserved. Sequence alignments of GLUTs reveal that 6 
transmembrane resident glycine residues are 100% conserved and these are located in TM1 
(G27), TM4 (G130), TM5 (G154, G167), TM7 (G286) and TM10 (G382) (Figure 5.3).  
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Figure 5.2: Δ Φ/Ψ angles in GLUT1 glycine calculated between GLUT1-e1 and GLUT1-
e2. Δ is calculated as e1 angle minus e2 angle. A. ΔΦ/Ψ angles for all glycines. B. ΔΦ/Ψ 
angles for transmembrane domain glycines. C. ΔΦ angles for transmembrane domain glycines. 
D. ΔΨ angles for transmembrane domain glycines.    
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Figure 5.3: GLUT1 topology based off of the 4PYP crystal structure. The amphipathic 
transport pore domains are colored in purple and blue. The hydrophobic, scaffold domains are 
colored in green. Glycines that are conserved in all GLUTs are yellow. Glycines where either 
the Φ or Ψ angle change by > 20° between e1 and e2 conformations are colored red. 100% 
conserved glycines with Δ Φ/Ψ > 20° are colored orange. 
 
 
  
R
M
E
P
S
S
K
K
L
T
G
L
L
M
AV
G
GA
V
LG
S
LQ
F
GY
N
TG
V
I
N
P
A
Q
K
V
I
E
E
F
Y
N
Q
T
W
V
R
Y G
E
S
I
L
P
T
L
TT
L
W S
T
L
S V
A
I F
S
V
G
G
G
M I
G
S F
S
V G
L
F V
N
FR
R
R
NS
M
L
M
M
N
L
L
AF
V
SA
V
LM
G
F
S
K
K
L G
S
F E
M
L
L
I
G R
F
II
G
V Y
C
G L
T
T
G
F
V P
M
Y V
G
E V
S P T A
L
R
GA
L
G
L
T
HQ
L
GI
V
VG
I
LI
A
QV
F
G
L
D
S I M G
N
K
D
L
W P
L
L
L
S
II
I
F
P
L
A
L
Q
C I
V
L
C
P
F
P
E
P
S
R
F
L
L
I
NRN
E
E
N
R
A
K
S
V
L
K
K
L
R
G
T
D
A
V T H D L Q E M K EE S R Q
M
M
R
E
K
K
V
T
I
LE
L
FR
S
P
AY
R
QP
I
LI
A
V V
L
QL
S
Q
L
S
I
G
A
F
N V
Y
Y
S
TS
I
FE
K
A G
V
Q
Q
P
V Y
A
T I
G
GS
I
V
T
A
N
T
F
V V
S
L F
V
V E
R R
A G
RT
L
HL
I
GL
G
A
G
A
M
C
A
IL
M
TI
A L
A
L
L
E Q L
M
P W
S
L
Y
S I
V
IA
FG
F
V
F
F
A
G
V
E
P
G
P
I
P
W
I V
F
A
E L F S
Q
P
G
R
PA
A
A I
V
AG
F
W
SN
S
N
T
FI
V
GM
C
F
Y
Q
Q
VE
C
H
Q
L
G
P
Y V
F
I I
F
T V
L
L V
L
F F
I
F T
Y
F
V
K
P
E
T
K
G
R
T
F
D
E
IASGFRQGGASQSDK
T
P E E L F H P L G A D S Q V
100% Conserved 
Δdihedral > 20° 
100% Conserved+Δdihedral > 20°
 183 
Mutagenesis of Δ(Φ/Ψ) Mutants 
 Examination of alpha-helix residues with a Δ(Φ/Ψ) > 20° for either the Φ or Ψ angles 
identifies residues in TM1 (G31), TM2 (G75, G76, G79), TM4 (G138, G145) TM5 (G175), TM7 
(G286), and TM10 (G382, G384) (Figure 5.4). Mutation of G76 and G384 to alanine had the 
most pronounced effect on cell surface normalized (Table 5.1) 2DG uptake (Table 5.2). Mutation 
of G76 to alanine resulted in a decrease in uptake to 29.7 ± 5.9% compared to wtGLUT1. 
Mutation of G384 to alanine resulted in a decrease in uptake to 22.2 ± 6.5 % of wtGLUT1 
uptake. 
Mutagenesis of Conserved Glycines  
 Mutagenesis of the 6 conserved glycines, reveals that the G130A mutation has the greatest 
impact on transport, decreasing cell-surface expression normalized (Table 5.1) 2DG uptake (at 
0.1 mM sugar) to 23.6 ± 5.9% of wtGLUT1. Mutation of G27 to alanine reduces uptake to 33.1 
± 5.9% of wtGLUT1 uptake while the G154A mutation reduces uptake to 44.2 ± 6.5% of 
wtGLUT1 uptake (Figure 5.5). The G167A, G286A and G382A mutations reduce uptake by a 
less substantial amount.  
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Figure 5.4. Measurement of 2DG uptake in wtGLUT1 and glycine point mutants where Δ 
Φ/Ψ is > 20°. Uptake is adjusted to cell-surface expression. One-way ANOVA between WT 
and mutant was performed to determine statistical significance. p value < 0.0001 = **** and p 
value between 0.0001 and 0.001 = ***. 
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Figure 5.5: Measurement of uptake of 2DG into HEK cells transfected with wtGLUT1 or 
GLUT1 glycine mutants where the glycine is 100% conserved across the GLUT family. 
2DG uptake is normalized to cell-surface expression. One-way ANOVA between WT and 
mutant was performed to determine statistical significance. p value < 0.0001 = ****, p value 
between 0.0001 and 0.001 = ***, and p value between 0.001 to 0.01 = **. 
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Mutagenesis of GXXXG Residues 
 GXXXG domains promote helix packing and protein-protein interactions [194-196]. 
GLUT1 contains 6 such motifs in its N-terminal half (Figure 5.6). Mutagenesis of these glycines 
to alanine and its impact on cell surface expression normalized (Table 5.1) 2DG uptake are 
summarized in Figure 5.7. G18A, G22A, and G134A were not explored. G163A was constructed 
but cell-surface biotinylation measurements were unsuccessful. Mutation of G31, G75, G79, 
G138, G163, or G167 to alanine decrease cell-surface expression normalized 2DG uptake by less 
than 50% of wtGLUT1. However, mutation of G27, G130, and G145 inhibit cell surface 
expression-normalized 2DG uptake by 67 ± 5.9%, 76 ± 5.9 % and 64 ± 6.5% respectively. 
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Figure 5.6: GLUT1 topology based off of the 4PYP crystal structure. The amphipathic 
transport pore domains are colored in purple and blue. The hydrophobic, scaffold domains are 
colored in green. Glycines in GXXXG motif are colored maroon, while residues comprising 
the XXX are pink. Glycines in GXXXXXXG motif are colored orange while residues 
comprising the XXXXXX are yellow. 
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Figure 5.7. Measurement of 2DG uptake in wtGLUT1 and GXXXG glycine point 
mutants. G18A, G22A, and G134A were not measured. G163A does not have cell-surface 
biotinylation measured. One-way ANOVA between WT and mutant was performed to 
determine statistical significance. p value < 0.0001 = ****, p value between 0.0001 and 0.001 
= ***, and p value between 0.001 to 0.01 = **. 
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Table 5.1: Cell Surface Expression of Glycine Mutants. The quantification of western blots 
of cell surface biotinylated wtGLUT1 and GLUT1 glycine mutants are listed. Each average is 
computed from three separate experiments. Results are normalized to wtGLUT1 expression. 
 
 
  
Sample Average Cell Surface Expression
WT 1
G27A 2.76026735
G31A 1.15914591
G75A 1.50370343
G76A 1.52999604
G79A 1.33965169
G130A 1.92409894
G138A 1.22494908
G145A 1.99651374
G154A 1.66175401
G167A 1.30768416
G175A 1.16212615
G286A 1.32601458
G312A 1.00381441
G382A 1.44598959
G384A 1.94188772
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Michaelis Menten Kinetics of Transport by Glycine Mutants. 
 The concentration dependence of the initial rate of 2DG uptake by HEK293 cells 
expressing wtGLUT1 or GLUT1 expressing glycine to alanine mutants is well approximated by 
Michaelis-Menten kinetics. The steady-state kinetics of 2DG uptake were measured for G27A, 
G31A, G75A, G76A, G130A, G138A, G154A, G286A, G312A, and G384A. Uptake was 
normalized to cell-surface expression and compared to simultaneous measurements of 2DG 
uptake in wtGLUT1. A minimum of two dose responses was carried out for each mutant. The 
data presented in Figures 5.8. 5.9, 5.10, and 5.11 show the average of all measurements for each 
mutant while paired two- or one-tailed T-tests were carried out to compare Km(app) and Vmax in 
each individual uptake measurement. G31A, G75A, G138A, G154A, G286A, and G312A 
mutations do not show statistically significant differences for either Km(app) or Vmax when using 
either two-tailed or one-tailed T-tests (Figure 5.8). G75A and G130A show an increase in Km(app) 
and a decrease in Vmax (Figure 5.9). G27A shows a decrease in Vmax and no statistically 
significant change in Km(app) (Figure 5.10). Mutation of G384 to alanine decreases Vmax but has no 
significant effect on Km(app) (Figure 5.11).  
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Figure 5.8: Net 2DG dose responses for glucose uptake into wtGLUT1 (○) and glycine 
mutants (●). A. Uptake of wtGLUT1 (Km(app) = 3.821 ± 3.811 mM; Vmax = 8.04x10-12 ± 
4.353x10-12 mol/mg protein/min) and G31A (Km(app) = 2.11 ± 1.482 mM; Vmax = 4.874x10-12 ± 
1.635x10-12 mol/mg protein/min). B. Uptake of wtGLUT1 (Km(app) = 2.429 ± 1.314 mM; Vmax = 
7.263x10-12 ± 1.927x10-12 mol/mg protein/min) and G75A (Km(app) = 2.399 ± 2.477 mM; VMAX 
= 4.432x10-12 ± 2.232x10-12 mol/mg protein/min). C. Uptake of wtGLUT1 (KM(app) = 2.251 ± 
0.8074 mM; Vmax = 4.784x10-12 ± 8.292x10-13 mol/mg protein/min) and G138A (Km(app) = 
2.664 ± 1.102 mM; Vmax = 3.912x10-12 ± 8.083x10-13 mol/mg protein/min). D. Uptake of 
wtGLUT1 (Km(app) = 4.095 ± 1.166 mM; Vmax = 5.069x10-12 ± 7.978x10-13 mol/mg 
protein/min) and G154A (Km(app) = 5.488 ± 2.051 mM; Vmax = 3.033x10-12 ± 6.782x10-13 
mol/mg protein/min). E. Uptake of wtGLUT1 (Km(app) = 1.938 ± 0.1993 mM; Vmax = 4.253x10-
12 ± 2.057x10-13 mol/mg protein/min) and G286A (Km(app) = 2.152 ± 0.224 mM; Vmax = 
3.569x10-12 ± 1.78x10-13 mol/mg protein/min). F. Uptake of wtGLUT1 (Km(app) = 3.114 ± 
0.9515 mM; Vmax = 6.384x10-12 ± 7.873x10-13 mol/mg protein/min) and G312A (Km(app) = 3.96 
± 1.577 mM; Vmax = 5.868x10-12 ± 1.022x10-12 mol/mg protein/min). Measurements for this 
mutant were made 0.25-10 mM 2DG. 
 
 
  
 193 
 
  
 194 
Figure 5.9: Net 2DG dose responses for glucose uptake into wtGLUT1 (○) and glycine 
mutants (●). A. Uptake of wtGLUT1 (Km(app) = 2.745 ± 0.4961 mM; Vmax = 6.042x10-12 ± 
4.481x10-13 mol/mg protein/min) and G76A (Km(app) = 5.382 ± 1.379 mM; Vmax = 4.878x10-12 ± 
6.326x10-13 mol/mg protein/min). B. The results of 5 separate experiments are shown as 
scatter dot plots for Km(app) for G76A. Results are shown as mean ± SEM. Paired t-test analysis 
indicates that Km(app) increases 2-fold (p = 0.0324). C. The results of 5 separate experiments are 
shown as scatter dot plots for Vmax for G76A. Results are shown as mean ± SEM. Paired t-test 
analysis indicates that Vmax decreases (p = 0.0062). D. Uptake of wtGLUT1 (Km(app) = 1.985 ± 
0.4394 mM; Vmax = 4.752x10-12 ± 4.968x10-13 mol/mg protein/min) and G130A (Km(app) = 
3.932 ± 1.399 mM; Vmax = 2.529x10-12 ± 4.923x10-13 mol/mg protein/min). E. The results of 3 
separate experiments are shown as scatter dot plots for Km(app) for G130A. Results are shown 
as mean ± SEM. Paired t-test analysis indicates that Km(app) increases 2-fold (p = 0.0489). F. 
The results of 3 separate experiments are shown as scatter dot plots for Vmax for G130A. 
Results are shown as mean ± SEM. Paired t-test analysis indicates that Vmax decreases by half 
(p = 0.0387). 
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Figure 5.10: Net 2DG dose responses for glucose uptake into wtGLUT1 (○) and glycine 
mutants (●). A. Uptake of wtGLUT1 (Km(app) = 2.097 ± 0.7206 mM; Vmax = 4.363x10-12 ± 
7.151x10-13 mol/mg protein/min) and G27A (Km(app) = 2.823 ± 1.313 mM; Vmax = 1.85x10-12 ± 
4.352x10-13 mol/mg protein/min). B. The results of 2 separate experiments are shown as 
scatter dot plots for Km(app) for G27A. Results are shown as mean ± SEM. Paired t-test analysis 
indicates that Km(app) does not change significantly. C. The results of 2 separate experiments 
are shown as scatter dot plots for Vmax for G27A. Results are shown as mean ± SEM. Paired t-
test analysis indicates that Vmax decreases (p = 0.0363).  
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Figure 5.11: Net 2DG dose responses for glucose uptake into wtGLUT1 (○) and glycine 
mutants (●). A. Uptake of wtGLUT1 (Km(app) = 1.758 ± 0.2325 mM; Vmax = 3.355x10-12 ± 
2.051x10-13 mol/mg protein/min) and G384A (Km(app) = 1.801 ± 0.2137 mM; Vmax = 1.85x10-12 
± 6.527x10-14 mol/mg protein/min). B. The results of 3 separate experiments are shown as 
scatter dot plots for Km(app) for G384A. Results are shown as mean ± SEM. Paired t-test 
analysis indicates that Km(app) does not change significantly. C. The results of 2 separate 
experiments are shown as scatter dot plots for Vmax for G384A. Results are shown as mean ± 
SEM. Paired t-test analysis indicates that Vmax decreases (p = 0.0042).  
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Discussion 
  This study uses homology modeling, sequence analysis and site-directed mutagenesis to 
examine the role of transmembrane domain glycines in GLUT1 mediated glucose transport 1 and 
asks: 1) Does disrupting GXXXG domains shown to be involved in helix packing in other 
membrane proteins, affect sugar transport? 2) Does mutagenesis of glycine residues conserved 
across the GLUT family disrupt GLUT1 mediated glucose transport? 3) Do “dynamic” glycine 
residues (those characterized by large changes in backbone dihedral angles) play important roles 
in GLUT1 mediated glucose transport?  Our results suggest that the mutation of 100% conserved 
glycine residues to alanine does not disrupt the transport cycle unless the residue is also found in 
a GXXXG motif or is one of the highly “dynamic” glycine residues.   
 The available structural biology data supports the alternating carrier access model for 
glucose transport (77,133-135). This model posits that the glucose transporter alternately 
presents outward and inward faces and facilitates glucose transport through a conformational 
change between the two states (99,124,145). Examination of the structures suggests the N-
terminal helices undergo a rigid body movement during the conformational change between N- 
and C-termini while the C-terminal helices move more independently.    
 While measurements of 2DG uptake at a single, subsaturating [2DG] (100 µM) suggests 
that mutation of any of the selected glycine residue to alanine, with the exception of G167, 
significantly reduces sugar uptake, a detailed Michaelis-Menten analysis presents a more 
complicated picture. 2DG dose response experiments of glycine mutants suggest that only when 
a reduction in 2DG uptake of > 50% is observed is this associated with a significantly altered 
Km(app) or Vmax (Table 5.2). The 100 µM assay is sensitive to changes in Km(app) but not Vmax, 
however changes in cell surface expression have a significant effect on single point uptake. This 
 198 
could explain the false positives in so many mutants. The overexpression of glycine mutants 
related to wtGLUT1 lead to lower normalized uptake without having an effect on the KM(app).  
 When steady-state Michaelis-Menten measurements are analyzed, four glycine point 
mutants, G27A, G76A, G130A, and G384A, have significant changes compared to wtGLUT1 
(Table 5.2). These four mutants, also have the lowest uptake of 100 µM 2DG relative to 
wtGLUT1. Both G27A and G384A have a significant decrease in Vmax compared to wtGLUT1 
but no change in Km(app). Altered Vmax compared to wtGLUT1 can best be characterized as 
resulting from a decreased turnover rate of the transporter. The affinity for glucose isn’t changed 
but the conformational change mediating sugar translocation decreases. G384 may be acting as a 
gate catalyzing or facilitating the conformational change. Additionally, this residue is located in 
a proline and glycine rich motif GXXP possibly conferring backbone flexibility similar to 
alamethicin voltage gated channels (199). Replacement of the P or G residues in the central 
domain of alamethicin reduces the high-amplitude hinge motion of the helix (199). The G27A 
mutation was analyzed only twice. In both experiments, Vmax decreases while Km(app) increases in 
one experiment but is unchanged in the second. This necessitates more replicates to fully 
characterize this mutation. 
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Table 5.2: Summarizing the effects of glycine to alanine mutants in GLUT1. %2DG 
uptake when compared to WT is summarized in column 4. One-way ANOVA between WT 
and mutant was performed to determine statistical significance. p value < 0.0001 = ****, p 
value between 0.0001 and 0.001 = ***, and p value between 0.001 to 0.01 = **. Column 5 
shows changes in KM(app) vs WT. Column 6 shows changes in VMAX vs WT. Statistically 
significant changes as evaluated by T-test (p < 0.05) are shown by arrows. X symbolizes 
untested residues. The ° in columns 5 and 6 symbolize one-way T-test.  
 
  
  
Glycine # Δ Φ/Ψ > 20° % Conserved GXXXG % Uptake vs WT Kmapp) vs WT Vmax vs WT
18 - 7 + X X X
22 - 62 + X X X
27 - 100 + 33.1**** - ↓°
31 + 54 + 67.8 **** - -
75 + 92 + 52.0 **** - -
76 + 62 - 29.7 **** ↑° 
*
↓
79 + 62 + 58.9 **** X X
130 - 100 + 23.6 **** ↑° ↓
134 - 85 + X X X
138 + 31 + 61.7 **** - -
145 + 54 + 35.5 **** X X
154 + 100 - 44.2 **** - -
163 - 23 + 95 ns X X
167 - 100 + 73.7 ** X X
175 + 69 - 67.1 *** X X
286 + 100 - 68.6 **** - -
312 - 54 - 68.9 *** - -
382 + 100 - 70.2 *** X X
384 + 77 - 22.2 **** - ↓
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Figure 5.12: GLUT1 homology model of the e2 open conformation. Residues 27-30, 75-79, 
and 130-134 are shown in cyan, red, and purple, respectively.  
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 G76A and G130A mutations are characterized by increased Km(app) and decreased Vmax. 
Mapping residues 75-79 and 130-134 onto the GLUT1 structure suggests that these regions 
interact as GXXXG stabilizing domains (Figure 5.12). While G76 does not represent a G in the 
GXXXG domain it is an interior residue that can potentially interact with the adjacent alpha 
helix. Disrupting the additional interior XXX residues is necessary to confirm that these are 
interacting domains. Additionally, G130 is implicated in GLUT1 deficiency syndrome 
potentially due to the disruption of transport by the loss of the GXXXG interaction (200). Both 
affinity for glucose and GLUT1 catalytic turnover are decreased by disruption of either 
“stabilization” motif.  
 While zero-trans sugar uptake experiments are useful for analyzing unidirectional sugar 
uptake they do not provide sufficient information to permit a full understanding of the kinetics of 
GLUT1-mediated sugar transport. Understanding the role of GLUT1 primary sequence in 
controlling glucose transport also requires measurements of equilibrium exchange transport in 
which intra- and extracellular [sugar] is identical and unidirectional sugar fluxes are measured 
using radioactive tracers. In red cells Vmax for equilibrium-exchange transport is some 2 to 50-
fold greater than Vmax for zero-trans uptake depending on the temperature at which the 
experiment is made (the lower the temperature, the greater the difference) (109). Specifically, 
disruption of GXXXG motifs in TMs 1 and 5 may impact exchange transport because these TMs 
interact with TM6, a scaffold domain whose GLUT1-specific sequence is absolutely required for 
accelerated exchange transport (116). 
 Additionally, design and analysis of the glycine hinge mutations were conducted using the 
3D crystal structures of GLUTs 1 and 3 and assuming that the transporter acts as an alternating 
access transporter. However, GLUT1 forms allosteric oligomers in red cell and HEK 293 cell 
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membranes. Further analyses of these mutants should examine their impact on GLUT1 
quaternary structure and whether their effects persist in the GLUT1-oligomerization deficient 
mutant in which TM9 of GLUT1 is replaced by TM9 of GLUT3 (116) and which loses the 
ability to catalyze exofacial trans-allostery (162). GXXXG motifs have been hypothesized to act 
as interacting regions in oligomeric transporters. At this time, the GLUT1 tetramerization 
domain (TM9) is known but the dimerization domain has not been definitively identified (140). 
The GXXXG motif in TM2 (G75:G79) is on the exterior lipid facing region of the protein 
suggesting a potential role in oligomerization. Studies examining the oligomeric state of 
GXXXG mutants by size-exclusion chromatography may help to identify the dimerization 
determinant(s).   
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Chapter 6: 
Discussion and Future Directions 
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 Recent advances in membrane protein crystallography coupled with the crystallization of 
the glucose transporters GLUT1, GLUT3, and GLUT5 and additional, related major facilitator 
superfamily proteins enable new analysis of GLUT1 mediated transport, ligand binding and 
allostery (6,77,131,133,134). GLUT1 kinetic and ligand binding studies have accumulated over 
decades a mountain of evidence on how GLUT1 mediates glucose transport (100,141). This 
evidence has led to the development of multiple models to explain GLUT1 mediated glucose 
transport. Specifically, two competing, compelling models have been proposed: the alternating 
access carrier (99,124,145) and the fixed-site carrier [125,126]. Neither model provides an 
adequate description of GLUT1 mediated glucose transport. Structural analyses favor the 
alternating access carrier model but this model cannot account for GLUT1 allostery observed 
with transport and ligand binding (77,133-135).  
 As more sugar transporter structures become available the number of analyses that support 
the alternating access carrier model increase. These studies have interpreted transporter structure 
in the context of the alternating access model in which the transporter cycles between states 
alternately presenting either an exofacial (e2) or endofacial (e1) sugar binding cavity (77,133-
135). Sugar binding promotes a gated transition in which bound sugar is occluded or shielded 
from the interstitium (e2o) or cytoplasm (e1o) (119). Occlusion then triggers rigid body 
movements leading to conversion of the occluded state to the opposite open state. The catalytic 
cycle concludes via the reverse sequence of conformational changes with or without a bound 
sugar.   
 This thesis utilizes sugar transporter crystallographic information to probe potential ligand 
interaction sites and the residues involved in the gated transitions between outward and inward 
conformations. Additionally, it interrogates transporter behaviors that are not explained by 
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structural studies, specifically the well-documented GLUT1 transport allostery, to combine 
structural evidence and transport physiology into a new model for GLUT1 function. 
Ligand Interaction Sites 
 Molecular docking reveals that the GLUT1-e2 exofacial cavity presents 3 potential, non-
overlapping β-D-Glc interaction sites. Maltose interaction sites overlap with both the core and 
peripheral β-D-Glc interaction sites. This suggest that GLUT1-e2 can simultaneously 
accommodate core β-D-Glc and peripheral maltose. These three β-D-Glc interaction sites may 
represent progressive steps in β-D-Glc binding or co-existent interaction sites. Molecular 
docking indicates that it is highly unlikely the GLUT1-e1 or GLUT1-e2 simultaneously interacts 
with both endofacial and exofacial ligands. Docking analysis of the GLUT1 e1 and GLUT1 e1o 
structures suggests that the CB binding site overlaps with β-D-Glc core site. This steric 
hindrance implies that GLUT1 cannot bind an occluded sugar and CB simultaneously. Thus the 
experimental observation of CB-promoted glucose occlusion can only be explained if CB 
binding to one GLUT1 subunit in an oligomeric complex promotes glucose occlusion within an 
adjacent subunit (119). Molecular docking analysis is a useful tool for understanding GLUT1 
domains involved in ligand binding and glucose transport. It can be used to develop testable 
hypothesis of side chain interactions (Q282) and to explain biological phenomena (e.g. CB 
occlusion of glucose in GLUT1 [119], changes in affinity of forskolin ligands (84) and BAY 
compounds based on side-chain interactions). 
GLUT1 transmembrane domain glycines 
  Analysis of the crystal structures of sugar transporters, suggest that GLUT1 functions as an 
alternating access carrier where the N-terminal helices undergo a rigid body movement during 
the transition between the outward and inward conformations while the C-terminal helices move 
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more independently. Glycine is frequently found in transmembrane alpha helices and is 
hypothesized to play multiple roles (structural and functional) in membrane transporters. This 
includes acting as a gating hinge [190, 191], conferring conformational flexibility [192], and 
enhancing packing and oligomerization through GXXXG/GXXXXXXG motifs [194-196]. 
 GLUT1 contains 31 transmembrane domain resident glycines, 9.2% of total 
transmembrane domain amino acids. This study, utilized glycine to alanine mutations, to 
stabilize “dynamic” glycine residues, conserved glycine residues and to disrupt GXXXG motfis. 
Mutation of glycines conserved across all GLUTs does not appear to have a significant effect 
unless these glycines are “dynamic” or GXXXG resident. Alternatively, stabilization of G384, 
which resides in a GXXP motif significantly reduces Vmax for net sugar import. This glycine may 
act as a gating residue for the GLUT1 translocation conformational change. Disruption of the 
GXXXG motifs in TM2 (G76A) and TM4 (G130A) significantly reduces both affinity and VMAX 
for zero-trans uptake. Interestingly, inspection of the GLUT1 e1 and homology-modelled 
GLUT1 e2 structures suggests these two motifs may be interacting. While demonstrating that 
GXXXG domains can play a role in mediating glucose transport, zero-trans uptake experiments 
are not, in themselves, sufficient for understanding this role. More detailed kinetic analyses (e.g. 
examining accelerated exchange transport) and reviewing the roles of GXXXG motifs in TMs 1 
and 5 may provide an interesting area for future study as these TMs interact with the scaffold 
domain TM6 implicated in GLUT1 mediated accelerated exchange (116). 
GLUT1 Allostery and Oligomerization 
 Molecular docking reveals a core binding site in GLUT1 e2, e2o, e1o, and e1 
conformations. Analysis of this pocket suggests that Q282 plays a key role in forming hydrogen 
bonds with sugar molecules. We asked if conversion of the Q282 side chain to alanine affected 
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zero-trans 2DG uptake by the transporter. Mutation of this residue doubles Km(app) for 2DG 
uptake while not affecting Vmax signifying a change in transporter substrate affinity. We next 
examined if the core site mutation has an effect on GLUT1 allostery. The Q282A mutant 
eliminates maltose stimulation of 2DG uptake (cis-allostery). However, the Q282A mutant 
decreases CB stimulation of 2DG uptake (trans-allostery) without eliminating it. This suggests 
that cis- and trans-allostery involve different mechanisms. GLUT1 tetramerization deficient 
mutants GLUT1(GLUT3-H9) catalyze cis-allostery. Addition of the Q282A mutant to the 
tetramerization deficient mutant eliminates maltose stimulation of 2DG uptake. However, the 
GLUT1(GLUT3-H9) mutation eliminates CB stimulation of 2DG uptake. Similarly, the Q282A 
mutant in GLUT1(GLUT3-H9) does not exhibit trans-allostery. 
 Cis- and trans-allostery require that GLUT1 must bind inhibitor and sugar simultaneously. 
For cis-allostery, GLUT1 presents 2 co-existent exofacial maltose interaction sites, and glucose 
competes for maltose binding at both sites. However, trans-allostery is more difficult to explain 
as GLUT1 only presents one e1 CB interaction site. This suggests that GLUT1 is an alternating 
access carrier capable of exofacial cis-allostery but, if analysis of the structural data is taken at 
face value, that GLUT1 is incapable of trans-allostery.  
 GLUT1 forms mixtures of dimeric and tetrameric complexes in both red blood cells and 
HEK 293 cells and the oligomeric distribution is affected by cellular redox state such that 
reducing conditions favor dimeric GLUT1 (140). Tetrameric GLUT1 presents 0.5 CB binding 
sites per molecule of GLUT1 while reduced, dimeric GLUT1 presents 1 CB site per GLUT1 
molecule (17,95,96). Additionally, extracellular reductant inhibits sugar transport in RBCs and 
eliminates trans- but not cis-allsotery (80).  
 The molecular mechanisms by which Q282 and transmembrane helix 9 promote cis- and 
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trans-allostery are unknown. Our observations support a model where dimeric GLUT1 comprises 
two physically independent GLUT1 molecules. Each subunit displays cis- but not trans-allostery 
in net sugar uptake, binds 1 molecule of CB and because transport is rate-limited by 
conformational changes between unliganded e1 and e2 starts, transport is characterized by a low 
kcat. Tetrameric GLUT1 exists as a noncovalent dimer of two associated and functionally coupled 
GLUT1 molecules. Intra-dimer interactions produce a functional, anti-parallel arrangement of 
subunits. If one GLUT1 molecule presents an e2 conformation its cognate partner in the dimer 
must present an e1 conformation. When an e2 subunit undergoes a transport cycle from eS2 to 
eS1, its dimeric partner undergoes the reverse conformational change. This couples transport via 
one subunit to the regeneration of an e2 sugar uptake site on the second subunit, bypasses slow 
relaxation and accelerates net sugar transport. Each subunit functions as an allosteric alternating 
access transporter for sugar import. Trans-allostery in sugar import is obtained when one e1 
subunit interacts with an endofacial ligand with high affinity. The dimer presenting this 
liganaded e1 conformation is locked in an inhibited state but its occupancy state is 
communicated to the adjacent dimer, increasing that dimer’s affinity for β-D-Glc or kcat for 
transport. Raising the endofacial ligand concentration leads to occupation of both e1 subunits and 
inhibition of uptake.  
 In conclusion, each GLUT1 molecule appears to present a core, catalytic sugar binding 
site. The exofacial conformer of GLUT1 presents at least one and possibly two additional sugar 
interaction sites. Occupancy of additional sugar interaction sites affects transport via the catalytic 
site. Trans-allostery requires at least one subunit to bind an endofacial ligand and one to bind an 
extracellular, imported sugar. Disrupting the oligomeric state prevents trans-allostery but not cis-
allostery. Disrupting the core sugar interaction site eliminates cis-allostery but not trans-
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allostery. This model is consistent with the emerging body of structural data, but unlike the 
simplified analyses accompanying the structural analyses, is also compatible with the 
transporter’s biochemical and transport behavior.  
Future Directions 
 This study has advanced our understanding of previously unexplained phenomena 
observed in GLUT1 mediated glucose transport. It additionally has shown some of the gaps 
present in current structural analysis of MFS transporters. Future work on GLUT1 most 
necessarily will involve further analysis of oligomeric structure. This could be accomplished 
through computational protein:protein docking of GLUT1, utilizing software optimized for 
membrane proteins. This would allow for determination of domains involved in mediating the 
dimeric interface. Alternatively, cryo-EM could be used to analyze both GLUT1 dimers and 
tetramers with the caveat that the use of detergents that stabilize GLUT1 oligomeric structure 
(122) should be preferred. Structural biologists traditionally crystalize mono-dispersed proteins 
(201) (202) but the use of detergents that cause GLUT1 tetramers to dissociate [122] may 
prevent the analysis of physiologically relevant GLUT1 structures. Structural analysis of GLUT1 
has progressed significantly but it is biased towards an inward open conformation. Further 
characterization of GLUT1 crystal structures requires obtaining outward open and occluded 
conformations.  
 Analysis of both GLUT1 allostery and conformational changes are currently hampered by 
GLUT1 oligomeric structure. While, GLUT1 cis-allostery is observed in both dimers and 
tetramers, it is not currently possible to determine if cis-allostery is an intra- or an intermolecular 
phenomena. Development of a monomeric GLUT1 molecule can assist in studying cis-allostery. 
Additionally, while cis-allostery has been demonstrated in the dimeric GLUT3, trans-allostery 
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has not been explored. Further probing of the oligomeric state and allosteric behavior of the 
GLUTs to determine if this behavior is unique to GLUT1 or carried across the family.  Similarly 
studying residues involved in GLUT1 conformational changes should be undertaken in both 
dimeric GLUT1 TM9 background and in a potential GLUT1 monomer. Disruption of GXXXG 
motifs, should be tested for oligomeric size as GXXXG motifs have been speculated to be 
involved in oligomerization. Similarly, the glycine mutants were tested for zero-trans uptake, 
expanding this to include equilibrium exchange will allow for characterization of the turnover 
rate potentially mitigated by glycine flexibility.  
 Ligand interaction maps generated by ligand docking to GLUT1 provide an interesting 
avenue for testing ligand affinity for GLUT1 and for other GLUTs. Specifically, inhibitors can 
be designed to use the GLUT1 binding pockets, and then compared to binding pockets of the 
other GLUTs to allay specificity concerns. The variability of poses generated by molecular 
docking also demonstrates an area of concern for this analysis. Ligand docking may be best used 
to develop testable hypotheses and to explain biological data. However, highest scoring protein-
ligand interactions do not always correspond with biochemical data, (β-D-glucose poses) 
confirming that best practice demands that we test potential ligand side chain interactions in the 
experimental setting.   
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